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ABSTRACT 
Cardiac rehabilitation (CR) participation is associated with significantly lower mortality 
and improved psychosocial well-being. However, women are less likely to participate than men. 
CR4HER was a single-blind, 3 parallel-arm, pragmatic, randomized controlled trial comparing 
CR program adherence, functional capacity, and health behaviors between women referred to 
mixed-sex, women-only, or home-based CR. The study occured between November 2009-July 
2013. Low-risk patients with coronary artery disease were recruited from six sites in Ontario. 
Consenting participants completed a pre-program survey assessing health behaviors (physical 
activity, diet, medication adherence, and smoking), wore pedometers for 7 days, and clinical data 
were extracted from charts. Participants were referred to CR at one of 3 sites. After intake 
assessment, including a graded exercise stress test, eligible patients were randomized to 
supervised mixed-sex, supervised women-only, or home-based CR. Six months later, CR 
adherence and exit assessment data were ascertained, and participants were mailed follow-up 
surveys and pedometers. 
Among 264 consenting patients, 169 (64.0%) were eligible and randomized. Twenty-
seven (16.0%) did not attend CR and 43 (25.4%) attended a different model than that to which 
they were randomized, with most women switching to a model other than home-based CR. 
Program adherence was moderate overall (54.46±35.14%). Analysis of variance revealed no 
significant differences based on per protocol analysis (PP; p=.63), but as-treated, home-based 
participants attended significantly more than women-only (p<.05).  
Overall, there was a significant increase in functional capacity pre to post-program 
(p<.001). While there were no significant differences in functional capacity by model at CR exit 
based on PP, there was a significant difference on an as-treated basis, which sustained 
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adjustment. Women attending mixed-sex CR attained significantly higher post-CR functional 
capacity than women attending home-based programs (p<.05).  
Self-reported physical activity increased among women randomized to, and who 
attended, mixed-sex and women-only CR (ps<.05). Diet improved among women attending 
women-only CR (p<.05). However, analyses adjusted for confounding variables revealed no 
significant differences in any outcome by model.  
Offering women alternative program models may not promote greater CR adherence, functional 
capacity, or behavioral outcomes. Nevertheless, replication is warranted. Other proven strategies 
such as action planning and self-monitoring should be applied.  
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INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for women 
world-wide, representing over 30% of global deaths 1. Cardiac rehabilitation (CR) is an 
outpatient secondary prevention program composed of structured exercise and comprehensive 
education and counseling. CR participation results in lower morbidity and mortality, among 
other benefits. Unfortunately, women are significantly less likely to adhere to these programs 
than men 2. While the traditional model of CR care is a hospital-based mixed-sex program, 
women are the minority in such programs, and state that these programs do not meet their care 
preferences. Two other models of CR care have been developed: hospital-based women-only 
(sex-specific) and monitored home-based programs. Women’s adherence to these program 
models is not well known.  
Cardiac Rehabilitation for her Heart Event Recovery (CR4HER) was a 3 parallel arm 
pragmatic randomized controlled trial (RCT) designed to compare women’s program adherence 
to traditional hospital-based CR with males and females attending (mixed-sex), home-based CR, 
and women-only hospital-based CR. 
Power calculations based on a pilot study suggested a sample size of 261 patients was 
needed to detect a difference in adherence by program model. Participants were female acute 
coronary syndrome, percutaneous coronary intervention or bypass surgery patients recruited 
from six inpatient and outpatient cardiac settings in Ontario, Canada. The primary outcome 
variable was program adherence operationalized as CR site-reported percentage of prescribed 
sessions completed by phone or on-site, as reported by a staff member who was blind to study 
objectives. The secondary outcomes included functional capacity, and health behaviours such as 
exercise, dietary habits, smoking and medication adherence. It was hoped that by identifying the 
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CR program model which resulted in the greatest adherence for women, their participation and 
potentially their cardiac outcomes could be optimized. 
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REVIEW OF THE LITERATURE 
Burden of Cardiovascular Disease in Women 
CVD is the leading cause of hospitalization in Canada3, as well as one of the leading 
causes of death among Canadian men and women (accounting for 19.7% of all deaths in 20114). 
It is also the leading cause of morbidity and mortality for women in Canada5. There is a plethora 
of mixed evidence with regard to sex (e.g., biology, physiology) and gender (e.g., psychosocial 
roles) differences in CV morbidity and early mortality in the literature6–10. These can often be 
explained by differences in defining of clinical endpoints, and particularly by the choice of 
prognostic factors which are statistically controlled in analyses. However, it is well established 
that women with CVD have a unique and hazardous constellation of risk factors (notably older 
age, and higher prevalence of co-morbidities such as hypertension and diabetes11,12), and may 
fare worse than men13–15. For instance, women who suffer an acute coronary event are more 
likely than men to incur morbidity and mortality during the first year of recovery16, have lower 
physical function, are less physically active, and are at greater risk in the context of smoking and 
diabetes17. Since CVD affects women on average 10 years later than it does men18, the medical 
problems experienced by women with CVD are compounded by those experienced simply due to 
ageing19.  
Women and Treatment of Cardiovascular Disease 
Sex and gender have been associated with health inequity, and additionally have been 
shown to impact access to health care services and quality of care20–22. In particular, there may be 
sex or gender disparities in treatment after a cardiac diagnosis or event with regard to delays in 
diagnosis and treatment11,13,23–26, receipt of information from health professionals27, prescription 
of evidence-based medications13, and less aggressive use of diagnostic testing, revascularization 
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and other interventional procedures24,28–30. Furthermore, fewer women with heart disease get 
access to secondary prevention services6,31–33. 
Physician-supervised CR programs were originally developed when the benefits of 
walking during prolonged hospital stays following cardiac events were observed34. In its present-
day form, CR is an outpatient secondary prevention program composed of structured exercise 
training and comprehensive education and counseling addressing cardiac risk factors35. It is a 
multi-disciplinary approach, and has been defined by the Canadian Association of Cardiac 
Rehabilitation as “the enhancement and maintenance of cardiovascular health through 
individualized programs designed to optimize physical, psychosocial, social, vocational, and 
emotional status”3. Indeed, CR has been shown to reduce mortality by 25%36, to reduce the need 
for re-hospitalization and the use of invasive revascularization procedures37,38, and improved 
survival, functional status, and psychosocial well-being36. Participation in CR programs is 
associated with beneficial effects on cardiac risk factors such as systolic blood pressure and total 
cholesterol36, while the average gains in aerobic capacity post-CR are 11-36%39. These benefits 
are all achieved in a cost-effective and economically justified manner40,41. CR participation also 
results in significant health behaviour changes such as increased exercise42, improved diet, and 
lower self-reported smoking (OR=.6436). However,  reductions in weight are generally not 
achieved43. Unfortunately, these studies do not always consider patient characteristics such as 
age, ethnicity, or sex and gender. However, given this abundance of empirical evidence, Class I, 
Level A clinical practice guideline recommendations3,44 promote CR access for all patients. 
Cardiac Rehabilitation Use 
In spite of its many benefits, CR services are grossly under-used45, with only 
approximately 15–30% of eligible patients in the United States and Canada participating in CR46. 
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Low adherence to prescribed medical regimens is a multifaceted yet common problem, in 
particular among patients with chronic conditions. In relation to health care, adherence describes 
the extent to which patients’ actual usage corresponds to prescribed interventions47. However, 
there is currently no “gold standard” for the measurement of adherence and many authors do not 
clearly define or even measure adherence in their studies48. There are several different types of 
adherence, and these include: seeking care (in a timely manner), participating in health programs 
(screening or secondary prevention), attending follow-up appointments, and following doctors' 
advice regarding treatment49. For the purposes of this study, adherence was defined as the 
percentage of CR sessions received (the number of CR sessions attended divided by the number 
of CR sessions prescribed). It should be noted that overall CR participation rates as described 
above do not offer a suitable representation of underserved groups within the cardiac population. 
The rates of CR utilization among patients of low socioeconomic status are low50, with lower 
patient income predicting lower rates of CR participation 45. Similarly, significantly lower CR 
participation rates have been reported among ethnic minorities as compared to whites45,51. 
Women and Cardiac Rehabilitation 
Clinical practice guidelines3,52,53, and those specifically developed for women with 
CVD54 recommend that all women should participate in CR following acute coronary syndrome 
(ACS) or revascularization intervention (e.g., coronary artery bypass graft [CABG] or 
percutaneous coronary intervention [PCI]). Yet the rate of women who participate in CR is much 
lower than men, at approximately 11–20% 32,40,55–57. The percentage of women in CR is lower 
relative to what should be expected relative to their representation in the CVD patient 
population58. As such a treatment-risk paradox is observed, such that while women are in greater 
need of CR programs and their associated benefits, they are significantly less likely to access 
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it56,59,60. Although this sex bias has been recognized for over a decade, there has been little 
improvement in women’s CR participation during this time61. This is especially disconcerting 
because there exists a dose-response relationship between degree of participation and mortality62. 
While there is a dearth of literature reporting on CR program adherence, fourteen studies 
(reporting on data collected between 1980 and 2014, N=8176 of which 27.3% were women) 
were recently identified and compared (Oosenbrug E, unpublished data, November 2015). 
Overall CR program adherence was found to range from 36.7 to 87.0% of CR sessions, with a 
mean CR program adherence of 66.40±29.91% of prescribed CR sessions. CR adherence rates 
for men ranged from 38.61% to 89.00% (with a mean of 68.59±29.16%), whereas rates for 
women ranged from 34.72% to 85.00% (with a mean of 64.19±30.66%). It should be noted that 
while most of the 14 studies relied on patient-report alone in order to ascertain CR adherence and 
women accounted for less than a third of study participants, Oosenbrug’s meta-analysis did find 
that CR program adherence was significantly greater in men compared to women. 
Andersen’s Behavioral Model of Healthcare Utilization 
The reasons why women are missing from CR programs are multi-factorial, and include 
health system-level (including provider-related factors) and patient-level factors56 that can be 
informed by Andersen’s Behavioral Model of Healthcare Utilization63. Andersen’s model is an 
explanatory framework identifying predictors of health care utilization that can be applied to a 
broad range of health services sectors and diseases. The goal of the model is to identify 
conditions that either facilitate or impede healthcare utilization, so as to develop measures of 
medical care access and explain patients’ differing levels of use.  The multilevel model (see 
Figure 1) states that there are three predictors of health care utilization; predisposing factors that 
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exist prior to illness, enabling factors that are the logistical aspects of obtaining care, and need 
factors that are the most direct cause of health service use64. 
With regard to health system / provider factors, while physician referral practices could 
be optimized for both men and women, it has been suggested that physicians may be less likely 
to refer female patients46,59,65–67. Indeed men are referred almost twice as often as women51, and 
physicians may recommend participation more strongly among men than women68.  
With regard to patient factors, these are conceived as predisposing, enabling and need factors as 
outlined above in Andersen’s model. Predisposing factors exist prior to the onset of illness and 
describe the inclination of individuals to use health services, enabling factors are the barriers and 
facilitators to the use of health services, while need factors are the objective and subjective 
aspects of the decision to use health services. Studies investigating moderators and barriers to 
CR participation have revealed the following patient-level barriers specific to females: older age 
(on average 10 years older than men56), poor spousal support and / or unmarried status, and 
competing work and care-giving responsibilities, which are also related to social norms 
(predisposing factors); travel-related barriers, costs, lower socioeconomic status, and 
concomitant illness56,59,69–73 (enabling factors); and greater disease severity55,74,75 (need factor). 
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Figure 1. Behavioral Model of Health Service Use 
 
Ronald M. Andersen’s Behavioral Model of Health Services Use63 states that there are three predictors of health care 
utilization; predisposing factors, enabling factors, and need factors. The CR4HER baseline survey assessed 
predictors from each category. 
Gender and Cardiac Rehabilitation 
Male or female sex is related to biological features, including physical and physiological 
traits. Gender, on the other hand, can be defined as “the socially constructed roles, behaviours, 
expressions and identities”76 of men and women. It is an important determinant of health, since 
its relationship to differing and often unequal income, education, and social and physical 
environments, influences how women and men access health services. The literature also 
suggests that social reality is in part derived from social beliefs77; how one is expected to act 
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influences how one does in fact act. Female gender itself, while expressed at the individual level 
but structured by social relations, is thus a patient-level factor predisposing lack of CR 
utilization, as social expectations of women can hinder their desired participation in healthy 
behaviours. Indeed prior research has shown that women feel health behaviors, such as exercise, 
are activities to be set aside until they are done caring for their family and spouses78. Many 
women may therefore be constrained by their roles as mothers and wives — preventing them 
from taking on their roles as recovering cardiac patients. 
Where women do participate in CR, they generally obtain the same benefits as men19. 
Studies of the effectiveness of CR have generally revealed no major differences between men 
and women in terms of changes in risk factors, functional capacity, and quality of life79,80 59,67, 
although sex differences are found for quality of life in some studies81. However, sex-specific 
data are lacking with regard to mortality and morbidity in particular59. Where compared, women 
accrue the same benefits as men, thus the consensus in the literature is that women do indeed 
benefit from CR59,80. There is no evidence to suggest that women are less likely to benefit than 
men; indeed women often present with lower physical fitness, and as such have greater potential 
to benefit from CR since the greatest improvements are normally seen in patients with the lowest 
fitness at the start of the program39. Although the studies examining women’s outcomes post-CR 
are limited, they have been positive42,59,82. However, this literature suffers from low sample sizes, 
and lack of randomization and control groups. There are even fewer studies assessing women’s 
behavioral outcomes following CR participation83,84. While studies of the effectiveness of CR 
have generally revealed no major differences between men and women, female-specific data are 
lacking on the effect of CR on mortality and morbidity85. In spite of national policy initiatives 
recommending that sex and gender-based analyses be included in the design of health research86, 
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these are rarely incorporated into studies36,41. Instead most studies on the treatment of CVD focus 
and report only on outcomes involving men, and where women are included most studies fail to 
conduct gender-based analyses33,87. This also holds true for CR trials. For example, in a 
Cochrane review of CR, only 11% of patients enrolled in comprehensive CR studies were 
women41. 
 Once women do enroll in CR, they are less likely to adhere to these programs than men 
and most studies report higher dropout rates for women than men46,88. In a study of 157 female 
CABG patients, 8% did not attend CR at all following referral, and 22% attended irregularly, 
citing health, time constraints and inconvenience to explain their non-adherence89. Given that full 
participation is needed for patients to achieve the benefits of CR, research is needed to improve 
adherence among women. Indeed, where women complete CR, they experience relative benefits 
even greater than those of men 2. 
 The low rates of enrollment and adherence in CR programs among women raise the 
question of whether CR programs are equally appealing to both men and women90. CR was 
originally developed in the 1970s with special regard to the needs of Caucasian middle-aged men 
to promote return to work post-myocardial infarction (MI)91. Women generally have substantial 
differences from men at the time of a cardiac event or procedure92. For instance, they are often 
10 years older, more likely to be widowed and living alone, and of lower socioeconomic status 
than men92. They often have greater household and care-giving responsibilities55,72,73, yet report 
fewer social support networks71. They are more likely to suffer from co-morbid conditions such 
as arthritis and osteoporosis59,72,73 (all conditions which may impact on motivation to exercise 
due to pain, fatigue, and even fear93). They have lower functional capacity59,79, and a greater 
burden of modifiable risk factors79. These differences suggest that women may have dissimilar 
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needs and preferences for CR programs than men85. Indeed, as outlined herein, examination of 
women’s CR preferences reveal they are not always met by traditional CR, which could be one 
of the main causes of low CR adherence. 
While the traditional model of CR care is a hospital-based mixed-sex program, women 
are the minority participants in such programs. Women report perceiving these programs as 
male-oriented and failing to meet their care preferences94. For example, women report sometimes 
being the only woman in a group of men, most of whom are younger than themselves. This 
makes them self-conscious and hinders their involvement95. Indeed, women have reported 
preferring a women-only CR program due to an increased sense of comfort in a women-only 
environment 96. In a qualitative study by Moore, female hospital-based CR participants reported 
their likes and dislikes of the traditional program model. While their ‘likes’ included being 
monitored during exercise, receiving nutrition information, and being part of a group, their 
‘dislikes’ included the lack of exercise alternatives to the treadmill and cycle ergometry, lack of 
emotional support from staff, lack of socialization opportunities, being weighed and the crowded 
physical space, and overall perceived the program as a “men’s club”(p.126)97. The implication is 
that women may find a CR program more appealing if there is a stronger psychological 
emphasis, more varied exercise options, and a greater presence of female participants. The 
feature for which women’s preferences were least well-met was the ability to choose their own 
exercises, with additional preferences of discussing progress, not tiring, flexible hours and 
setting goals. Women’s preference not to experience pain or tire while exercising was 
significantly less well met than it was for men. Overall, women may be less likely to participate 
as they do not perceive the programs as meeting their needs88. The totality of evidence suggests 
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that women may benefit from alternative CR approaches59,90, although there is a dearth of 
empirical evidence to test this contention. 
Alternative Models of Cardiac Rehabilitation 
Home-Based Cardiac Rehabilitation 
In response to patient preference among other logistical considerations, home-based 
models of CR care were developed in the early 1980s. While there is no universally recognized 
definition of what constitutes a home-based program98, for the purposes herein they will be 
considered monitored CR programs which make similar use of graded exercise tests to develop 
an individualized exercise prescription, provision of exercise protocols taught by CR personnel 
to be performed independently, in addition to provision of reading materials on lifestyle changes, 
all of which is discussed during scheduled telephone calls between allied health care providers at 
the CR program and patients. Home-based CR programs have been implemented to overcome 
distance and transportation barriers, as well as time constraints such as those due to domestic 
responsibilities; barriers which are commonly reported by women69. Women tend to put family 
obligations ahead of lifestyle change, as caring for family/household is a more central component 
to their self-concept and self-esteem72,99,100, and thus home-based CR programs provide a 
feasible alternative for those patients who are either unable or unwilling to attend in-hospital CR 
programs101. Costs analyses comparing the two models suggest that home-based CR programs 
are cost-effective, both to the provider and to the patient 102. Specifically where the patient is 
concerned, there are no travel costs associated with home-based CR programs, although the 
program would still be associated with a certain time investment.  
A Cochrane review found that home-based CR programs are as effective as traditional in-
hospital programs in improving clinical and quality of life outcomes for both men and women103. 
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Specifically, research suggests that home-based CR programs result in benefits similar to 
hospital-based CR programs with regard to morbidity, exercise capacity, cardiac risk reduction 
and health behaviour changes104,105, again among both men and women. In a meta-analysis98, 
home-based CR outcomes were compared to both usual care (18 trials, N=3,925) and hospital-
based CR (6 trials, N=818). With regard to the former, results showed that compared to usual 
care home-based participants realized a 4 mm Hg greater reduction in systolic blood pressure 
(95% CI 6.5, 1.5) and a reduced relative risk of being a smoker (0.71, 95% CI 0.51, 1.00). No 
significant differences in exercise capacity, total cholesterol, anxiety and depressive symptoms, 
and mortality were found, although more trials are needed to adequately compare these 
outcomes. Two trials reported a significant reduction in re-admission rates following home-based 
CR, even 6 months later. With regard to comparison to hospital-based CR, results revealed no 
significant differences in exercise capacity, systolic blood pressure and total cholesterol. Results 
of one trial found no differences in emotional outcomes, smoking or mortality. Finally, evidence 
suggests that home-based CR programs are more cost-effective than hospital-based CR 
programs106–108, and that there are no differences in patient healthcare costs following hospital or 
home-based CR participation102. There have been no training-related complications reported in 
the literature due to home-based CR, and such programs are considered safe for low to moderate 
risk patients98.  
Given the evidence that hospital-based mixed-sex CR programs may not meet women’s 
needs, an alternative program model such as home-based CR may be preferable. In a previous 
study conducted by the Grace lab, 80 home and hospital-based CR graduates were surveyed 
regarding their preferred program model109. Program model preference was not related to sex, 
but results showed that white patients with perceived time constraints due to work preferred 
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home-based CR programs over hospital-based CR. In another study110, 106 MI patients in the 
United Kingdom (UK) were offered hospital-based CR or home-based CR with the Heart 
Manual. Overall, 47 (44%) chose the home-based program, and 41 (87%) completed it, while 35 
(33%) chose the hospital-based program and 17 (49%) completed it. There were no significant 
sex differences in program preferences. In the CHARMS trial with preference arms104, 45% of 
279 eligible patients expressed a preference for CR program model, with 57% choosing home-
based, and 43% choosing hospital-based CR, and no significant sex difference. Participation in 
home-based CR was 71% (with 75% completing at least 4 of 6 weeks of the Heart Manual) 
versus 87% for hospital-based CR. In the BRUM trial of 525 cardiac patients randomized to 
hospital-based or home-based CR again using the Heart Manual, patients in the home-based arm 
completed a significantly greater number of CR sessions than patients in the hospital-based arm 
(p<.001)105. Program adherence was not analyzed by sex. Overall, these results suggest male and 
female patients prefer home over hospital-based CR, and although evidence is mixed, that 
adherence might be greater in home than hospital-based programs. 
Women-Only Cardiac Rehabilitation 
 With the evidence of women’s benefit from CR participation, their under-utilization of 
CR, and differential CR needs and preferences, it is surprising that gender-specific CR programs 
or features are not more systematically discussed in practice guidelines, and have not been 
thoroughly evaluated. Where the Canadian guidelines are concerned, the only women-specific 
recommendation is that they should be provided with gender-tailored information3. 
Indeed, a recent review called into question whether contemporary CR programs are equally 
suited to men and women90, while the need to adapt CR services to suit women was highlighted 
in another review of interventions to increase CR adherence111. Fear and embarrassment is a 
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common concern voiced by women regarding exercise, especially among patients who are older 
and/or belong to certain ethno-cultural groups19. More specifically, women are often hesitant to 
exercise due to a lack of prior experience, low levels of ability, and self-consciousness of their 
body image112,113. Taking into account the barriers outlined above, women-only programs may 
encourage more women to attend CR. 
While a few gender-specific behaviour change programs to meet the needs of women 
following a cardiac event or procedure have been developed and evaluated (e.g., CHANGE114), 
there are only five comprehensive women-specific CR programs globally. This model of CR has 
not been defined and is operationalized in various ways; however, women-centered CR generally 
refers to the provision of exercise and/or educational sessions to women solely, and in a manner 
which is tailored to empirically ascertain the needs of women85. There is a women-only lower-
intensity exercise CR program established in Glasgow, Scotland, preliminary results of which 
reveal a 74% uptake by women post-MI (vs. 6% prior to program inception), although adherence 
was not reported115. Uptake may have been increased due to provision of exercise at a level 
which does not cause pain or fatigue, and also which does not impact women’s co-morbidities. 
In the US, Beckie and colleagues have developed a 3-month women-only CR program, 
consisting of 10 psycho-educational sessions, social support, and 36 on-site exercise sessions116. 
Adherence was greater in the women-specific group.  
There are 3 women-only CR programs in Canada to date. Canada’s first women-only 
comprehensive CR program was developed in 1996 to address women’s needs and preferences 
for care as identified in the literature97,117,118. The 6-month program offers weekly 2-hour 
women-only exercise and education sessions119. These sessions are offered in a gender-sensitive 
manner, with female-focused content and delivery120. Individual interviews and focus groups 
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with 100 female patients were used to develop the program, and its evidence is supportive. A 
retrospective review of 315 participants between 1996 and 2004 revealed 85% program 
adherence119. Second, the CR program in Hamilton, Ontario has instituted women-only exercise 
and education sessions, and uncontrolled preliminary analyses reveal significant increases in 
self-efficacy and emotional well-being, with 75.71±22.19% program adherence121. Finally, the 
Toronto Rehabilitation Institute (TRI) and Toronto Western Hospital (TWH) also currently offer 
a women-only CR program.  
 Overall, there is a paucity of data on the ability of alternative CR program models to meet 
women’s needs following a cardiac event. In Arthur’s review of the literature80, final research 
recommendations were for “more study … regarding different approaches to programming … 
which may be more suitable for women,” and “investigation of novel approaches to increasing 
women’s participation in CR”(p. 61D). 
RESEARCH OBJECTIVES 
There are no RCTs comparing women’s cardiac health behaviours across alternative CR 
program models. While Beckie’s recent work contributed to reducing this large knowledge gap, 
her study did not include a home-based program model, and the mixed-sex and women-only 
program model differed slightly in terms of content116. While this dissertation examines the 
subject area in a Canadian context, it also draws comparisons between traditional in-hospital 
mixed-sex CR and women-only CR, as well as home-based CR. Gender-specific CR programs or 
features are not discussed in Clinical Practice Guidelines, and have only recently been 
investigated85. 
The primary objective of the CR4HER study was to compare women’s program 
adherence across the 3 types of CR program models, to determine which program model results 
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in the greatest adherence. The secondary objectives were to compare women’s functional 
capacity and health behaviours, namely exercise, diet, medication adherence and smoking, by 
CR program model. 
Hypothesis 
CR program adherence will be significantly greater and functional capacity and health 
behaviours post-CR will be better in the women-only and home-based CR program models, 
compared to the traditional mixed-sex CR program model. 
CANDIDATE’S ROLE 
This trial was funded by a Heart and Stroke Foundation of Ontario grant from 2009-2013 
(Grant in Aid #NA 6682). There was a funded data manager, as well as other recruitment 
personnel that supported the conduct of this trial. 
The candidate was responsible for patient recruitment at 2 sites (TRI and SHSC) for 11 
months (September 2012-July 2013), including determining patient eligibility and obtaining 
informed consent; communication of patient referrals and program dates to sites and participants; 
communication with the SHSC Research Ethics Board; maintaining study binder and 
documentation; participant follow-up (phone and mail); clinical data extraction; and data entry 
(CRFs [Case Report Forms], pedometer logs, intake report forms, post-test surveys, and 
discharge report forms); and contributing knowledge transfer to academic, clinical and policy 
audiences. The candidate also performed the statistical analyses for the objectives herein. For the 
last year of the trial, the candidate also took on the role of study coordinator, during which time 
she was in charge of ethics renewals, amendments, and eventually terminations. The candidate 
also closed-out the trial, including ensuring that data will be stored in accordance with University 
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Health Network (UHN) standard operating procedures long-term, and updating the study status 
on clinicaltrials.gov. 
METHODOLOGY 
Design 
 This study (registered on clinicaltrials.gov [NCT01019135]) was part of a three parallel-
arm pragmatic randomized controlled trial using individual patient randomization, comparing the 
following CR program models: (1) mixed-sex traditional hospital-based CR (co-ed), (2) women-
only hospital-based CR, and (3) monitored home-based CR. Refer to the trial overview in Figure 
2.  
Setting 
 This was a multi-center study involving CR programs at TWH and TRI of the UHN, as 
well as Hamilton Health Sciences (HHS). These CR programs were within close geographic 
proximity to all recruitment sites that did not offer on-site CR programs (Toronto General 
Hospital [TGH], Mount Sinai Hospital [MSH], and Sunnybrook Health Sciences Centre 
[SHSC]), to rule out potential patient distance barriers to program adherence. Available 
supervised CR programs were offered twice per week for a duration of 4 months (TWH and 
HHS), or on a weekly basis for a duration of 6 months (TRI). Home-based programs were 
offered on a weekly basis, regardless of site. 
 All programs included the core components of CR as recommended by the Canadian 
Association of CR guidelines3. Patients participated in an intake assessment, including a full 
medical history, physical and medical examination, an exercise treadmill test and personalized 
orientation. All intake and discharge stress testing was done with patients taking their usual 
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medication, employing a modified Bruce protocol where possible122–125, however this depended 
on the functional capacity of the patients. 
 Exercise training was then individually prescribed for all patients. The type, frequency, 
intensity (based on stress test and ratings of perceived exertion), duration and rate of progression 
of aerobic exercise prescriptions were based on national guidelines3. Typically, female patients 
were encouraged to perform 30 to 60 minutes of walking, at an intensity corresponding to 60% 
of the peak heart rate achieved during baseline graded exercise testing and/or a perceived 
exertion rating of 11 (fairly light) to 13 (somewhat hard) at least 5 days/week126. In addition to 
exercise training, participants received education on CVD, risk factors and lifestyle modification 
(i.e., diet, medication, smoking, weight as applicable) guided by a multidisciplinary team. At 
TRI, education sessions were given on a weekly basis, while at TWH and HHS patients received 
a single “education day”.  
 The traditional hospital-based mixed-sex CR programs included on-site group exercise 
training sessions 1-2 days/week, as described above. Participants were encouraged to walk at 
home on alternate days of the week. Education sessions were also given in a group format. 
Similarly, in the women-only CR programs, participants engaged in on-site female-only group 
exercise sessions, as well as female-only group education sessions. In the monitored home-based 
programs, patients similarly attended an intake appointment where an exercise test was 
performed as the basis for exercise prescription. Patients were given written guidelines for 
aerobic conditioning based on their treadmill test. They were prescribed a walking regimen based 
on the parameters as outlined above, which produced an equivalent duration, mode, intensity and 
frequency of exercise as the hospital-based programs. While geographic and / or meteorological 
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factors were not accounted for, all patients received education on exercising in adverse weather 
conditions as well as directions to indoor walking locations throughout the area. 
Patients were cautioned about symptoms, and taught how to check their heart rate during 
walking sessions. In the event of a change in clinical status, patients were advised to defer 
exercise training and to contact the program staff. Patients were provided with reading materials 
regarding CVD, risk factors and lifestyle modification. These were discussed with an allied 
health professional from the home-based CR program by telephone during weekly scheduled 
telephone calls. The average call duration was approximately 15 minutes. These individual 
sessions were similar to the group education sessions as offered in the hospital-based programs. 
Procedure 
 The study protocol was submitted for approval by the research ethics boards at all 
participating institutions. The site recruiter then approached female cardiac inpatients at TGH, 
TWH, MSH, SHS, and SHSC to obtain informed consent, and screen for study eligibility. A 
person within the patient’s circle of care made the initial contact with the patient by introducing 
the study, and then asking for permission to have the recruiter approach them to discuss the 
study. Study recruiters explained the study in full and allowed the patient as much time as they 
wished to consider participating in the study. If the patient agreed to participate, both the patient 
and recruiter signed and dated 2 copies of the informed consent form (ICF [Appendices A-D]). 
One copy of the signed ICF was provided to the patient, and another was retained for the study. 
In the instance of SHSC, 3 copies were signed and the additional copy was placed in the patient’s 
chart. A note was also written in the patient’s chart stating that they had consented to participate 
in the study. 
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The site recruiter also contacted low-risk female patients already referred to cardiac 
rehabilitation (prior to starting the program and being assigned to a class) and previously 
identified by CR staff, as well as female patients at the TRI surgical outpatient clinic and early 
education class at TWH. These patients were provided or mailed 2 copies of the applicable 
consent form (1 to keep and 1 to return) and the survey, to be returned in a provided postage-paid 
envelope.  
Consenting and eligible patients were provided a baseline survey (Appendix E). In the 
event that the patient could not complete the baseline survey at the time of recruitment, a pre-
paid, pre-addressed envelope was provided to her, in order to return the survey in the mail in the 
days following. The recruiter followed-up with those participants who had not returned the 
baseline survey via phone and /or mail at 2 week intervals, until the patient informed the staff 
that she was not interested in completing the survey and would like to withdraw from the study, 
or 6 weeks had passed since the patient was approached and the patient hadn’t indicated they 
were working on survey completion.  
Clinical data was extracted from medical charts to the case report form (CRF [Appendix 
F]). Clinical data extracted from medical charts included name of cardiac specialist and general 
practitioner, disease severity indicators (i.e., Canadian Cardiovascular Society (CCS)127 and New 
York Heart Association (NYHA)128 class), comorbid conditions, prescribed cardiac medications, 
blood pressure, and lipid profile. This data was needed to complete CR referral, and to describe 
the sample. If all clinical data was not available in the hard-copy chart during hospitalization, 
electronic records were reviewed 2 weeks later to extract any missing data and to verify all data 
points. The supervisor verified study eligibility, and signed and dated the CRF. 
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For participants recruited as in-patients, physician clearance for referral was secured. 
Physician contact information was obtained from the College of Physicians and Surgeons of 
Ontario (CPSO) website (http://www.cpso.on.ca/docsearch/). The recruiter solicited approval for 
CR referral through the specialist or general practitioner by faxing or mailing the physician 
clearance form (Appendix G). In the instance of non-response, a telephone call was made to the 
physician and/or administrative assistant, and a hard copy of the clearance form was delivered in 
person to the physician’s office if necessary. Efforts were made to receive a response from the 
physicians up to 6 weeks post-patient discharge. If there was a discrepancy between GP and 
specialist responses regarding the clearance of the patient, attempts to clarify the reason for non-
approval were undertaken via phone. Unless the physician provided signed approval, the patient 
was considered ineligible for the study. If clearance was not received or provided by a physician 
by 6 weeks post-discharge, the recruiter contacted the patient via telephone to inform them that 
they were not eligible for the study. The patient was invited to re-visit CR referral with their 
physician, should their health status change in future. 
When the consent form was complete, clearance was received in the affirmative (as 
applicable), and when CRF data had been extracted demonstrating patients met 
inclusion/exclusion criteria, participants were randomized via the online randomize.net software 
(www.randomize.net129), assigned in blocks of 6, and stratified by cardiac condition 
(PCI/coronary artery disease (CAD) vs. CABG/valve vs. MI). When a patient was randomized 
the recruiter used online map software and patient home and CR site postal codes to determine 
which of the sites offering the assigned program model was closest to the patient’s home (or 
work if desired by the patient). Participants were allocated to the randomized program model at 
the closest site, at a maximum of 45 minutes travel time one-way. CR sites were informed of 
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program assignment, and the recruiter completed and submitted the corresponding CR referral 
form (Appendices H-J) for recruited inpatients. Because the recruiter was not an MD, “study 
coordinator” was entered where the MD was to sign for the referral, and the MD signature on the 
clearance form was attached.  
The recruiter called participants to inform them to which CR program they had been 
randomly allocated. Participants were informed that their referral information had been sent, 
which CR site they would be attending, and that a staff member from the CR program would be 
contacting them shortly with an intake appointment booking. Participants recruited as outpatients 
were allocated to attend the CR site to which they were referred. Participants were provided with 
enrollment appointment dates, location and CR contact information by the CR program. Due to 
the participatory nature of the study, participants and CR programs could not be blind to 
condition assignment. However, the CR staff conducting the assessments and recording them 
were unaware of the study objectives as to reduce any bias.  
Baseline assessments generally occurred in the first 4 weeks post-recruitment, and 
follow-up assessments generally occurred 6 months after the exercise start date at CR. The 
baseline survey to be completed prior to CR enrollment assessed baseline exercise behaviour, 
medication adherence, diet and smoking status. Surveys were only identifiable by a numeric 
research ID for blinding. Once physician clearance for CR was received, patients were mailed a 
Digi-Walker SW200 pedometer. Participants were asked to wear the pedometer for the 7 days 
prior to their CR intake appointment, and to record their daily total number of steps on an 
activity log that was mailed in to the study coordinator in a postage-paid and addressed envelope 
(Appendix K).  
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A recruiter extracted stress test results from the intake appointment, as well as lipid 
values, waist circumference, and blood pressure using the intake report form (Appendix L). 
Information extracted was directly entered online (in a password-protected file, on a secure UHN 
network via remote access) or was handwritten and couriered to the central site. However, the 
persons conducting the assessments and recording them for communication to the central study 
site were unaware of the study objectives, to mitigate the potential of bias.  
The post-test survey (Appendix M) was mailed to participants 6 months after starting 
their CR program, accompanied by a post-test survey cover letter (Appendix N). Considering 
they had consented and to retain trial integrity, any participants who became ineligible after 
randomization and referral to a CR program (e.g., had a subsequent cardiac event or 
hospitalization) were also mailed a post-test survey.  This survey again assessed self-reported 
exercise, medication, diet and smoking behaviour. Participants were also re-mailed a Digi-
Walker SW200 pedometer and activity log, along with an instruction sheet, and a postage paid 
return package. Response rate was optimized through repeated and personalized contacts. This 
included a replacement survey mailing with an appropriate cover letter (Appendix O), telephone 
calls and email (where possible).  
Program adherence, exit stress test and other outcome data was obtained from CR sites 
and recorded into a discharge report form (Appendix P). It was also entered into a password-
protected excel file from a shared drive within UHN Research Information Systems through 
remote access. 
Participants 
 Female in-patients with documented CAD, and/or ACS, and/or undergoing 
revascularization (e.g., CABG or PCI) and/or valve surgery (either percutaneous or open heart 
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repair or replacement) were approached at SHSC, MSH, HHS, and UHN when stable. These 
indications for inclusion were based on eligibility for CR3, evidence of benefit from CR, and 
prevalence among female patients. ACS diagnoses were confirmed based on indication in patient 
chart of detailed history, focused physical examination, diagnostic electrocardiogram changes 
(i.e., Q waves, and/or ST-T segment changes), and/or troponin levels above the 99th percentile of 
normal. Patients were not excluded from the study on the grounds of age.  
Inclusion Criteria 
 The following criteria had to be met: residency in Toronto (North to Highway 7, East to 
the far end of Scarborough, and West to Highway 427) or Hamilton (within 45 min travel time to 
HHS), proficiency in the English language, written approval to participate in CR by the patient’s 
cardiac specialist or general practitioner (in the case of inpatient recruitment), and eligibility for 
home-based CR (i.e., low to moderate risk as demonstrated by: [1] lack of complex ventricular 
dysrhythmia, [2] NYHA Class of 1 or 2, and left ventricular ejection fraction (LVEF) >40%, or 
[3] CCS Class 1 or 2).  
Exclusion Criteria 
 The following criteria could not apply: musculoskeletal, neuromuscular, visual, cognitive 
or non-dysphoric psychiatric condition, or any serious or terminal illness not otherwise specified 
which would preclude CR eligibility based on CR guidelines3 (most patients were expected to 
have co-morbid conditions, but given that exercise prescriptions are individually-tailored based 
on graded exercise testing, most patients would be eligible for CR); physician deemed patient not 
suitable for CR at time of intake exercise stress test (i.e., < 3 minutes completed on Bruce 
protocol treadmill stress test, or < 6 minutes on modified Bruce protocol treadmill stress test, or 
achieved a workload of < 300 kpm on a cycle ergometer test, or significant ST segment 
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depression, uncontrolled dysrhythmias, abnormal heart rate or blood pressure measurements in 
response to exercise); were planning to leave the area prior to the anticipated end of 
participation; were being discharged to a long-term care facility; previous participation in CR; 
participation in another clinical trial with behavioural interventions; and in the case of inpatient 
recruitment having been referred to a CR program by their healthcare provider before study 
randomization was completed.  
Measures 
 The baseline survey assessed correlates from each category of health care utilization from 
Andersen’s Behavioral Model of Health as they related to CR130,131. Sociodemographic 
characteristics such as age and social factors including education (Appendix E, Section N, Item 
6), marital status (Appendix E, Section N, Item 5), number and age of children (Appendix E, 
Section N, Item 3), and caregiving responsibilities assessed predisposing factors. Enabling 
factors were evaluated by inquiring about family resources such as income (see Appendix E, 
Section N, Item 7), as well as wait time to start CR. Need-based factors were reflected in survey 
items asking about clinically evaluated needs such as the presence or absence of cardiac risk 
factors. 
The constructs of gender and sex are important predisposing factors in Andersen’s model. 
The sample included only women, and this constitutes the sex of the sample. A validated gender 
assessment tool is the Bem Sex-Role Inventory132. Published in 1974, this instrument assesses 
how people identify themselves utilizing individuals' perceptions of gender roles, or the 
expectations about what are appropriate traits for either sex. Respondents answer sixty questions 
rated from one to seven (with one indicating never or almost never true, and seven indicating 
always or almost always true). Responses are categorized into one of four different gender 
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constructs: masculine, feminine, androgynous and undifferentiated. In this research however, 
items assessing gender more specific to the issue of CR utilization were developed. This 
included most importantly women’s caregiving roles and responsibilities. In the pre-test survey, 
see section N questions 2-4, and in the post-test survey sections B and section S question 4.  
Clinical data extracted from medical charts provided further need factors, including 
disease severity indicators (i.e., CCS127 and NYHA133 class), comorbid conditions, prescribed 
cardiac medications (i.e., name, dose and frequency), blood pressure, lipid profile, and left 
ventricular ejection fraction. This data was used to describe the sample, and for completion of 
program referral forms. 
Outcomes 
 The primary dependent variable of program adherence was assessed as follows: masked 
CR program staff members recorded the number of on-site or telephone sessions (in the case of 
home-based programs) prescribed and completed as per usual practice. A masked research 
assistant then extracted these data from the CR program charts to calculate adherence, where 
program adherence was defined as the number of on-site or phone sessions attended divided by 
the number of sessions prescribed. For patients who did not complete the program, whether the 
reason was clinical or not was denoted. Where the patient prematurely ended the program for 
clinical reasons, the date was documented and program adherence was also calculated based on 
participation to the clinical event. It was also ascertained whether the patient enrolled (defined as 
patient attendance at CR intake)134 and completed (defined as attending at least some of the CR 
intervention components and having a formal re-assessment by the CR team at the end) the 
program. 
28 
 
 The secondary outcomes were assessed pre- and post-CR. Functional capacity was 
operationalized as peak volume oxygen consumption per minute (VO2 peak) on the exercise 
stress tests, measured in mL.min-1. Exercise testing is a cardiovascular stress test using treadmill 
exercise with electrocardiogram and blood pressure monitoring, used to determine exercise 
capacity, assess the extent of coronary disease, estimate prognosis, and the effects of therapy 
such as CR. All patients underwent symptom-limited graded exercise testing assessed via a 
modified Bruce protocol122–125. This protocol has two 3-minute warm-up stages at 1.7mph and 
0% grade, and at 1.7mph and 5% grade. Stage 2 is 2.5mph at 12% grade (equivalent to 7 
metabolic equivalents [METs]). Stage 3 is 3.4mph at 14% grade (equivalent to 9 METs). Blood 
pressure, heart rate, and 12-lead electrocardiogram data were measured continuously throughout 
the test. Most assessments were done by direct measurement of oxygen uptake 
(CardioPulmonary Exercise Test; CPET) using a metabolic cart, with incremental data collected 
every 15 seconds. Where patients had CPETs done, VO2 was measured breath by breath, and the 
VO2 peak was defined as the averaged value of the three measurements taken in the last minute 
of exercise. As per ACC/AHA guidelines125, exercise testing was terminated in the presence of 
the following indications: a drop in systolic blood pressure of greater than 10mmHg from 
baseline despite an increase in workload, moderate to severe angina, increasing nervous system 
symptoms, signs of poor perfusion, sustained ventricular tachycardia, patient desire to stop, and 
ST elevations ≥1mm in leads without diagnostic Q waves (other than V1 or AVR). 
Exercise behavior was assessed via pedometer and self-report (i.e., Godin Leisure-Time 
Exercise Questionnaire [GLTEQ]135). With regard to the former, customary physical activity was 
measured by the Yamax Digi-Walker SW-200, which is a body-borne spring-levered pedometer. 
The SW-200 mechanical pedometer is the most widely-used research pedometer136–139, and has 
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been shown to be valid and reliable in a wide range of settings140–142. Pedometers were worn on 
belts, at the right hip. Participants were asked to wear the Digi-Walker pedometer provided for 7 
consecutive days before CR intake (from the time of waking up until the time of going to bed, 
while the fact that the pedometer could not be exposed to water was highlighted in the included 
instruction manual), and instructed to record the total number of steps taken per day in an 
activity log (Appendix K). One week following completion of the CR program, participants were 
asked to again wear the pedometer for 7 consecutive days, and record their total number of steps 
taken per day in an activity log. The average number of steps taken per day at pre-test and post-
test were computed. While 10,000 steps/day is generally considered indicative of an active 
lifestyle, this target may be too high for patients with chronic diseases143. As such, pedometer 
data were interpreted and scored using a pedometer index for patients with CVD, whereby 
6,500–8,500 steps/day are recommended to achieve the total amount of physical activity energy 
expenditure generally recommended for secondary prevention144.  
With regard to the latter, the GLTEQ 135 was administered in the pre- and post-test 
surveys. It is a brief and reliable instrument to assess usual leisure-time physical activity 
behaviour during a one-week period. For the first question, weekly frequencies of strenuous, 
moderate, and light activities were multiplied by nine, five, and three, respectively. Part two of 
the questionnaire calculated the frequency of weekly leisure-time activities pursued. Total 
weekly leisure activity was calculated by summing the products of the separate components, 
where higher scores indicated greater physical activity 135. The Canadian Physical Activity 
Guidelines 145 recommend that adults should accumulate at least 150 minutes of moderate- to 
vigorous-intensity aerobic physical activity per week. Using the GLTEQ formula for computing 
a weekly leisure-time activity score [(9 x Strenuous) + (5 x Moderate) + (3 x Mild)]135,146, this 
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level of exercise is equivalent to a starting score of 25 units 147. However, the Canadian Society 
for Exercise Physiology does not currently have a guideline for cardiac populations. The Core 
Components of Cardiac Rehabilitation 148 suggest that patients accumulate 30-60 minutes per 
day of moderate-intensity physical activity on at least 5 days of the week (a GLTEQ score of 25). 
On the other hand, a joint American Heart Association / American College of Cardiology 
statement for preventing heart attack and death in cardiac patients encourages a minimum of 30 
to 60 minutes of moderate-intensity activity, at least 3 or 4 times weekly 149 (a GLTEQ score of 
15 to 20). Thus, participants in the current study were characterized as ‘active’ if they reported 
meeting the mid-point of these guidelines (a GLTEQ score ≥20). The Godin scale provided 
information on the approximate intensity of physical activity in which participants engaged, 
which was not available from the pedometers.  
The pre- and post-test surveys also included the Diet Habit Survey150 to assess diet, an 
inexpensive, reliable, and valid instrument for rapid assessment of eating habits and diet 
composition. Its 39 questions assess the following diet categories: meat, fish, and poultry; dairy 
products and eggs; fats and oils; sweets and snacks; grains, beans, fruits, and vegetables; 
beverages; salt; restaurants and recipes; and seafood. Greater scores indicate better diets, both for 
the total score and for each area. The total score indicates the level of fat in the diet (with scores 
≥236 corresponding to a low-fat diet [20% or less]151). Specifically, CR education content 
encourages consumption of a low fat diet. 
Medication adherence was measured via a self-report list from bottles (categorized by 
type – i.e., statins, beta-blockers), as well as the 4-item Morisky Medication Adherence Scale 
(MMAS-4)152,153. The latter is scored as yes = 0, no = 1, such that a higher score indicates higher 
medication adherence. Patients scoring 2 or above can be considered adherent. 
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Finally, smoking habits were investigated via an investigator-generated and piloted item 
(smoking history; never smoked vs. currently smoke vs. quit smoking). Biochemical data from 
the 2007-2009 Canadian Health Measures Survey confirmed that self-reported smoking status 
provides an accurate estimate of the prevalence of cigarette smoking154. 
Statistical Analyses 
Preliminary Analyses 
 SPSS 22.0 was used for all analyses155.  Once the principal investigator was satisfied that 
all data had been collected, entered and thoroughly cleaned and screened, the randomization 
variable was merged into the SPSS data file, thereby unblinding the data set. For the primary 
outcome of program adherence, this data cleaning consisted of a random check of 5% of data 
points for number of sessions prescribed and attended against CR charts. If any errors were 
observed they were corrected and another 5% of the data points were checked. This was 
reiterated until no errors were observed. 
Retention rate was computed by recruitment site, by CR site, by program model to which 
participants were allocated, by program model which they attended, and by CR completion (yes / 
no). The number and percentage of participants who completed the program to which they were 
randomly allocated was also described.  
The time between CR completion (where applicable) and post-test survey completion 
was computed. Pearson’s correlations were performed to determine the association between the 
primary outcome measure and time from CR graduation to survey completion. Similarly, time 
elapsed (in days) between the first day wearing the post-test pedometer and the last day of CR in 
those who graduated was calculated. Pearson’s correlation between the time in days and the 
pedometer count was performed, to test whether this may have been an alternative explanation 
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for pedometer counts. Seasonal effects in the pedometer data were explored by comparing the 
mean steps in patients with pre- and post-test values in December through February as compared 
to other months of the year. Finally, association between the pedometer data and GLTEQ 135 
scores at each time point were calculated using Pearson’s correlations. Mean, standard deviation, 
and median time (in days) between completion of pre- and post-test surveys were also calculated, 
and compared by site.  
Overall adherence was compared by site as well as CR program model on a PP and as-
treated basis. CR program adherence was also compared between study participants recruited as 
in-patients versus those recruited as out-patients. Further, the relationship of program-reported 
versus patient self-reported program adherence was evaluated by Pearson’s correlations 
coefficients. Lastly, Pearson’s correlations and t-tests as appropriate were used to assess if CR 
program adherence was associated to predisposing, enabling, and/or need factors as per 
Andersen’s model63 (Figure 1).  
Respondent Characteristics 
First, the equivalence of participant baseline sociodemographic and clinical 
characteristics by program model was tested using analysis of variance (ANOVA) with post-hoc 
Least Significant Difference (LSD) tests, or chi-square analyses as appropriate. This served as a 
check of the randomization process. Second, retention rate was computed. Third, 
sociodemographic and clinical characteristics of retained participants versus those lost-to-follow-
up were compared to evaluate if there was a retention bias in the sample, using t-tests and chi-
square as appropriate. Baseline differences in characteristics of participants who did not 
complete CR for clinical versus non-clinical factors were tested in similar fashion. Finally, 
patient adherence to randomization was described. The number and percentage of patients who 
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attended the CR program to which they were referred, who attended the program model to which 
they were allocated, and who completed any program was described.  
Testing Objectives 
For the primary outcome of program-verified CR adherence, ANOVAs were performed, 
with program model as the independent variable and percentage of sessions completed as the 
dependent variable. For this analysis, statistical significance was defined by p<.05 (2-sided). 
These were performed on a “per protocol” (PP; i.e., by random allocation, where outcomes were 
ascertained) and “as-treated” basis (i.e., the CR model actually attended). Post-hoc LSD tests 
were used for multiple comparisons. 
With regard to functional capacity, first assessment of change from pre to post-test using 
paired t-tests was conducted, overall and by model. Change scores were also computed, and 
significant differences in these change scores were tested. To test the secondary objective, 
analysis of covariance (ANCOVA) was computed, with baseline VO2 peak, along with any 
differences in participant characteristics which impacted retention as covariates to the model. All 
tests were again performed on a PP and as-treated basis, with the same approach to post-hoc 
analyses as above. 
 In terms of health behaviors, first a pre-test descriptive examination of the number and 
percent of participants meeting Canadian Physical Activity Guidelines145 as assessed via 
pedometer and self-report was described, and those that met the cut-off to be considered 
“adherent” to medical therapy on the MMAS-4. Following categorization of medications 
reported by patients at both time points, the number and percentage of patients on each class of 
evidence-based pharmacotherapy was described. A descriptive examination of the Diet Habit 
Survey and its subscales, as well as those abstaining from tobacco use was also undertaken. 
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Second, assessment of change in health behaviours from pre to post-test using paired t-
tests was conducted. These analyses were as above conducted in the total sample, regardless of 
model and by model, on a PP and as-treated basis. Smoking behaviour entailed analyzing pre-
post differences in a dichotomous item, and was therefore assessed using McNemar's test.  
A descriptive examination of heart-health behaviors at post-test was then undertaken, 
particularly in relation to established thresholds. ANCOVAs were also computed for all the post-
test scores by program model, again on a PP and as-treated basis. Post-test scores served as the 
dependent variable, program model as the independent variable, and corresponding baseline 
scores along with any participant socio-demographic and clinical characteristics related to 
retention identified above as covariates.  
Testing Objectives - Enrollees Only 
In addition to running analyses in the cohorts previously outlined, ANOVAs (for CR 
program adherence) and paired t-tests (for functional capacity and health behaviours) were also 
undertaken in the sample of CR enrollees only (as they would not have 0% adherence, which 
may have influenced the outcomes of the tests). 
RESULTS 
Preliminary Results 
Routine data cleaning did not reveal any discrepancy in the number of sessions 
prescribed and attended when the patient database was checked against CR charts. However, 
several missing data values were discovered. While efforts were made to mitigate this, CR 
program attendance data was missing in 16 of the patients charts. 
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Overall, retention rates were as follows; 62 (36.7%) for the CPET, 55 (32.5%) for the 
pedometer, and 116 (68.6%) for the survey (see Tables 1-5). On the other hand, study 
participants recruited at TRI were more likely than those recruited at TGH, TWH, or HHSC to 
have a post-CR CPET (p=.0001). There were no differences in retention by CR recruitment site 
for the pedometer (p=.18) or the survey (p=.18). By CR site, participants attending CR at TRI 
were more likely than those at TWH or HHSC to have a post-CR CPET (p=.0001). Additionally, 
participants attending CR at HHSC were more likely than those at TWH to have a post-CR 
CPET (p=.0001). There were no differences in retention by CR site for the pedometer (p=.19) or 
the survey (p=.44), and no differences in retention by CR program model (PP [CPET, p=.96; 
pedometer, p=.32; survey, p=.80]).  
There were, however, differences in retention by CR program model on an as-treated 
basis (p=.0001), predictably with participants attending any CR model being more likely than 
those who did not start CR to have a post-CR CPET. As well, participants attending mixed-sex 
CR were more likely than those attending women-only CR or home-based CR to have a CPET, 
while participants attending women-only CR were more likely to do so than those attending 
home-based CR. There were no differences in retention by CR program model (as-treated) for 
the pedometer (p=.33) or the survey (p=.62). Lastly, there were differences in retention by CR 
completion for all three post-program components. Women completing CR were of course more 
likely to have a CPET (p=.0001), but were also more likely to return a pedometer (p=.008) and 
to return a survey (p=.0001). 
Sixty-nine (51.5%) participants completed the program to which they were randomly 
allocated. An additional 27 (20.1%) participants completed the CR program, but switched to 
another CR program model. 
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Mean time between CR completion and post-test survey completion was 41.34±81.32 
days (median=32.0). There was a positive correlation between CR adherence and time from CR 
graduation to survey completion (Pearson’s r=.32, p=0.01). Among those who graduated CR, 
mean time elapsed between the first day wearing the post-test pedometer and the last day of CR 
was 29.07±41.13 days (median=29.1). There was no correlation between the time in days and the 
pedometer count (p=.068). Women who wore the pre-program pedometer during the winter 
(December through February) attained fewer mean daily steps (4062±2389) than those who wore 
the pre-program pedometer at other times (6053±2894; p=.012). Such differences were not 
observed, however, among women post-program (p=.28). There was no significant correlation 
between the pedometer data and GLTEQ 135 scores at pre-program (p=.95). At post-program, 
meanwhile, there was a positive correlation between the two outcomes (Pearson’s r=.41, 
p=0.003).  
There were no differences in adherence by site overall (p=0.19), nor by CR program 
model on a PP (women-only, p=0.19; mixed-sex, p=0.34; home-based, p=0.17) or an as-treated 
basis (women-only, p=0.24, mixed-sex, p=0.17, home-based, p=0.16). There was no difference 
in CR program adherence between study participants who had been recruited as in-patients 
versus those recruited as out-patients (p=.70; Figure 3). Participants self-reported a high degree 
of CR program adherence (84.53±27.18%, median=98.5%). There was no difference in self-
reported CR adherence by CR program model on a PP (p=.85) or an as-treated (p=.14) basis. 
There was a positive correlation between program and patient-report of CR program adherence 
(Pearson’s r=.61, p=0.0001).  
A need factor (Indication for CR = Valve, p=.009), was significantly associated with CR 
program adherence. There was also a trend towards CR program adherence being associated with 
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predisposing factors (age, p=.062; caregiving, p=.052). There were no significant associations 
between CR program adherence and any other predisposing, enabling, or need factors (ps>.05). 
Respondent Characteristics 
A diagram of study flow is shown in Figure 4. A total of 2016 patients were approached, 
of which 739 (36.7%) declined to participate, mainly due to wanting to attend the CR model of 
their choice. Overall, 264 patients consented, of which 169/264 (64.0%) eligible patients were 
randomized.  One hundred thirty-three of the 169 (78.7%) completed a pre-CR stress test (of 
which n=107/143 or 74.8% were CPETs). Furthermore, of the 169, 144 (85.2%) completed the 
pre-CR survey and 66 (39.1%) remitted a pre-CR pedometer log. 
Table 6 displays the socio-demographic and clinical characteristics of participants by 
randomized model. There were no significant differences between patients randomized to each 
of the three models.  
Through chart extraction, CR enrollment was ascertained for 164/169 (97.0%) 
participants. Overall, 20/169 (11.8%) did not attend CR even once for an intake assessment 
despite referral (“did not enroll”), and an additional 7/169 (4.1%) patients did not initiate the 
program following intake (Figure 4 – Allocation “did not attend”). Forty-three of the 169 
(25.4%) attended a different model than the program to which they were randomly-allocated 
(Figure 4 – Allocation “did not receive allocated intervention”). The model to which these 
participants switched and reasons are reported elsewhere96, and form the basis for the as-treated 
analyses. There were no differences in CR enrollment on a PP basis (p=.55). 
Ninety-six of the 169 (56.8%) participants completed their CR program. Six of the 169 
(3.6%) patients did not complete CR for medical reasons. They were significantly less likely to 
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live with someone requiring caregiving (p=.02) and less likely to have hypertension (p=.009) 
than the 19 patients who did not complete CR for non-clinical reasons. No other socio-
demographic or clinical differences between these groups were observed (Table 7). 
Of the 96 patients who completed their CR program, 62 (64.6%) had an exit CPET, while 
58 (60.4%) had both a pre and post-CR CPET. Table 8 displays the socio-demographic and 
clinical characteristics of participants who completed an exit CPET (retained) versus those who 
did not. Patients who completed an exit CPET had lower incidence of MI, dyslipidemia, 
musculoskeletal impairment, lower resting heart rate at CR intake, smaller waist circumference 
at CR intake, and higher CR adherence than those who did not.  
The response rate for the post-CR survey was 68.6% (116 participants), while 105 
(62.1%) had both a pre and post-CR survey. Table 9 displays the socio-demographic and clinical 
characteristics of participants who completed a post-CR survey (retained) versus those who did 
not. As shown, retained participants were significantly older, less likely to provide care to 
someone in their household, and had higher CR adherence than those lost to follow-up.  
The response rate for the post-CR pedometer log was 32.5% (55 participants), while 38 
(22.5%) had both a pre and post-CR pedometer log. The socio-demographic and clinical 
characteristics of the 55 (32.5%) participants who remitted a post-CR pedometer log (retained; 
Table 10) versus those who did not were also compared. Participants who wore a pedometer 
post-CR were older (p=.017), had higher intake VO2 peak (p=.024), and had higher CR 
adherence (p=.003) than participants who did not. No other differences in socio-demographic or 
clinical characteristics were observed. 
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Primary Outcome – Cardiac Rehabilitation Program Adherence 
Overall, the mean number of sessions prescribed was 23.03±14.66 (median=24.00). The 
mean number of sessions prescribed did not differ by randomized model (p=.12). The mean 
number of sessions attended was 14.05±11.00 (median=15.00). The mean percentage of 
prescribed sessions attended was 54.46±35.14% overall (regardless of program model). 
Participants who did not enroll in CR post-referral effectively had 0% adherence; removing these 
participants provides a truer indication of program adherence. Among all participants who 
enrolled, the mean percentage of prescribed sessions attended was 63.60±29.29%.   
Among the 6 patients who did not complete CR for medical reasons, the percentage of 
prescribed sessions attended until the date of their adverse clinical event was 58.96±25.13%. A 
new adherence outcome variable was computed, such that for participants who did not drop out 
for clinical reasons adherence was based on the number of prescribed sessions attended to those 
prescribed, and for patients who did drop out for clinical reasons, adherence was based on the 
number of sessions attended to those prescribed to the date of the clinical event.  This variable 
was used for the analyses below. 
With regard to the primary objective, there were no significant differences in the 
percentage of CR sessions attended by randomized model (PP; Figure 5a; p=.63, observed 
power=.12). However, there was a significant difference in the as-treated analysis (Figure 5b; 
overall model p<.001, observed power=1.00), with participants who did not initiate CR 
obviously adhering to significantly fewer sessions than those who initiated any other program 
(post-hoc LSD test p=.001), but also with home-based CR participants attending a higher 
percentage of sessions than women-only participants (Figure 5b; post-hoc LSD test p=.03).  
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Secondary Outcome – Functional Capacity 
In the overall sample, participants achieved a significant increase in functional capacity 
from pre- to post-program (Table 11). As shown, paired t-tests revealed there was a significant 
increase in VO2 peak across all 3 models over time when considered on a PP and as-treated 
basis, except in the home-based group for the as-treated analysis, where the increase was not 
significant. The degree of change did not differ by model (p=.78 PP, p=.97 as-treated).  
An ANCOVA adjusted for pre-CR values and confounding retention variables; there 
were too many variables to adjust for given 58 pts with both pre- and post-CR CPETs, and 
therefore dyslipidemia, musculoskeletal impairment, resting heart rate, and waist circumference 
were included. There were no significant differences in functional capacity at CR exit by 
program model in the PP analysis (Figure 6a; p=.84, observed power=.74). However, there were 
significant differences in functional capacity in the adjusted as-treated analysis, with women 
attending a mixed-sex program achieving higher functional capacity at CR exit than women who 
attended a home-based program (Figure 6b; overall model p=.046, observed power=.60, with 
post-hoc LSD test p=.025). 
Secondary Outcome – Heart-Health Behaviours 
Prior to CR, 25/66 (37.9%) participants were sufficiently active (i.e., met the 6,500 
step/day guideline144), 63/135 (46.7%) were ‘active’ as per self-report (i.e., Godin scores ≥20135), 
18/140 (12.9%) consumed reduced-fat diets (i.e., total Diet Habit survey score ≥236, 
corresponding to a 20% or less fat diet150), and 114/116 (98.3%) were adherent to their 
medications (i.e., MMAS-4 score ≥2152,153). The categories of medications most often reported 
by patients at both time points were lipid lowering statins (pre-CR 81.3%; post-CR 78.8%), ASA 
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– Aspirin (79.9%; 73.7%), and beta-blockers (68.7%; 63.2%) (Table 12). Diet Habit Survey 
scores by category are listed in Table 13. Finally, 129/138 (93.5%) were non-smokers. 
Regardless of model, there was a significant pre-post CR increase in self-reported 
physical activity (Table 14). In terms of the Diet Habit Survey subscale scores (Table 13), there 
was a significant improvement in salt intake (from 16.52±4.41 to 17.63±5.08; p=.013) and a 
significant worsening in “Restaurants and Recipes” (from 35.62±4.24 to 34.13±5.76; p=.013; 
indicating participants made fewer low-fat choices when eating in restaurants and/or cooking). 
No other changes were observed.  
Post-CR, 22/55 (40.0%) met the 6,500 step/day guideline, 78/108 (72.2%) were active as 
per self-report, 14/115 participants (12.2%) consumed 20% or lower fat diets, and 113/116 
(97.4%) were adherent to their medications. Finally, 109/116 (94.0%) were non-smokers.  
As also shown in Table 14, by program model, paired t-tests revealed an increase in self-
reported physical activity among participants randomized to mixed-sex and women-only CR pre 
to post-CR (PP; p=.002 and p=.001, respectively). Significant increases in self-reported physical 
activity among participants attending mixed-sex (as-treated; p=.014) and women-only CR (as-
treated; p=.001), and significant increases in total Diet Habit Survey scores among participants 
attending women-only CR (as-treated; p=.039) were also observed. In terms of the diet subscale 
scores, there was a significant improvement in “Seafood” among women randomized to home-
based CR (PP; from 6.75±2.20 to 7.63±1.75; p=.002) and in “Salt” among women randomized to 
mixed-sex CR (PP; from 16.56±4.67 to 18.14±5.22; p=.043). There was also a significant 
improvement in “Salt” among women attending mixed-sex CR (as-treated; from 17.08±4.53 to 
18.59±5.43; p=.038) and in “Seafood” among women attending home-based CR (as-treated; 
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from 6.71±2.17 to 7.40±2.06; p=.038), and a significant decline in “Restaurants and Recipes” 
among women attending mixed-sex CR (as-treated; from 36.44±4.31 to 34.23±6.27; p=.028). No 
other differences were observed. McNemar's test revealed no significant differences in smoking 
by randomized CR program model (PP) or attended model (as-treated). 
ANCOVAs adjusting for pre-CR values and confounding retention variables were 
computed to test for significant differences in post-test health behavior scores by program model, 
on a PP and as-treated basis. No differences by program model were observed (Figures 7a-10b). 
Testing Objectives - Enrollees Only 
When an ANOVA for CR program adherence was undertaken in the sample of CR 
enrollees only, there was still no significant difference by randomized CR program (Figure 11; 
p=.52). Note that an ANOVA was not conducted on an as-treated basis, as an ANOVA using 
enrollees only would have generated the same results as one using the whole participant 
population since non-enrollees would have been among the group that did not start CR. In the 
sample of enrollees only, paired t-tests for pre to post-CR functional capacity and health 
behaviours resulted in slightly different values than when using the entire participant population. 
However, the same trends were observed in the data; in the sample regardless of CR program 
model, participants achieved a significant increase in functional capacity from pre to post-
program (Table 15), and as before, there was a significant increase in VO2 peak across all 3 CR 
program models over time. Similarly, regardless of model, there was a significant increase in 
self-reported physical activity. As also shown in Table 15, by CR program model, paired t-tests 
revealed an increase in self-reported physical activity among participants randomized to mixed-
sex and women-only CR pre to post-CR. Again, as-treated analyses were not done using only 
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enrollees as these would have been redundant with the as-treated analyses using the full 
participant sample. 
DISCUSSION 
This was the first study to have investigated women’s CR program adherence, functional 
capacity, and health behaviours following the 3 most-available CR program models. Significant 
seasonal differences in daily steps were observed prior to CR, yet not following CR. The 
education that CR patients receive includes a module on exercising in adverse weather 
conditions. Furthermore, CR programs provide patients with directions to indoor walking 
locations (most often shopping centers). This finding may indicate that these education strategies 
are effective. Note that it remains unknown whether similar results would be maintained in the 
long-term. Existing research suggests that at 6 months following CR, only 30%–60% of patients 
report regular exercise 156–158. However, the post-CR pedometer results from the CR4HER study 
are on average less than a month following CR. Similarly, prior to CR the pedometer data and 
the self-reported activity scores were not correlated, while at post-program the two measures 
were positively related. Although results herein suggest that women may have been over-
estimating their physical activity even at post-test, it is possible that this may have been 
occurring to a lesser degree post-CR, potentially due to women being better educated where 
physical activity is concerned, or possibly paying more attention and actually measuring. 
All the CR programs that were offered in this study were based on the Canadian 
Association of Cardiovascular Prevention and Rehabilitation guideline model of care3, basing 
their exercise prescriptions on an exercise test, and offering multidisciplinary, comprehensive 
cardiovascular care. However this was a pragmatic trial, wherein there were some inherent 
differences between CR programs which could not be controlled for (including program site, 
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timing of the classes, etc). In spite of these variations, there were no differences in overall CR 
program adherence by CR site either on a PP or an as-treated basis. 
Surprisingly, there was no difference in CR program adherence between study 
participants who had been recruited as in-patients versus those recruited as out-patients. It is 
known that physician endorsement is related to significantly greater patient participation in 
CR159, thus greater CR program adherence among patients who had been recruited to the study 
after being cleared for and referred to CR via their physician or cardiac specialist was expected. 
At the same time, however, it has also been shown that female patients perceive significantly 
lower physician endorsement for CR 160,161. Unfortunately, this may explain the lack of 
difference in CR program adherence in outpatient study recruits.  
There was a significant association between CR program adherence and a need factor, as 
per Andersen’s model. Although not significant, two predisposing factors also showed a trend 
towards association to CR program adherence; age and caregiving, which have previously been 
proposed as barriers to women’s CR participation 56. In the case of CR program adherence, 
Andersen’s model is perhaps only moderately explanatory, and could potentially be 
supplemented with another framework to further explain women’s CR program adherence. 
Primary Outcome – Cardiac Rehabilitation Program Adherence 
Women adhered moderately to all the CR models; contrary to the initial hypothesis and 
the trial by Beckie et al.116, there were no significant differences by randomized model (PP). On 
an as-treated basis, participants who attended home-based CR had significantly higher program 
adherence rates than those who attended women-only CR. However, many women did not attend 
a home-based program despite allocation, and adherence was to phone calls only, thus higher 
rates of adherence to this model should be interpreted with caution. Where cross-over was 
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concerned, unfortunately model switching does occur in trials. Patients were randomized, and 
when they learned of the availability of other models and other times for sessions at the site, they 
sometimes asked program staff to switch. Ethically, this could not be prevented or reversed. As 
previously reported, a semi-structured telephone interview was conducted with the participants 
who attended a different CR model 96. The items assessed reasons for switching from the model 
to which they were initially randomized, through a series of closed and open-ended questions. 
Participants most frequently switched to a supervised CR model due to the preference for on-site 
facilities and due to a perception that they could thereby reap greater health benefits.  
High adherence to CR results in reduced morbidity and mortality for heart patients. Alter 
et al. recently described a 4% decrease in the predicted probability of death or hospitalization 
two years post-CR with each 10% increase in on-site attendance162. Martin et al. also reported a 
1% decrease in mortality with each additional session attended163.  Specifically among women, 
Colbert et al. recently found a 64% relative risk reduction in mortality in CR completers2. It was 
hoped the present study would identify a model in which women would be more likely to 
participate. Promoting wider availability of a program model found to be most attractive to 
women would represent an important and relatively simple means to improve women’s meagre 
participation in CR. Clearly, other means to improve women’s adherence to CR than program 
model choice are warranted.  In a recent update to the Cochrane review on interventions to 
promote greater CR adherence, three of eight studies demonstrated improvement in adherence to 
CR164. Successful interventions included: self-monitoring of activity, action planning, and 
tailored counselling by CR staff. Many of these strategies were employed in the women-only CR 
arm of Beckie et al.’s trial116,165 (although not herein), and indeed they showed greater program 
46 
 
adherence among women compared to those in mixed-sex CR, thereby suggesting that more 
tailored CR models are needed in order to address hard to reach populations.  
Secondary Outcome – Functional Capacity 
Program model allocation had no association with functional capacity, yet attended 
program model (as-treated) did influence functional capacity at program exit. Contrary to Beckie 
et al.’s findings116, women who attended mixed-sex CR had significantly higher functional 
capacity at program exit than those attending home-based CR. This could be due to staff 
encouragement of patients to exercise at their target heart rate for the full prescribed duration in 
supervised settings. 
Overall (in the whole patient sample, regardless of CR model), functional capacity was 
significantly improved at CR exit. This overall increase was roughly half of what has previously 
been reported among women completing CR (2.89 mL.min-1, or 0.83 metabolic equivalents, as 
opposed to 1.65 metabolic equivalents) 166. Increased functional capacity is also associated with 
a lower mortality rate167. A one MET increase in aerobic capacity equates to 13 and 15% 
decreases in all-cause mortality62 and cardiovascular events, respectively168. This magnitude of 
improvement was observed on average, except among home-based CR participants. It was 
curious that home-based participants tended toward greater program adherence (as-treated only) 
but had fewer gains in functional capacity. This was likely due to the fact that women had to 
adhere to a call only and not make a visit on site, and they may have exercised at a lower 
intensity as they were not supervised. It may be concluded that home-based CR is of no 
particular advantage for women, and that instead mixed-sex may be advantageous. However, 
replication is warranted as the latter conclusion was based on as-treated analyses. 
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Secondary Outcome – Heart-Health Behaviours 
Improvements in self-reported physical activity were observed with participation in 
supervised CR models (i.e., mixed-sex and women-only). While there were no significant 
changes in self-reported physical activity among home-based participants, their pre-CR self-
reported physical activity was almost as high as the post-CR physical activity reported by the 
mixed-sex and women-only participants. Overall, the hypotheses regarding better behavioural 
outcomes following women-only CR were not supported. However, on an unadjusted basis, 
dietary improvements were only observed in women attending women-only CR. Taken as a 
whole, the findings herein suggest that behavioural outcomes were largely equivalent regardless 
of program model.  
Women were consistently adherent to their medications, mainly non-smoking, and 
reported consuming roughly 25% of their calories from dietary fat. Lack of observed change or 
model differences in the former two health behaviours may be explained by a ceiling effect. On 
the other hand, an increase in self-reported physical activity was reported by patients attending 
supervised CR models, but well less than half were meeting the guideline post-CR when 
measured objectively via pedometer logs. While there were no program model-related 
differences in health behaviours in the adjusted analyses, women who did not attend CR did not 
realize any significant improvements in health behaviours. This is in line with previous research 
showing that women benefit when they do participate in CR19.  
Knowledge Transfer 
Knowledge transfer activities for CR4HER were focused on several end-users: scientists 
and clinicians. With regard to the former, traditional academic dissemination occurred via 
various conference abstracts both in locally in Toronto (e.g., Canadian Association of 
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Cardiovascular Prevention and Rehabilitation Symposium, American Psychological Association 
Convention) and internationally (e.g. American Heart Association Scientific Sessions; Chicago, 
U.S.A.). Two manuscripts based on the data presented herein have also been accepted to high 
impact peer-reviewed journals for publication.  
Where clinicians were concerned, debriefing meetings were offered to staff at the patient 
recruitment sites involved in the study. A debriefing letter was also e-mailed to all the 
recruitment sites. It was initially hoped that results could have been used to promote greater 
physician referral of women to CR programs which result in the greatest adherence, and 
refinements of the CR program models examined herein. Yet as the study was under-powered, 
they cannot be used to inform clinical practice or policy.  
In terms of citizen engagement, debriefing letters were mailed to participants regarding 
study results169. As the study was inconclusive, it was not thought possible to do media releases 
in order to ensure reach to a wide audience of Canadians, as was planned at the onset of the 
study.  
Implications 
The present trial was designed to test whether participation in women-only CR results in 
improved program adherence, functional capacity, and health behaviours among women when 
compared to participation in other commonly-available models. While it was hypothesized that 
patients would be more engaged in women-only CR, and hence have better adherence, functional 
capacity, and heart-health behaviours, it may be concluded that no CR program model was of 
particular advantage for women. Instead, promoting greater use of CR among women170 and 
wider availability of motivationally-focused CR programs as implemented by Beckie et al.116 
may represent important means to improve women’s cardiac outcomes. Another key implication 
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of this trial was that although women perceived they increased their physical activity with CR 
participation, they were well below guideline recommendations for physical activity. Strategies 
to promote greater exercise among women should therefore be implemented. 
Limitations 
 Caution is warranted when interpreting these findings. First, there may be selection bias, 
particularly given the low response rate. Women who consented to participate may have been 
more willing to attend CR and/or may have been more motivated to exercise and/or may have 
been doing better pre-CR than those who did not. However, emerging evidence suggests 
nonresponse bias may be less impactful than previously thought171.  
Second, while we achieved quite fulsome ascertainment of the primary objective, the 
secondary outcomes were assessed in a smaller proportion of the sample. In particular, functional 
capacity and mean daily steps were only evaluated in less than half of the sample, as perhaps the 
study requirements were too demanding of participants’ time and effort. Indeed “high protocol 
burden and extensive time commitments” have previously been reported as a significant barrier 
to study participation by women 172; factors not unlike those that also prevent women from 
participating in CR. Some retention bias was also noted, which limits the credibility and 
generalizability of the findings. However, the models were adjusted by these factors to mitigate 
this threat. Furthermore, it would only be expected to observe differences in functional capacity 
among patients who participate in CR, lending credence to the findings herein.  
Third, the pilot study suggested a 45% recruitment rate and an 80% retention rate, 
meaning 725 women would need to be approached in order to end up with 261 participants at 
post-test. Yet, due to recruitment challenges, which have also been reported in other RCTs of 
women and CR172, this target sample size to adequately test the primary outcome was not 
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reached. It was unfortunately not possible to extend the recruitment period, as research funds had 
run out prior to reaching the target number. Post-hoc analysis of power suggested the sample size 
was lacking for the PP analysis. Therefore, due to the possibility of Type II error, caution is 
warranted in concluding that women’s participation in alternate program models will not result 
in improved adherence. Similarly, testing differences in functional capacity and health 
behaviours was a pre-specified secondary outcome for the trial. However, power calculations for 
these outcomes were not undertaken a priori. Therefore, the lack of significant effects in the 
adjusted models may be due to the lack of power.  
Fourth, the operationalization of program adherence was different in the home-based arm 
(phone calls vs. on-site visits) leading to assessment bias. Fifth, while the content of the 
education sessions was consistent across sites and model arms as per clinical practice 
guidelines173, the delivery method differed (i.e., in-person for the mixed-sex and women-only 
arms vs. printed material for the home-based arm). Indeed, CR includes multiple components, 
and as this trial was pragmatic in design, differences in the delivery of these components may 
have contributed to differences in CR program adherence, functional capacity, and health 
behaviours observed. While explanatory trials evaluate how an intervention works under ideal 
conditions, pragmatic trials take into account the realities of broad routine clinical practice and 
are designed to test interventions in the full spectrum of everyday clinical settings in order to 
maximize applicability and generalizability174,175. Yet because pragmatic trials aim towards 
maximal heterogeneity (in treatments, clinical settings, etc.), these studies must be large enough 
as to overcome the inherited heterogeneity which may lead to a dilution of the effect.  
Sixth, similar to previous studies, we found significant gains in self-reported physical 
activity pre to post-CR in patients that attended supervised CR176; however, no significant gains 
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in mean daily steps walked using objective assessment were observed. This discrepancy was 
likely due to women over-estimating their physical activity. Furthermore, only a small group of 
patients returned both the pre and post-test pedometers. Future research is needed to robustly test 
the impact of CR program model on objectively-assessed physical activity among women (i.e., 
via accelerometers). Finally, generalizability of these findings is limited to women suitable for 
unsupervised exercise, and receiving care in a healthcare system where CR services are 
reimbursed. 
Future Directions 
CR4HER was a seminal trial, as it was the first to address the gap in knowledge about 
women’s CR program adherence, functional capacity, and health behaviours following non-
mixed-sex or non-hospital based CR. Although under-powered, the study did subsequently raise 
several questions that now warrant future research. Calculations based on a pilot study suggested 
a sample size of 261 patients was needed to detect a difference in adherence by CR program 
model at 80% power at the 5% significance level, yet this target was not achieved. Indeed, 
recruiting challenges in trials involving women and older adults have been previously 
documented 172. It may be tempting to suggest that the study be replicated, potentially with a 
longer recruitment period in order to achieve fulsome sample. However, due to all the cross-over 
that was observed post-randomization 96, it may be more feasible to modify the trial design. 
Instead of a three-arm RCT, it may be more reasonable to conduct a trial with preference arms 
only including mixed-sex and women-only CR programs. Although random assignment has long 
been held as the gold standard in clinical trials, there exists the possibility that such an allocation 
process may not agree with the patient’s preferences for the intervention or treatment. It is 
possible that patients may resent not receiving their treatment of choice, which may lead to non-
52 
 
adherence to treatment. Patient preference arms are an alternate trial design whereby patients 
with no treatment preference are randomly allocated as usual, but patients expressing a treatment 
preference are allocated to receive their preferred treatment 177. Indeed, a randomized study of 
CR that included patient preference was successfully conducted in order to compare the clinical 
effectiveness of home-based CR versus hospital-based CR 104. Calculations for 80% power at the 
5% significance level suggest that 126 study participants would be required for such a two-armed 
CR4HER follow-up study, which is an achievable sample size.  
Regardless of the CR site in the CR4HER study, women-only CR programs were 
generally offered on a more restricted schedule than mixed-sex CR classes. Given that 
inconvenient program time has been shown to be a factor affecting the CR participation of 
women,178 any type of study replication should be carried out with a wider availability of 
women-only CR classes.  
Lastly, as CPETs were coordinated by the CR staff, rather than study personnel, study 
participants who did not enrol in CR or who did not complete CR did not have a pre-CR CPET 
or a post-program CPET performed, respectively. In fact, out of the 169 study participants, only 
58 had both a pre and post-program CPETs done. While budgetary considerations would have to 
be accounted for, and though there may still be a certain degree of patients lost to follow up, it 
would be beneficial if any future study evaluated the functional capacity of all study participants 
at post-CR, even if they were non-completers. As such, resulting data may give a truer sense of 
the degree of improvement in functional capacity. 
CONCLUSION 
Results do not clearly favour any single model, but instead demonstrate women achieve 
clinically and statistically significant increases in functional capacity with any CR participation. 
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Overall however, women only attended half of prescribed exercise sessions. While diet improved 
with women-only CR participation, and physical activity with supervised CR participation, 
overall adjusted results of this trial suggest that women’s outcomes are largely equivalent 
regardless of participation in women-only, mixed-sex or home-based CR. Although the initial 
hypotheses regarding the three CR program models were not proven, CR4HER still added to the 
knowledge gap where women and CR is concerned. Taken as a whole, study findings suggest 
that rather than promote different CR models with the same program content, more tailored CR 
models are needed in order to adequately reach women. Overall then, further research is needed 
on the utility of personalized program models for promoting greater CR engagement among 
women, including proven strategies such as self-monitoring, action planning and tailored 
counselling. 
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TABLES 
Table 1. Retention Rates by Study Recruitment Site  
 CPET Pedometer Survey 
TGH 9 (17.3%)  22 (42.3%) 39 (75.0%) n=52 (30.8%) 
TWH 4 (26.7%) 3 (20.0%) 11 (73.3%) n=15 (8.9%) 
SBH 0 (0.0%) 0 (0.0%) 0 (0.0%) n=2 (1.2%) 
TRI 43 (65.2%) 18 (27.3%)   41 (62.1%) n=66 (39.1%) 
HHSC 6 (18.2%) 12 (36.4%) 24 (72.7%) n=33 (19.5%) 
Advertisement 0 (0.0%) 0 (0.0%) 1 (100.0%) n=1 (0.6%) 
Total 62 (36.7%)*** 55 (32.5%) 116 (68.6%) n=169 
Differences in retention by study recruitment site were tested using chi-square; *p<.05; **p<.01; ***p<.001 
CPET (CardioPulmonary Exercise Test); TGH (Toronto Genera Hospital); TWH (Toronto Western Hospital); SBH 
(Sunnybrook Hospital); TRI (Toronto Rehabilitation Institute); HHSC (Hamilton Health Science Centre) 
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Table 2. Retention Rates by CR Site 
 CPET Pedometer Survey 
TWH 0 (0.0%) 18 (41.9%) 32 (74.4%) n=43 (25.4%) 
TRI 56 (60.2%) 25 (26.9%) 60 (64.5%) n=93 (55.0%) 
HHSC 6 (18.2%) 12 (36.4%) 24 (72.7%) n=33 (19.5%) 
Total 62 (36.7%)*** 55 (32.5%) 116 (68.6%) n=169 
Differences in retention by CR site were tested using chi-square; *p<.05; **p<.01; ***p<.001 
CPET (CardioPulmonary Exercise Test); TWH (Toronto Western Hospital); TRI (Toronto Rehabilitation Institute); 
HHSC (Hamilton Health Science Centre) 
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Table 3. Retention Rates by CR Program Model (PP) 
 CPET Pedometer Survey 
Women-only 21 (38.2%) 21 (38.2%) 38 (69.1%) n=55 (32.5%) 
Mixed-sex 21 (35.6%) 15 (25.4%) 42 (71.2%) n=59 (34.9%) 
Home-based 20 (36.4%) 19 (34.5%) 36 (65.5%) n=55 (32.5%) 
Total 62 (36.7%) 55 (32.5%) 116 (68.6%) n=169 
Differences in retention by CR program model were tested using chi-square; all ps>.05 
PP (per protocol); CPET (CardioPulmonary Exercise Test) 
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Table 4. Retention Rates by CR Program Model (As-Treated) 
 CPET Pedometer Survey 
Women-only 16 (35.6%) 16 (35.6%) 30 (66.7%) n=45 (26.6%) 
Mixed-sex 39 (55.7%) 21 (30.0%) 51 (72.9%) n=70 (41.4%) 
Home-based 7 (25.9%) 12 (44.4%) 19 (70.4%) n=27 (16.0%) 
Did not start 0 (0.0%) 6 (22.2%) 16 (59.3%) n=27 (16.0%) 
Total 62 (36.7%)*** 55 (32.5%) 116 (68.6%) n=169 
Differences in retention by CR program model were tested using chi-square; *p<.05; **p<.01; ***p<.001 
CPET (CardioPulmonary Exercise Test) 
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Table 5. Retention Rates by CR Completion 
 CPET Pedometer Survey 
Completed 62 (64.6%) 41 (42.7%) 81 (84.4%) n=96 (71.6%) 
Did not complete 0 (0.0%) 7 (18.4%) 17 (44.7%) n=38 (28.4%) 
Total 62 (46.3%)*** 48 (35.8%)** 98 (84.5%)*** n=134 
Differences in retention by CR completion were tested using chi-square; *p<.05; **p<.01; ***p<.001 
Due to missing data, valid percentages are reported. 
CPET (CardioPulmonary Exercise Test) 
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Table 6. Pre-Test Participant Characteristics by CR Model Randomization (PP) 
Characteristics Women-Only Mixed-sex Home-Based Total 
 n=55 (32.5%) 
n=59 
(34.9%) 
n=55 
(32.5%) n=169 
Socio-demographic§     
Age, years (mean±SD) 66.22±10.21 61.56±9.73 63.13±10.94 63.64±10.42 
Marital Status (% married) 28 (63.6%) 20 (39.2%) 24 (49.0%) 72 (50.0%) 
Work Status (% retired) 26 (59.1%) 24 (47.1%) 22 (44.9%) 72 (50.0%) 
Ethnicity (% white) 26 (59.1%) 32 (62.7%) 32 (65.3%) 90 (62.5%) 
Education, (% post-secondary) 18 (40.9%) 18 (35.3%) 18 (36.7%) 54 (37.5%) 
Gross Annual Family Income (% 
<$50,000 CDN) 15 (39.5%) 23 (51.1%) 20 (47.6%) 58 (46.4%) 
Provide care to someone in 
household  6 (20.0%) 5 (15.2%) 5 (16.7%) 16 (17.2%) 
Have children 39 (88.6%) 39 (79.6%) 42 (87.5%) 120 (85.1%) 
Clinical      
Indication for CR     
PCI 26 (47.3%) 28 (50.0%) 27 (50.0%) 81 (49.1%) 
Angina/ACS/CAD 20 (36.4%) 20 (36.4%) 19 (35.8%) 59 (36.2%) 
MI 19 (34.5%) 22 (38.6%) 18 (34.0%) 59 (35.8%) 
CABG 16 (29.1%) 12 (21.4%) 14 (25.9%) 42 (25.5%) 
Valve 10 (18.5%) 11 (19.3%) 11 (20.4%) 32 (19.4%) 
Risk Factors     
Dyslipidemia 33 (84.6%) 38 (80.9%) 33 (84.6%) 104 (83.2%) 
Hypertension  38 (88.4%) 32 (68.1%) 31 (70.5%) 101 (75.4%) 
Obesity  16 (45.7%) 19 (46.3%) 14 (35.0%) 49 (42.2%) 
Diabetes  16 (40.0%) 14 (36.8%) 8 (21.6%) 38 (33.0%) 
Comorbidities     
Musculoskeletal Impairment  7 (14.3%) 6 (12.8%) 7 (19.4%) 20 (15.2%) 
Depression  5 (10.4%) 6 (12.8%) 4 (11.1%) 15 (11.5%) 
Cancer  2 (4.2%) 2 (4.3%) 4 (11.4%) 8 (6.2%) 
Hyperthyroid  0 (0.0%) 3 (6.3%) 3 (8.6%) 6 (4.6%) 
Renal Disease  1 (2.1%) 2 (4.3%) 1 (2.9%) 4 (3.1%) 
PAD/PVD 0 (0.0%) 1 (2.1%) 1 (2.9%) 2 (1.5%) 
Intake Assessment     
Resting Heart Rate (bpm) 75.98±12.77 76.27±17.55 74.24±14.44 75.54±15.06 
Waist Circumference (cm) 96.03±16.99 92.49±12.59 93.60±12.24 94.15±14.34 
Peak VO2 (mL/(kg·min) 17.34±4.77 18.12±7.57 17.39±8.29 17.62±6.97 
CR Utilization     
Adherence (% sessions) 54.40±34.72 51.33±35.70 58.12±35.39 54.46±35.14 
The equivalence of participant baseline socio-demographic and clinical characteristics by program model was tested 
using ANOVA and chi-square as appropriate. 
All p>.05 
§n=144 participants completed the baseline socio-demographic survey. Some participants did not respond to certain 
items, and therefore due to missing data valid percentages are reported.  
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PP (per protocol); PCI (Percutaneous Coronary Intervention); ACS (Acute Coronary Syndrome); CAD (Coronary 
Artery Disease); MI (Myocardial Infarction); CABG (Coronary Artery Bypass Graft); PAD/PVD (Peripheral 
Vascular Disease/Peripheral Arterial Disease)  
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Table 7. Participant Characteristics by Reason for CR Non-Completion 
Characteristics Medical Non-Medical Total 
 n=6 (24.0%) 
n=19 
(76.0%) n=25 
Socio-demographic§    
Age, years (mean ± SD) 58.50 ± 14.65 63.24 ± 9.29 62.26 ± 10.78 
Marital Status, n (% married) 5 (83.3%) 6 (42.9%) 11 (55.0%) 
Work Status, n (% retired) 1 (16.7%) 6 (42.9%) 7 (35.0%) 
Ethnicity, n (% white) 6 (100.0%) 8 (57.1%) 14 (70.0%) 
Education, n (% post-secondary) 1 (16.7%) 8 (57.1%) 9 (45.0%) 
Income, n (% <$50,000 CDN) 1 (16.7%) 6 (42.9%) 7 (35.0%) 
Provide care to someone in household, n  0 (0.0%) 5 (62.5%) 5 (35.7%)* 
Have children, n  5 (83.3%) 14 (100.0%) 19 (95.0%) 
Clinical    
Indication for CR    
MI  3 (50.0%) 10 (55.6%) 13 (54.2%) 
PCI  5 (83.3%) 7 (41.2%) 12 (52.2%) 
Angina/ACS/CAD  2 (33.3%) 5 (27.8%) 7 (29.2%) 
CABG  0 (0.0%) 7 (41.2%) 7 (30.4%) 
Valve  1 (16.7%) 0 (0.0%) 1 (4.2%) 
Risk Factors    
Dyslipidemia  3 (60.0%) 11 (84.6%) 14 (77.8%) 
Hypertension  1 (20.0%) 11 (84.6%) 12 (66.7%)* 
   Diabetes 3 (75.0%) 5 (41.7%) 8 (50.0%) 
Obesity 3 (50.0%) 5 (38.5%) 8 (42.1%) 
Comorbidities    
Musculoskeletal Impairment  2 (50.0%) 2 (14.3%) 4 (22.2%) 
Depression  1 (25.0%) 1 (7.1%) 2 (11.1%) 
Hyperthyroid  1 (25.0%) 0 (0.00%) 1 (5.6%) 
Renal Disease  0 (0.00%) 1 (7.1%) 1 (5.6%) 
Intake Assessment    
Resting Heart Rate (bpm) 69.83 ± 8.18 72.88 ± 18.92 72.43 ± 16.23 
Waist Circumference (cm) 97.67 ± 23.95 101.72 ± 18.43 100.22 ± 18.78 
Peak VO2 (mL/(kg·min) 17.23 ± 4.67 17.56 ± 8.68 17.78 ± 8.07 
CR Utilization    
Adherence (% sessions) 58.96±25.13 31.78±23.29 35.48±24.82 
Socio-demographic and clinical characteristics of participants who did not complete CR due to medical reasons 
versus those who did not complete due to non-medical reasons were compared to evaluate if there was a bias in the 
sample, using t-tests and chi-square as appropriate. 
*T-test or chi-square p<.05 
§n=144 participants completed the baseline socio-demographic survey. Some participants did not respond to certain 
items, and therefore due to missing data valid percentages are reported. 
PCI (Percutaneous Coronary Intervention); ACS (Acute Coronary Syndrome); CAD (Coronary Artery Disease); MI 
(Myocardial Infarction); CABG (Coronary Artery Bypass Graft); PAD/PVD (Peripheral Vascular 
Disease/Peripheral Arterial Disease) 
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Table 8. Participant Characteristics by Retention Status – Post-Program CardioPulmonary 
Exercise Test 
Characteristics CPET at discharge No CPET/did not enrol Total 
 n=62 (36.7%) 
n=107 
(63.3%) n=169 
Socio-demographic§    
Age, years (mean±SD) 63.93±8.53 63.47±11.40 63.64±10.42 
Marital Status, n (% married) 31 (57.4%) 41 (45.6%) 72 (50.0%) 
Work Status, n (% retired) 29 (53.7%) 43 (47.8%) 72 (50.0%) 
Ethnicity, n (% white) 30 (55.6%) 60 (66.7%) 90 (62.5%) 
Education, n (% post-secondary) 20 (37.0%) 34 (37.8%) 54 (37.5%) 
Gross Annual Family Income (% 
<$50,000 CDN) 24 (47.1%) 34 (45.9%) 58 (46.4%) 
Provide care to someone in household, n  3 (8.8%) 13 (22.0%) 16 (17.2%) 
Have children, n  44 (83.0%) 76 (86.4%) 120 (85.1%) 
Clinical     
Indication for CR    
PCI 32 (53.3%) 49 (46.7%) 81 (49.1%) 
Angina/ACS/CAD 19 (32.8%) 40 (38.1%) 59 (36.2%) 
MI 15 (25.0%) 44 (41.9%) 59 (35.8%)* 
CABG 15 (25.0%) 27 (25.7%) 42 (25.5%) 
Valve 13 (21.7%) 19 (18.1%) 32 (19.4%) 
Risk Factors    
Dyslipidemia 35 (94.6%) 69 (78.4%) 104 (83.2%)* 
Hypertension 35 (81.4%) 66 (72.5%) 101 (75.4%) 
Obesity 14 (40.0%) 35 (43.2%) 49 (42.2%) 
Diabetes 10 (32.3%) 28 (33.3%) 38 (33.0%) 
Comorbidities    
Musculoskeletal Impairment 3 (6.1%) 17 (20.5%) 20 (15.2%)* 
Depression 6 (12.2%) 9 (11.0%) 15 (11.5%) 
Cancer 1 (2.0%) 7 (8.8%) 8 (6.2%) 
Hyperthyroid 3 (6.0%) 3 (3.7%) 6 (4.6%) 
Renal Disease 1 (2.0%) 3 (3.7%) 4 (3.1%) 
PAD/PVD 1 (2.0%) 1 (1.2%) 2 (1.5%) 
Intake Assessment    
Resting Heart Rate (bpm) 72.35±14.11 77.36±15.35 75.54±15.06* 
Waist Circumference (cm) 91.35±12.46 96.90±15.60 94.15±14.34* 
Peak VO2 (mL/(kg•min)) 16.33±4.74 18.63±8.19 17.62±6.97 
CR Utilization    
Adherence (% sessions) 75.39±19.12 41.58±36.54 54.46±35.14*** 
Socio-demographic and clinical characteristics of participants retained for stress testing versus those lost to follow-
up were compared to evaluate if there was a retention bias in the sample, using t-tests and chi-square as appropriate. 
*T-test or chi-square p<.05; **p<.01; ***p<.001 
§n=144 participants completed the baseline sociodemographic survey. Some participants did not respond to certain 
items, and therefore due to missing data valid percentages are reported. 
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CPET (CardioPulmonary Exercise Test); PCI (Percutaneous Coronary Intervention); ACS (Acute Coronary 
Syndrome); CAD (Coronary Artery Disease); MI (Myocardial Infarction); CABG (Coronary Artery Bypass Graft); 
PAD/PVD (Peripheral Vascular Disease/Peripheral Arterial Disease) 
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Table 9. Participant Characteristics by Retention Status – Post–Program Survey 
Characteristics Retained Lost to Follow-Up Total 
 N=116 (68.6%) 
N=53 
(31.4%) N=169 
Socio-demographic§    
Age, years (mean±SD) 64.79±9.57 61.10±11.80 63.64±10.42* 
Marital Status, n (% married) 50 (47.6%) 22 (56.4%) 72 (50.0%) 
Work Status, n (% retired) 56 (53.3%) 16 (41.0%) 72 (50.0%) 
Ethnicity, n (% white) 65 (61.9%) 25 (64.1%) 90 (62.5%) 
Education, n (% post-secondary) 40 (38.1%) 14 (35.9%) 54 (37.5%) 
Gross Annual Family Income (% <$50,000 CDN) 47 (50.0%) 11 (35.5%) 58 (46.4%) 
Provide care to someone in household, n (% yes) 6 (9.1%) 10 (37.0%) 16 (17.2%)** 
Have children, n (% yes) 88 (85.4%) 32 (84.2%) 120 (85.1%) 
Clinical (% yes)    
Indication for CR    
PCI 56 (49.1%) 25 (49.0%) 81 (49.1%) 
Angina/ACS/CAD 37 (33.0%) 22 (43.1%) 59 (36.2%) 
MI 40 (35.4%) 19 (36.5%) 59 (35.8%) 
CABG 29 (25.4%) 13 (25.5%) 42 (25.5%) 
Valve 26 (23.0%) 6 (11.5%) 32 (19.4%) 
Risk Factors    
Dyslipidemia 70 (84.3%) 34 (81.0%) 104 (83.2%) 
Hypertension 68 (73.1%) 33 (80.5%) 101 (75.4%) 
Obesity 35 (44.9%) 14 (36.8%) 49 (42.2%) 
Diabetes 23 (28.7%) 15 (42.9%) 38 (33.0%) 
Comorbidities    
Musculoskeletal Impairment 14 (15.9%) 6 (13.6%) 20 (15.2%) 
Depression 10 (11.4%) 5 (11.6%) 15 (11.5%) 
Cancer 6 (6.7%) 2 (4.9%) 8 (6.2%) 
Hyperthyroid 4 (4.5%) 2 (4.8%) 6 (4.6%) 
Renal Disease 2 (2.3%) 2 (4.8%) 4 (3.1%) 
PAD/PVD 1 (1.1%) 1 (2.4%) 2 (1.5%) 
Intake Assessment    
Resting Heart Rate (bpm) 75.15±14.80 76.38±15.73 75.54±15.06 
Waist Circumference (cm) 92.53±12.95 97.28±16.42 94.15±14.34 
Peak VO2 (mL/(kg•min)) 18.10±7.29 16.59±6.17 17.62±6.97 
CR Utilization    
Adherence (% sessions) 62.54±33.22 35.66±32.49 54.46±35.14*** 
Socio-demographic and clinical characteristics of participants returning a post-program survey versus those lost to 
follow-up were compared to evaluate if there was a retention bias in the sample, using t-tests and chi-square as 
appropriate. 
*T-test or chi-square p<.05; **p<.01; ***p<.001 
§n=144 participants completed the baseline sociodemographic survey. Some participants did not respond to certain 
items, and therefore due to missing data valid percentages are reported. 
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PCI (Percutaneous Coronary Intervention); ACS (Acute Coronary Syndrome); CAD (Coronary Artery Disease); MI 
(Myocardial Infarction); CABG (Coronary Artery Bypass Graft); PAD/PVD (Peripheral Vascular 
Disease/Peripheral Arterial Disease) 
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Table 10. Participant Characteristics by Retention Status – Post–Program Pedometer 
Characteristics Pedometer 
 
No pedometer Total 
 n=55 (32.5%) 
n=114 
(67.5%) n=169 
Socio-demographic§    
Age, years (mean±SD) 66.39±9.55 62.29±10.61 63.64±10.42* 
Marital Status, n (% married) 30 (56.6%) 42 (46.2%) 72 (50.0%) 
Work Status, n (% retired) 30 (56.6%) 42 (46.2%) 72 (50.0%) 
Ethnicity, n (% white) 35 (66.0%) 55 (60.4%) 90 (62.5%) 
Education, n (% post-secondary) 22 (41.5.0%) 32 (35.2%) 54 (37.5%) 
Gross Annual Family Income (% <$50,000 CDN) 18 (34.0%) 40 (44.0%) 86 (59.7%) 
Provide care to someone in household, n 3 (8.6%) 13 (22.4%) 16 (17.2%) 
Have children, n 48 (90.6%) 72 (81.8%) 120 (85.1%) 
Clinical    
Indication for CR    
PCI  23 (42.6%) 58 (52.3%) 81 (49.1%) 
Angina/ACS/CAD  14 (26.9%) 45 (40.5%) 59 (36.2%) 
MI  21 (39.6%) 38 (33.9%) 59 (35.8%) 
CABG  12 (22.2%) 30 (27.0%) 42 (25.5%) 
Valve  15 (28.3%) 17 (15.2%) 32 (19.4%) 
Risk Factors    
Dyslipidemia  31 (79.5%) 73 (84.9%) 104 (83.2%) 
Hypertension  30 (73.2%) 71 (76.3%) 101 (75.4%) 
Obesity 16 (42.1%) 33 (42.3%) 49 (42.2%) 
Diabetes 10 (25.0%) 28 (37.3%) 38 (33.0%) 
Comorbidities     
Musculoskeletal Impairment  8 (20.0%) 12 (13.0%) 20 (15.2%) 
Depression  4 (10.0%) 11 (12.1%) 15 (11.5%) 
Cancer  2 (4.9%) 6 (6.7%) 8 (6.2%) 
Hyperthyroid  0 (0.0%) 6 (6.6%) 6 (4.6%) 
Renal Disease  0 (0.0%) 4 (4.4%) 4 (3.1%) 
PAD/PVD  0 (0.0%) 2 (2.2%) 2 (1.5%) 
Liver Disease  1 (2.5%) 0 (0.0%) 1 (0.8%) 
Intake Assessment    
Resting Heart Rate (BPM) 78.53±16.60 74.19±14.18 75.54±15.06 
Waist Circumference (cm) 91.20±12.06 95.35±15.07 94.15±14.34 
Peak VO2 (mL/(kg•min) 19.65±7.58 16.72±6.52 17.62±6.97* 
CR Utilization    
Adherence (% sessions) 62.97±33.29 48.53±34.74 54.46±35.14** 
 
 
Sociodemographic and clinical characteristics of participants returning a post-program pedometer log versus those 
lost to follow-up were compared to evaluate if there was a retention bias in the sample, using t-tests and chi-square 
as appropriate. 
*T-test or chi-square p<.05; **p<.01; ***p<.001 
§n=144 participants completed the baseline sociodemographic survey. Some participants did not respond to certain 
items, and therefore due to missing data valid percentages are reported. 
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PCI (Percutaneous Coronary Intervention); ACS (Acute Coronary Syndrome); CAD (Coronary Artery Disease); MI 
(Myocardial Infarction); CABG (Coronary Artery Bypass Graft); PAD/PVD (Peripheral Vascular 
Disease/Peripheral Arterial Disease) 
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Table 11. Functional Capacity Indicators in Participants Completing CardioPulmonary 
Exercise Test Both Pre and Post-Program, N=58 
VO2 peak Per Protocol As-treated 
 Pre-CR Post-CR Change Pre-CR Post-CR Change 
Overall 16.34±4.66 19.23±5.14 2.89***    
     Mixed-sex 15.50±3.39 19.40±4.97 3.91** 15.76±4.04 19.11±5.18 3.35*** 
     Women-only 17.29±3.91 19.54±4.70 2.26** 18.01±5.94 20.07±5.53 2.06* 
     Home-based 16.05±6.52 18.63±6.11 2.58** 14.92±3.01 17.32±3.67 2.40 
Assessment of change in functional capacity from pre to post-test was conducted using paired t-tests; *p<.05; 
**p<.01; ***p<.001  
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Table 12. Categories of Medications Reported by Participants Pre and Post-CR 
 Per Protocol As-treated 
 Pre-CR Post-CR Pre-CR Post-CR 
Lipid Lowering-Statins 109 (81.3%) 89 (78.8%) - - 
Mixed-sex 35 (74.5%) 30 (73.2%) 47 (82.5%) 36 (72.0%) 
Women-only 33 (80.5%) 28 (75.7%) 28 (82.4%) 23 (76.7%) 
Home-based 41 (89.1%) 31 (88.6%) 18 (81.8%) 16 (94.1%) 
Did not start - - 16 (76.2%) 14 (87.5%) 
ASA – Aspirin 107 (79.9%) 84 (73.7%) - - 
Mixed-sex 37 (78.7%) 28 (68.3%) 45 (78.9%) 36 (70.6%) 
Women-only 33 (80.5%) 31 (81.6%) 29 (85.3%) 26 (86.7%) 
Home-based 37 (80.4%) 25 (71.4%) 18 (81.8%) 12 (70.6%) 
Did not start - - 15 (71.4%) 10 (62.5%) 
Beta-Blockers 92 (68.7%) 72 (63.2%) - - 
Mixed-sex 34 (72.3%) 27 (65.9%) 37 (64.9%) 28 (54.9%) 
Women-only 26 (63.4%) 24 (63.2%) 24 70.6%) 22 (73.3%) 
Home-based 32 (69.6%) 21 (60.0%) 17 (77.3%) 13 (76.5%) 
Did not start - - 14 (66.7%) 9 (56.3%) 
Antiplatelets 70 (52.2%) 40 (35.4%) - - 
Mixed-sex 25 (53.2%) 17 (42.5%) 33 (57.9%) 22 (44.0%) 
Women-only 23 (56.1%) 12 (31.6%) 15 (44.1%) 7 (23.3%) 
Home-based 22 (47.8%) 11 (31.4%) 12 (54.5%) 5 (29.4%) 
Did not start - - 10 (47.6%) 6 (37.5%) 
ACE Inhibitors 53 (40.2%) 51 (44.7%) - - 
Mixed-sex 16 (34.0%) 17 (41.5%) 24 (42.9%) 25 (49.0%) 
Women-only 16 (40.0%) 15 (39.5%) 11 (32.4%) 10 (33.3%) 
Home-based 21 (46.7%) 19 (54.3%) 11 (50.0%) 10 (58.8%) 
Did not start - - 7 (35.0%) 6 (37.5%) 
Diuretics 27 (20.3%) 22 (19.5%) - - 
Mixed-sex 8 (17.0%) 6 (15.0%) 11 (19.3%) 8 (16.0%) 
Women-only 10 (25.0%) 7 (18.4%) 10 (30.3%) 8 (26.7%) 
Home-based 9 (19.6%) 9 (25.7%) 4 (18.2%) 4 (23.5%) 
Did not start - - 2 (9.5%) 2 (12.5%) 
Psychoactives 22 (16.4%) 29 (25.4%) - - 
Mixed-sex 7 (14.9%) 13 (31.7%) 11 (19.3%) 18 (35.3%) 
Women-only 5 (12.2%) 8 (21.1%) 5 (14.7%) 4 (13.3%) 
Home-based 10 (21.7%) 8 (22.9%) 4 (18.2%) 4 (23.5%) 
Did not start - - 2 (9.5%) 3 (18.8%) 
Anticoagulants 22 (16.8%) 21 (18.6%) - - 
Mixed-sex 6 (12.8%) 8 (20.0%) 7 (12.3%) 8 (16.0%) 
Women-only 7 (17.9%) 4 (10.5%) 6 (18.2%) 4 (13.3%) 
Home-based 9 (20.0%) 9 (25.7%) 6 (28.6%) 5 (29.4%) 
Did not start - - 3 (15.0%) 4 (25.0%) 
Angiotensin II Receptor Blockers 22 (16.4%) 19 (16.7%) - - 
Mixed-sex 7 (14.9%) 8 (19.5%) 10 (17.5%) 10 (19.6%) 
Women-only 5 (12.2%) 4 (10.5%) 4 (11.8%) 4 (13.3%) 
Home-based 10 (21.7%) 7 (20.0%) 4 (18.2%) 2 (11.8%) 
Did not start - - 4 (19.0%) 3 (18.8%) 
Calcium Antagonists 20 (15.0%) 15 (13.2%) - - 
Mixed-sex 4 (8.5%) 6 (14.6%) 8 (14.0%) 8 (15.7%) 
Women-only 9 (22.5%) 4 (10.5%) 7 (21.2%) 3 (10.0%) 
Home-based 7 (15.2%) 5 (14.3%) 2 (9.1%) 0 (0.0%) 
Did not start - - 3 (14.3%) 4 (25.0%) 
Nitrates 11 (8.2%) 11 (9.6%) - - 
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Some participants did not respond to certain items, and therefore due to missing data valid percentages are reported.  
Mixed-sex 5 (10.6%) 6 (14.6%) 10 (17.5%) 7 (13.7%) 
Women-only 2 (4.9%) 3 (7.9%) 0 (0.0%) 3 (10.0%) 
Home-based 4 (8.7%) 2 (5.7%) 1 (4.5%) 1 (5.9%) 
Did not start - - 0 (0.0%) 0 (0.0%) 
Insulin 8 (6.0%) 5 (4.4%) - - 
Mixed-sex 5 (10.6%) 5 (12.2%) 6 (10.5%) 4 (7.8%) 
Women-only 1 (2.4%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 
Home-based 2 (4.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Did not start - - 1 (4.8%) 1 (6.3%) 
Oral Hypoglycemics 4 (3.0%) 12 (10.5%) - - 
Mixed-sex 1 (2.2%) 5 (12.2%) 2 (3.4%) 5 (9.8%) 
Women-only 2 (4.8%) 4 (10.5%) 1 (2.9%) 2 (6.7%) 
Home-based 1 (2.2%) 3 (8.6%) 0 (0.0%) 2 (11.8%) 
Did not start - - 1 (5.0%) 3 (18.8%) 
Digoxin 4 (3.0%) 2 (1.8%) - - 
Mixed-sex 3 (6.4%) 2 (4.9%) 3 (5.3%) 2 (3.9%) 
Women-only 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Home-based 1 (2.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Did not start - - 1 (4.8%) 0 (0.0%) 
Antiarrhythmics 4 (3.0%) 0 (0.0%) - - 
Mixed-sex 2 (4.3%) 0 (0.0%) 2 (3.5%) 0 (0.0%) 
Women-only 0 (0.0%) 0 (0.0%) 1 (3.0%) 0 (0.0%) 
Home-based 2 (4.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Did not start - - 1 (4.8%) 0 (0.0%) 
Prescribed Antismoking Medications 2 (1.5%) 2 (1.8%) - - 
Mixed-sex 2 (4.3%) 1 (2.4%) 2 (3.5%) 1 (2.0%) 
Women-only 0 (0.0%) 1 (2.6%) 0 (0.0%) 0 (0.0%) 
Home-based 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Did not start - - 0 (0.0%) 1 (6.3%) 
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Table 13. Mean (± standard deviation) Diet Habit Survey Sub-Category Scores in 
Participants Pre and Post-CR 
 Per Protocol As-treated 
 Pre-CR Post-CR Change Pre-CR Post-CR Change 
Meat, Fish, and 
Poultry 17.98±5.18 18.78±4.33 0.81 - - - 
Mixed-sex 17.39±5.38 18.16±4.29 0.77 17.14±5.11 18.47±4.24 1.33 
Women-only 18.58±5.53 19.14±4.70 0.56 19.47±4.67 19.68±5.11 0.21 
Home-based 17.94±4.60 19.09±4.01 1.14 18.04±4.65 18.47±3.97 0.43 
Did not start - - - 17.47±6.96 18.28±3.27 0.81 
Dairy Products 
and Eggs 22.39±6.60 23.31±6.23 0.92 - - - 
Mixed-sex 21.34±7.14 22.08±6.42 0.73 21.90±7.11 23.29±7.00 1.40 
Women-only 22.71±5.92 22.71±6.03 -.0059 23.19±5.34 23.39±5.44 0.21 
Home-based 23.26±6.72 25.42±5.87 2.17 21.85±6.50 23.30±5.77 1.45 
Did not start - - - 23.22±8.06 23.23±6.31 0.0091 
Fats and Oils 19.08±4.57 19.93±4.13 0.85 - - - 
Mixed-sex 18.13±5.11 19.03±4.25 0.91 18.23±5.03 19.12±4.19 0.89 
Women-only 19.40±3.96 20.17±4.34 0.77 20.25±4.12 21.28±4.44 1.03 
Home-based 19.85±4.45 20.73±3.67 0.87 18.76±4.29 20.01±3.32 1.24 
Did not start - - - 20.18±3.64 19.82±3.88 -0.36 
Sweets and Snacks 10.23±3.38 10.61±3.46 0.39 - - - 
Mixed-sex 10.08±3.56 10.29±3.66 0.21 9.49±3.71 10.22±3.68 0.73 
Women-only 10.24±3.24 10.88±3.22 0.64 11.04±2.79 10.98±3.35 -.059 
Home-based 10.38±3.41 10.70±3.57 0.32 10.19±2.59 10905±3.30 0.71 
Did not start - - - 11.22±3.70 10.85±3.36 -0.38 
Grains, Beans, 
Fruits, and 
Vegetables 
58.23±25.60 60.02±22.87 1.79 - - - 
Mixed-sex 57.21±25.20 60.02±19.48 2.81 62.40±30.64 62.53±20.77 0.13 
Women-only 55.11±25.51 57.61±21.37 2.50 52.70±16.87 58.89±22.11 6.19 
Home-based 62.84±26.33 62.66±26.00 -0.17 63.33±22.55 58.55±29.11 -4.78 
Did not start - - - 47.37±22.47 54.91±24.31 7.54 
Beverages 13.48±2.33 13.26±2.69 0.22 - - - 
Mixed-sex 13.40±1.99 12.80±3.06 -0.60 13.71±2.22 12.89±3.18 -0.82 
Women-only 13.32±2.57 13.50±2.47 0.18 12.79±2.44 13.29±1.86 0.50 
Home-based 13.73±2.48 13.50±2.49 -0.23 13.68±2.52 13.85±2.03 0.18 
Did not start - - - 14.00±2.11 13.80±3.26 -0.20 
Salt 16.52±4.41 17.63±5.08 1.11* - - - 
Mixed-sex 16.56±4.67 18.14±5.22 1.58* 17.08±4.53 18.59±5.43 1.51* 
Women-only 15.51±3.83 16.63±4.34 1.12 16.50±4.16 17.20±4.94 0.70 
Home-based 17.58±4.57 18.15±5.65 0.56 17.00±4.39 16.94±4.52 -.059 
Did not start - - - 13.55±3.88 15.91±4.61 2.36 
Restaurants and 
Recipes 35.62±4.24 34.13±5.76 -1.49* - - - 
Mixed-sex 36.17±4.26 34.40±6.45 -1.76 36.44±4.31 34.23±6.27 -2.21* 
Women-only 35.12±3.78 33.06±4.80 -2.06 34.96±4.13 34.05±4.66 -0.91 
Home-based 35.55±4.75 35.00±5.88 -0.55 34.41±4.08 33.91±6.38 -0.50 
Did not start - - - 35.82±4.33 34.27±5.90 -1.55 
Seafood 6.77±2.09 7.12±2.05 0.35 - - - 
Mixed-sex 6.49±2.38 6.68±2.44 0.19 6.59±2.28 6.96±2.34 0.37 
Women-only 7.07±1.63 7.11±1.78 0.044 7.33±1.28 7.67±1.35 0.35 
Home-based 6.75±2.20 7.63±1.75 0.88** 6.71±2.17 7.40±2.06 0.69* 
Did not start - - - 6.14±2.74 5.86±1.87 -0.27 
Assessment of change from pre to post-CR was conducted using paired t-tests; *p<.05; **p<.01  
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Table 14. Mean (± standard deviation) Health Behavior Scores in Participants Pre and 
Post-CR 
 Per Protocol As-treated 
 Pre-CR Post-CR Change Pre-CR Post-CR Change 
Step counts 5443±2875 6108±3762 666 - - - 
Mixed-sex 6339±2870 6022±2960 -317 5772±2799 5873±2797 101 
Women-only 4429±2327 5240±3106 811 5391±2675 6290±3055 900 
Home-based 5888±3317 7273±4984 1384 6074±3480 7803±5793 1728 
Did not start - - - 3184±2263 2998±2670 -186 
GLTEQ score 21.98±17.85 30.42±19.28 8.44*** - - - 
Mixed-sex 19.81±15.19 31.15±21.71 11.34** 20.12±16.84 30.16±20.86 10.04* 
Women-only 19.38±16.61 29.85±20.03 10.47** 22.38±17.56 33.58±19.26 11.19** 
Home-based 28.65±21.65 30.19±14.76 1.54 30.38±21.22 28.53±15.33 -1.84 
Did not start - - - 15.67±14.32 26.92±20.25 11.25 
Diet Habit 
Survey total 
score 
198.46±37.37 204.46±28.97 6.00 - - - 
Mixed-sex 196.71±34.11 201.05±28.10 4.34 202.78±38.35 206.00±30.32 3.22 
Women-only 192.07±42.15 200.74±24.20 8.67 198.31±24.72 205.66±27.50 7.35* 
Home-based 207.72±34.52 212.63±33.78 4.91 203.98±22.00 203.33±30.00 -0.64 
Did not start - - - 174.84±63.30 197.50±28.19 22.66 
MMAS-4 
score 3.69±0.74 3.60±0.72 -0.082 - - - 
Mixed-sex 3.53±0.95 3.50±0.88 -0.031 3.73±0.61 3.62±0.72 -0.11 
Women-only 3.74±0.59 3.74±0.53 0.00 3.73±0.63 3.73±0.55 0.00 
Home-based 3.81±0.56 3.59±0.69 -0.22 3.78±0.65 3.56±0.70 -0.22 
Did not start - - - 3.22±1.39 3.33±1.12 0.11 
Smoking (n, 
% current) 7 (6.7%) 6 (5.8%) 1 (1.0%) - - - 
Mixed-sex 3 (7.9%) 3 (7.9%) 0 3 (6.8%) 2 (4.5%) 1 (2.3%) 
Women-only 2 (5.9%) 1 (2.9%) 1 (2.9%) 0 1 (3.6%) 1 (3.6%) 
Home-based 2 (6.3%) 2 (6.3%) 0 2 (11.1%) 2 (11.1%) 0 
Did not start - - - 2 (14.3%) 1 (7.1%) 1 (7.1%) 
Assessment of change in daily steps, GLTEQ scores, Diet Habit Survey scores, and MMAS-4 scores from pre to 
post-CR was conducted using paired t-tests, and smoking using McNemar's test; *p<.05; **p<.01; ***p<.001  
GLTEQ (Godin Leisure Time Exercise Questionnaire); MMAS-4 (Morisky Medication Adherence Scale)  
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Table 15. Mean (± standard deviation) Health Behaviour Scores in Participants Pre and 
Post-CR – Enrolees Only 
 Per Protocol 
 Pre-CR Post-CR Change 
VO2 peak 16.33±4.74 19.12±5.17 2.80*** 
Mixed-sex 15.38±3.33 19.31±4.85 3.93** 
Women-only 17.29±3.91 19.54±4.70 2.26** 
Home-based 16.21±6.59 18.44±6.18 2.23** 
Step counts 5488.96±2938.77 6296.75±3776.60 807.79 
Mixed-sex 6339.42±2870.35 6022.13±2959.79 -317.29 
Women-only 4490.32±2402.23 5230.28±3131.44 939.96 
Home-based 5909.49±3478.52 7674.14±5019.02 1764.65 
GLTEQ score 22.34±18.03 30.62±18.91 8.28*** 
Mixed-sex 19.45±15.20 30.43±22.18 9.89** 
Women-only 19.95±16.77 29.84±19.18 10.98** 
Home-based 29.66±21.71 31.98±13.71 2.32 
Diet Habit Survey total score 200.79 ±31.30 204.45±29.10 3.66 
Mixed-sex 194.47±34.49 198.37±27.53 3.90 
Women-only 196.63±26.78 200.87±24.41 4.23 
Home-based 212.49±30.17 215.22±33.78 2.72 
MMAS-4 score 3.70±0.74 3.62±0.69 -0.076 
Mixed-sex 3.54±0.96 3.54±0.79 0.00 
Women-only 3.76±0.60 3.76±0.52 0.00 
Home-based 3.81±0.57 3.59±0.70 -0.23 
Assessment of change in functional capacity, daily steps, , GLTEQ scores, Diet Habit Survey scores, and MMAS-4 
scores from pre to post-CR was conducted using paired t-tests; *p<.05; **p<.01; ***p<.001 
GLTEQ (Godin Leisure Time Exercise Questionnaire); MMAS-4 (Morisky Medication Adherence Scale) 
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FIGURES 
Figure 2. CR4HER Trial Overview 
 
CR4HER was a 3 parallel arm pragmatic RCT designed to compare CR program adherence to traditional hospital-
based CR with males and females, home-based CR, and women-only hospital-based CR. The trial was registered on 
ClinicalTrials.gov (identifier number: NCT01019135). 
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Figure 3. CR Adherence by Study Participant Recruitment Type 
 
No significant difference between participants recruited as in-patients versus out-patients using t-test; p=.70  
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Figure 4. CR4HER Study Flow Diagram 
 
“Did not attend” includes both patients who did not enrol post-referral, as well as those who enrolled (i.e., attended 
an intake assessment) but then did not partake in at least some of the CR intervention components.   
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Figure 5a. CR Adherence by Program Model (PP), N=153 
 
No significant difference between participants randomized to different CR program models using ANOVA. 
Overall model p=.63, observed power=.12 
Error bars represent standard deviation.  
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Figure 5b. CR Adherence by Program Model (As-Treated), N=153 
 
Difference in mean program adherence between home-based vs. women-only is 15.38%. Denotes significant 
difference between participants attending different CR program models using ANOVA (LSD post-hoc test); *p<.05; 
**p<.001 
Overall model p<.001, observed power=1.00 
Error bars represent standard deviation.   
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Figure 6a. Post-CR Peak VO2 by Program Model (PP), N=58 
 
No significant difference in estimated marginal means between participants randomized to different CR program 
models using ANCOVA adjusting for dyslipidemia, musculoskeletal impairment, resting heart rate, waist 
circumference, and baseline peak VO2. 
Overall model p=.84, observed power=.074 
Error bars represent standard deviation.   
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Figure 6b. Post-CR Peak VO2 by Program Model (As-Treated), N=58 
 
Difference in estimated marginal means post-CR peak VO2 between home-based vs. mixed-sex is 4.19. Denotes 
significant difference between participants attending different CR program models using ANCOVA adjusting for 
dyslipidemia, musculoskeletal impairment, resting heart rate, waist circumference, and baseline peak VO2. (LSD 
post-hoc test); *p<.05 
Overall model p<.05, observed power=.60 
Error bars represent standard deviation.   
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Figure 7a. Post-CR Pedometer Step Counts by Program Model (PP) 
 
No significant difference in estimated marginal means between participants randomized to different CR program 
models using ANCOVA adjusting for age, intake peak VO2, CR program adherence, and baseline CR pedometer 
step counts. 
Overall model p=.98, observed power=.05 
Error bars represent standard deviation, and the horizontal line represents ≥6,500 steps/day which are recommended 
for patients with chronic diseases to achieve the total amount of physical activity energy expenditure generally 
recommended for secondary prevention.   
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Figure 7b. Post-CR Pedometer Step Counts by Program Model (As-Treated) 
 
No significant difference in estimated marginal means between participants attending different CR program models 
using ANCOVA adjusting for age, intake peak VO2, CR program adherence, and baseline CR pedometer step 
counts. 
Overall model p=.75, observed power=.12 
Error bars represent standard deviation, and the horizontal line represents ≥6,500 steps/day which are recommended 
for patients with chronic diseases to achieve the total amount of physical activity energy expenditure generally 
recommended for secondary prevention. 
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Figure 8a. Post-CR Self-Reported Physical Activity by Program Model (PP) 
 
 
 
 
 
 
 
 
 
 
 
 
No significant difference in estimated marginal means between participants randomized to different CR program 
models using ANCOVA adjusting for age, caregiving duties, CR program adherence, and baseline self-reported 
physical activity. 
Overall model p=.42, observed power=.20 
Error bars represent standard deviation, and the horizontal line represents scores ≥20 which are indicative of 
someone who is ‘active”.   
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Figure 8b. Post-CR Self-Reported Physical Activity by Program Model (As-Treated) 
 
 
 
 
 
 
 
 
 
 
 
 
No significant difference in estimated marginal means between participants attending different CR program models 
using ANCOVA adjusting for age, caregiving duties, CR program adherence, and baseline self-reported physical 
activity. 
Overall model p=.47, observed power=.22 
Error bars represent standard deviation, and the horizontal line represents scores ≥20 which are indicative of 
someone who is ‘active”.   
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Figure 9a. Post-CR Diet Habit Survey Score by Program Model (PP) 
 
No significant difference in estimated marginal means between participants randomized to different CR program 
models using ANCOVA adjusting for age, caregiving duties, CR program adherence, and baseline Diet Habit 
Survey score. 
Overall model p=.51, observed power=.16 
Error bars represent standard deviation, and the horizontal line represents scores ≥236 which corresponds to a low-
fat diet (20% or less).   
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Figure 9b. Post-CR Diet Habit Survey Score by Program Model (As-Treated) 
 
No significant difference in estimated marginal means between participants attending different CR program models 
using ANCOVA adjusting for age, caregiving duties, CR program adherence, and baseline Diet Habit Survey score. 
Overall model p=.24, observed power=.36 
Error bars represent standard deviation, and the horizontal line represents scores ≥236 which corresponds to a low-
fat diet (20% or less).   
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Figure 10a. Post-CR Medication Adherence Score by Program Model (PP) 
 
No significant difference in estimated marginal means between participants randomized to different CR program 
models using ANCOVA adjusting for age, caregiving duties, CR program adherence, and baseline MMAS-4 score. 
Overall model p=.62, observed power=.13 
Error bars represent standard deviation, and the horizontal line represents the cut-off for adherence (≥2).   
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Figure 10b. Post-CR Medication Adherence Score by Program Model (As-Treated) 
 
No significant difference in estimated marginal means between participants attending different CR program models 
using ANCOVA adjusting for age, caregiving duties, CR program adherence, and baseline MMAS-4 score. 
Overall model p=.77, observed power=.12 
Error bars represent standard deviation, and the horizontal line represents the cut-off for adherence (≥2). 
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Figure 11. CR Adherence by Program Model – Enrollees Only (PP), N=131 
 
No significant difference between participants randomized to different CR program models using ANOVA. 
Overall model p=.52, observed power=.16 
Error bars represent standard deviation.  
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Appendix A – Informed Consent Form (UHN) 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
Title A Randomized Controlled Trial of Women’s Adherence to 
Women-only, Home-based, and Traditional Cardiac 
Rehabilitation (Cardiac Rehabilitation for her heart event 
recovery [CR4HER]). 
Investigator Sherry L. Grace, PhD.  
Scientist and Associate Professor
(xxx) xxx-xxx
Co-Investigators Kenneth Melvin, MD. Cardiologist 
Heather Arthur, PhD. Professor and Research Chair 
Louise Pilote, MD. Associate Professor and Research Chair 
Paul Oh, MD. Medical Director and Assistant Professor. 
Stephanie Brister, MD. Medical Director and Associate 
Professor 
Donna E. Stewart, MD. Professor and Research Chair 
Caroline Chessex, MD. Cardiologist  
Sponsor Heart and Stroke Foundation of Ontario 
Introduction 
You are being asked to take part in a research study. Please read this explanation 
about the study and its risks and benefits before you decide if you would like to take 
part. You should take as much time as you need to make your decision. You should ask 
the study doctor or study staff to explain anything that you do not understand and make 
sure that all of your questions have been answered before signing this consent form. 
Before you make your decision, feel free to talk about this study with anyone you wish. 
Participation in this study is voluntary. 
Background and Purpose 
• You are being approached to consider participating in this study because you are a
female patient receiving cardiac care at University Health Network.
105
• This research study examines women’s participation in cardiac rehabilitation (CR)
programs.
• CR is a six-month outpatient program where you learn about heart disease and
behaviour changes that can improve your heart health. It is the standard of care for
heart patients. CR is proven to improve the health of participants, but not many women
attend.
• This study will explore different types of CR for female heart patients, to see which ones
women prefer to participate in. We are particularly interested in the number of sessions
women attend, and how this might be different depending on the type of program you
participate in.
• We will also explore women’s exercise, eating habits, pill-taking and smoking, and see if
they are different depending on what type of cardiac rehab program you participate in.
Finally, we will also explore whether your mood or supports might affect how many CR
sessions women attend.
• About 326 female heart patients from 3 hospitals will be in the study. If you agree to
participate, you will be one of 218 patients in this study recruited from University Health
Network, which includes Toronto General Hospital and Toronto Western Hospital.
 Study Design 
• If you agree, we would like to randomly (by chance) assign you to 1 of 3 study
conditions. One of these conditions is co-ed CR so there are women and men
participating, one of the conditions has only women participating, and one of the
conditions is home-based CR so you will be supported in making heart healthy changes
at home by telephone.
• This means that we will randomly refer 107 patients in each of the 3 CR types, and that
you will have an equal chance (33%) of being referred to any of the CR types. This is
like flipping a coin or rolling the dice. You will be referred to 1 CR type only.
• These CR types are offered at 2 local hospitals: Toronto Western Hospital , and Toronto
Rehabilitation Institute. We will refer you to the hospital offering the program type you
were randomly chosen to attend which is closest to your home or work.
• You will be in the study for 6 months.
Study Procedures 
A study recruiter will approach you in the hospital to determine your interest and eligibility for 
the study.  
1. first survey - After the study coordinator approaches you in the hospital for consent, she
will ask you to complete a paper-and-pencil survey, which will require approximately 30 
minutes of your time. The survey asks questions about your feelings, supports, your 
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exercise and eating habits, smoking status, alcohol use, medications and other health 
conditions. You will only be identified by a study identification number. Should your 
responses indicate that you are having suicidal thoughts or depression, for your safety we 
will send a letter to your family doctor. You can complete the survey in hospital or you can 
take it home, and return it to us in the pre-paid, pre-addressed envelope provided. 
We would also like your permission to access some basic medical information from your 
health records. This personal health information will help us refer you to CR. This will 
include the nature of your cardiac problem and heart history, your age, medications, other 
health problems, heart risk factors, diagnostic test results, and the name of your doctors. 
We would also like your consent to ask your family doctor or cardiac specialist if it would be 
safe for you to participate in a CR program. 
Once we have completed these steps, we will arrange your CR referral to the site closest to 
your home offering the CR program type you were randomized to. Copies of your heart-
related health records (i.e. blood work, ECG, discharge notes) will be sent to the CR 
program, in order to help them process the referral so that they are fully informed of your 
health status. They will contact you to book an intake appointment where a tailored program 
will be set up to meet your needs.  We are not involved in your direct relationship with the 
CR program, except that they will share some of your assessments with us.  
2. final survey - Six months after you complete the first survey or when you graduate from
CR, a second paper-and-pencil survey will be mailed to your home. This will also take 
approximately 30 minutes to complete. The survey asks questions about your feelings, 
supports, your exercise and eating habits, and other health conditions. In the mailed 
package we will include a pre-paid, pre-addressed return envelope so you can mail your 
completed survey back at no charge to you. 
If your survey responses suggest you attended a different type of CR program than we 
thought, we may call you to ask why, if you are willing. 
At both time points, interested participants will be mailed a pedometer package, to 
objectively measure exercise behaviour.  
3. measuring steps –For this portion, we would provide you a pedometer (a device
that measures the number of steps you take while walking around) that would record 
your physical activity during the time that you wear it. You would also receive an activity 
log. We would ask you to wear the pedometer for 7 days, and then note the number of 
steps showing, on a daily basis, on the log provided. Once the log is complete, we 
would ask you to return to us by mail (in a postage-paid envelope provided) the 
pedometer and the completed activity log-sheet. If you are interested, we would ask you 
to record your steps for 7 days before CR, and again 6 months later when you are 
asked to complete your second and final survey.  
If you enroll in CR after being referred, at both intake and discharge, CR programs will 
securely send some of your results they measure as part of standard care including 
personal health information to the central study coordinator at Toronto General Hospital 
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(i.e., stress test, waist circumference, blood pressure, quality of life, cholesterol).  We 
will also contact the CR program to ask about your participation level and dates. 
While you are in this study you may continue with everything your family doctor or cardiac 
specialist has recommended. In all groups, you will still receive your usual care from your 
family doctor and cardiac specialist. You do not have to stop or change anything. 
Risks Related to Being in the Study 
There are no medical risks if you take part in this study, but being in this study may make 
you feel uncomfortable. You may refuse to answer questions at any time if there is any 
discomfort. 
Benefits to Being in the Study 
You may receive direct benefit from being in this study. You may be offered a 
compensation of $20 for the final survey you complete and return. Also, the information 
learned from this study may help other people with heart disease in the future.  
Voluntary Participation 
Your participation in this study is voluntary.  You may decide not to be in this study, or 
to be in the study now and then change your mind later. You may leave the study at any 
time without affecting your care. You may refuse to answer any question you do not 
want to answer.  
We will give you new information that is learned during the study that might affect your 
decision to stay in the study.   
Confidentiality 
Personal Health Information 
If you agree to join this study, the study doctor and his/her study team will look at your 
personal health information and collect only the information they need for the study.  
Personal health information is any information that could be used to identify you and 
includes your: 
• name,
• address,
• date of birth,
• new or existing medical records, that includes types, dates and results of medical
tests or procedures.
The information that is collected for the study will be kept in a locked and secure area 
by the study doctor for 10 years.  Only the study team or the people or groups listed 
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below will be allowed to look at your records.  Your participation in this study also may 
be recorded in your medical record at this hospital.   
The following people may come to the hospital to look at the study records and at your 
personal health information to check that the information collected for the study is 
correct and to make sure the study followed proper laws and guidelines: 
• Representatives of the study organizing committee.
• University Health Network Research Ethics Board.
All information collected during this study, including your personal health information, 
will be kept confidential and will not be shared with anyone outside the study unless 
required by law.  Any information about you that is sent out of the hospital will have a 
code and will not show your name or address, or any information that directly identifies 
you.  You will not be named in any reports, publications, or presentations that may 
come from this study.   
If you decide to leave the study, the information about you that was collected before 
you left the study will still be used.  No new information will be collected without your 
permission.  
In Case You Are Harmed in the Study 
If you become ill, injured or harmed as a result of taking part in this study, you will receive 
care. The reasonable costs of such care will be covered for any injury, illness or harm that is 
directly a result of being in this study. In no way does signing this consent form waive your 
legal rights nor does it relieve the investigators, sponsors or involved institutions from their 
legal and professional responsibilities. You do not give up any of your legal rights by signing 
this consent form.  
Expenses Associated with  Participating in the Study 
You will not have to pay for any of the CR sessions involved with this study. You will not be 
reimbursed for transportation to CR sessions or for your time to complete the surveys. 
Those that participate in the pedometer portion of the study, upon return of the pedometer 
and log, you will receive a complimentary pedometer in the mail. 
Questions About the Study 
If you have any questions, concerns or would like to speak to the study team for 
any reason, please call: Sherry Grace, PhD at xxx-xxx-xxxx or the study 
coordinator at xxx-xxx-xxxx. 
If you have any questions about your rights as a research participant or have concerns 
about this study, call Ronald Heslegrave, Ph.D., Chair of the University Health Network 
Research Ethics Board (REB) or the Research Ethics office number at xxx-xxx-xxxx or 
Please call the Toronto Rehab Research Ethics Board Office at (xxx) xxx-xxxx.The 
REB is a group of people who oversee the ethical conduct of research 
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studies.These people are not part of the study team. Everything that you discuss will be 
kept confidential. 
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Consent  
This study has been explained to me and any questions I had have been answered. 
I know that I may leave the study at any time. I agree to take part in this study.  
Print Study Participant’s Name  Signature  Date  
(You will be given a signed copy of this consent form) 
My signature means that I have explained the study to the participant named above. I 
have answered all questions..  
Print Name of Person Obtaining Consent Signature Date 
 The consent form was read to the participant. The person signing below attests that 
the study as set out in this form was accurately explained to, and has had any 
questions answered. 
Print Name of Witness Signature Date 
Relationship to Participant 
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Appendix B – Informed Consent Form (MSH) 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
Title A Randomized Controlled Trial of Women’s Adherence to 
Women-only, Home-based, and Traditional Cardiac 
Rehabilitation (Cardiac Rehabilitation for her heart event 
recovery [CR4HER]).  
Investigator Sherry Grace, PhD., Scientist and Associate Professor
(xxx) xxx-xxxx
Co-Investigators Donna E. Stewart, MD, Professor and Scientist 
Kenneth Melvin, MD. Cardiologist 
Heather Arthur, PhD. Professor and Research Chair 
Louise Pilote, MD. Associate Professor and Research Chair 
Paul Oh, MD. Medical Director and Assistant Professor. 
Stephanie Brister, MD. Medical Director and Associate 
Professor 
Caroline Chessex, MD, Cardiologist  
Sponsor Heart and Stroke Foundation of Ontario 
Introduction 
You are being invited to take part in a research study. Please read this explanation 
about the study and its risks and benefits before you decide if you would like to take 
part. You should take as much time as you need to make your decision. You should ask 
the study doctor or study staff to explain anything that you do not understand and make 
sure that all of your questions have been answered before signing this consent form. 
Before you make your decision, feel free to talk about this study with anyone you wish. 
Participation in this study is voluntary. 
Background and Purpose 
• You are being approached to consider participating in this study because you are a
female patient receiving cardiac care at Mount Sinai Hospital. 
• This research study examines women’s participation in cardiac rehabilitation (CR)
programs.
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• CR is a six-month outpatient program where you learn about heart disease and
behaviour changes that can improve your heart health. It is the standard of care for
heart patients. CR is proven to improve the health of participants, but not many women
attend.
• This study will explore different types of CR for female heart patients, to see which ones
women prefer to participate in. We are particularly interested in the number of sessions
women attend, and how this might be different depending on the type of program you
participate in.
• We will also explore women’s exercise, eating habits, pill-taking and smoking, and see if
they are different depending on what type of cardiac rehab program you participate in.
Finally, we will also explore whether your mood or supports might affect how many CR
sessions women attend.
• About 326 female heart patients from 5 hospitals will be in the study. If you agree to
participate, you will be one of 109 patients in this study recruited from Mount Sinai
Hospital.
 Study Design 
• If you agree, we would like to randomly (by chance) assign you to 1 of 3 study
conditions. One of these conditions is co-ed CR so there are women and men 
participating, one of the conditions has only women participating, and one of the 
conditions is home-based CR so you will be supported in making heart healthy changes 
at home by telephone.  
• This means that we will randomly refer 109 patients in each of the 3 CR types, and that
you will have an equal chance (33%) of being referred to any of the CR types. This is
like flipping a coin or rolling the dice. You will be referred to 1 CR type only.
• These CR types are offered at 2 local hospitals: Toronto Western Hospital (all types),
and Toronto Rehabilitation Institute (all types). If you live in the Hamilton area, Hamilton
Health Sciences is also involved in the study (all types). We will refer you to the hospital
offering the program type you were randomly chosen to attend which is closest to your
home or work.
• You will be in the study for 6 months.
Study Procedures 
A study recruiter will approach you in the hospital to determine your interest and eligibility for 
the study.  
1. first survey - After the study coordinator approaches you in the hospital for consent, she
will ask you to complete a paper-and-pencil survey, which will require approximately 30 
minutes of your time. The survey asks questions about your feelings, supports, your 
exercise and eating habits, smoking status, alcohol use, medications and other health 
conditions. You will only be identified by a study identification number. Should your 
responses indicate that you are feeling depressed, we will send a letter to your family 
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doctor. You can complete the survey in hospital and seal it in the envelope provided. The 
study coordinator will pick it up from you.  
We would also like your permission to access some basic medical information from your 
health records. This personal health information will help us refer you to CR. This will 
include the nature of your cardiac problem and heart history, your age, medications, other 
health problems, heart risk factors, diagnostic test results, and the name of your doctors. 
We would also like your consent to ask your family doctor or cardiac specialist if it would be 
safe for you to participate in a CR program. 
Once we have completed these steps, we will arrange your CR referral to the site closest to 
your home offering the CR program type you were randomized to. Copies of your heart-
related health records (i.e. blood work, ECG, discharge notes) will be sent to the CR 
program, in order to help them process the referral so that they are fully informed of your 
health status. They will contact you to book an intake appointment where a tailored program 
will be set up to meet your needs.  We are not involved in your direct relationship with the 
CR program, except that they will share some of your assessments with us.  
2. final survey - Six months after you complete the first survey or when you graduate from
CR, a second paper-and-pencil survey will be mailed to your home. This will also take 
approximately 30 minutes to complete. The survey asks questions about your feelings, 
supports, your exercise and eating habits, and other health conditions. In the mailed 
package we will include a pre-paid, pre-addressed return envelope so you can mail your 
completed survey back at no charge to you. 
If your survey responses suggest you attended a different type of CR program than we 
thought, we may call you to ask why, if you are willing. 
At both time points, interested participants will be mailed a pedometer package, to 
objectively measure exercise behaviour.  
3. measuring steps –For this portion, we would provide you a pedometer (a device
that measures the number of steps you take while walking around) that would record 
your physical activity during the time that you wear it. You would also receive an activity 
log. We would ask you to wear the pedometer for 7 days, and then note the number of 
steps showing, on a daily basis, on the log provided. Once the log is complete, we 
would ask you to return to us by mail (in a postage-paid envelope provided) the 
pedometer and the completed activity log-sheet. If you are interested, we would ask you 
to record your steps for 7 days before CR, and again six months later when you are 
asked to complete your second and final survey.  
If you enroll in CR after being referred, at both intake and discharge, we will securely 
get some of your results they measure as part of standard care including personal 
health information  (i.e., stress test, waist circumference, blood pressure, cholesterol).  
We will also contact the CR program to find out your participation level and dates. This 
information will be kept with the central study coordinator at Toronto General Hospital 
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While you are in this study you may continue with everything your family doctor or cardiac 
specialist has recommended. In all groups, you will still receive your usual care from your 
family doctor and cardiac specialist. You do not have to stop or change anything. 
Risks Related to Being in the Study 
There are no medical risks if you take part in this study, but being in this study may make 
you feel uncomfortable. You may refuse to answer questions at any time if there is any 
discomfort. 
Benefits to Being in the Study 
You may receive direct benefit from being in this study. Information learned from this study 
may help other people with heart disease in the future. You also will be paid $20 to 
participate in this study after all your final assessments are completed. 
Voluntary Participation 
Your participation in this study is voluntary.  You may decide not to be in this study, or 
to be in the study now and then change your mind later. You may leave the study at any 
time without affecting your care. You may refuse to answer any question you do not 
want to answer. We will give you new information that is learned during the study that 
might affect your decision to stay in the study.   
Confidentiality 
Personal Health Information 
If you agree to join this study, the study doctor and his/her study team will look at your 
personal health information and collect only the information they need for the study.  
Personal health information is any information that could be used to identify you and 
includes your: 
• name,
• address,
• age,
• new or existing medical records, that includes types, dates and results of medical
tests or procedures.
The information that is collected for the study will be kept in a locked and secure area 
by the study doctor for 10 years.  Only the study team or the people or groups listed 
below will be allowed to look at your records.  Your participation in this study also may 
be recorded in your medical record at this hospital.   
The following people may come to the hospital to look at the study records and at your 
personal health information to check that the information collected for the study is 
correct and to make sure the study followed proper laws and guidelines: 
• Representatives of the study organizing committee.
• Research Ethics Board.
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All information collected during this study, including your personal health information, 
will be kept confidential and will not be shared with anyone outside the study unless 
required by law.  Any information about you that is sent out of the hospital will have a 
code and will not show your name or address, or any information that directly identifies 
you.  You will not be named in any reports, publications, or presentations that may 
come from this study.   
If you decide to leave the study, the information about you that was collected before 
you left the study will still be used.  No new information will be collected without your 
permission.  
In Case You Are Harmed in the Study 
If you become ill, injured or harmed as a result of taking part in this study, you will receive 
care. The reasonable costs of such care will be covered for any injury, illness or harm that is 
directly a result of being in this study. In no way does signing this consent form waive your 
legal rights nor does it relieve the investigators, sponsors or involved institutions from their 
legal and professional responsibilities. You do not give up any of your legal rights by signing 
this consent form.  
Expenses Associated with  Participating in the Study  
You will not have to pay for any of the CR sessions involved with this study. You will not be 
reimbursed for transportation to CR sessions or for your time to complete the surveys. 
Those that participate in the pedometer portion of the study, upon return of the pedometer 
and log, you will receive a complimentary pedometer in the mail. 
Questions About the Study 
If you have any questions, concerns or would like to speak to the study team for 
any reason, please call: Sherry Grace, PhD at xxx-xxx-xxxx or the Study 
Coordinator at xxx-xxx-xxxx or xxx@xxx.com.  
If you have any questions about your rights as a research participant or have concerns 
about this study, call  Ronald Heslegrave, Ph.D., of the Mount Sinai Hospital Research 
Ethics Board (REB) or the Research Ethics office number at xxx-xxx-xxxx, or Dr. Paul 
Oh, Chair of the Toronto Rehabilitation Institute Research Ethics Board, xxx-xxx-xxxx. 
The REB is a group of people who oversee the ethical conduct of research 
studies.These people are not part of the study team. Everything that you discuss will be 
kept confidential.  
Consent  
This study has been explained to me and any questions I had have been answered. 
I know that I may leave the study at any time. I agree to take part in this study.  
___________________ 
Print Study Participant’s Name Signature Date 
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(You will be given a signed copy of this consent form) 
My signature means that I have explained the study to the participant named above. I 
have answered all questions..  
Print Name of Person Obtaining Consent Signature Date 
 The consent form was read to the participant. The person signing below attests that 
the study as set out in this form was accurately explained to, and has had any 
questions answered. 
Print Name of Witness Signature Date 
Relationship to Participant 
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Appendix C – Informed Consent Form (HHS) 
INFORMATION / CONSENT FORM (PARTICIPANT) 
Title of Study A Randomized Controlled Trial of Women’s Adherence to 
Women-only, Home-based, and Traditional Cardiac Rehabilitation  
Local Investigator Heather M. Arthur, PhD. 
McMaster University & Hamilton Health Sciences 
(xxx) xxx-xxxx
Principal Investigator Sherry L. Grace, PhD.  
York University & University Health 
Network (xxx) xxx-xxxx
Sponsor Heart and Stroke Foundation of Ontario 
Invitation to Participate in Research 
You are being invited to be in a research study. You are being approached to consider 
participating in this study because you are a female patient receiving cardiac care at Hamilton 
Health Sciences.  
Participation in this study is voluntary. Choosing not to participate will not have any negative 
consequences for you. 
Why is This Study Being Done?   
This research study examines women’s participation in cardiac rehabilitation (CR) programs. 
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CR is a 4-6 month outpatient program where you learn about heart disease and behaviour changes that 
can improve your heart health. It is the standard of care for heart patients. CR is proven to improve the 
health of participants, but not many women attend.  
This study will explore different types of CR for female heart patients, to see which ones women 
prefer to participate in. We are particularly interested in the number of sessions women attend, and 
how this might be different depending on the type of program you participate in.  
We will also explore women’s exercise, eating habits, pill-taking and smoking, and see if they are 
different depending on what type of cardiac rehab program you participate in. Finally, we will also 
explore whether your mood or supports might affect how many CR sessions women attend.  
How Many Participants Will be Involved in this Study? 
About 326 female heart patients from 5 hospitals in the Greater Toronto Area will be in the study. If 
you agree to participate, you will be one of about 109 patients in this study recruited from Hamilton 
Health Sciences Centre.  
What Will Happen to Participants in This Study? 
• If you agree, we would like to randomly (by chance) assign you to 1 of 3 study conditions. One of
these conditions is co-ed CR so there are women and men participating, one of the conditions has
only women participating, and one of the conditions is home-based CR so you will be supported
in making heart healthy changes at home by telephone.
• This means that we will randomly refer 109  patients in each of the 3 CR types, and that you will
have an equal chance (33%) of being referred to any of the CR types. This is like flipping a coin or
rolling the dice. You will be referred to 1 CR type only.
• All of these CR types are offered in the Cardiac Health and Rehabilitation Center at the Hamilton
Health Sciences.
• You will be in the study for 6 months.
Study Procedures 
1. first survey - After the study coordinator approaches you for consent, she will ask you to complete
a paper-and-pencil survey, which will require approximately 30 minutes of your time. The survey asks 
questions about your feelings, supports, your exercise and eating habits, smoking status, alcohol use, 
medications and other health conditions. You will only be identified by a study identification number. 
Should your responses indicate that you are having suicidal thoughts, for your safety we will send a 
letter to your family doctor. You can complete the survey in hospital and seal it in the envelope 
provided. The study coordinator will pick it up from you.  
We would also like your permission to access some basic medical information from your health 
records. This will include the nature of your cardiac problem and heart history, your age, medications, 
other health problems, heart risk factors, diagnostic test results, and the name of your doctors.  
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If you were approached to participate when you were still in the hospital, we would also like your 
consent to ask your family doctor or cardiac specialist if it would be safe for you to participate in a CR 
program. Once we have completed these steps, we will arrange your CR referral to the Hamilton 
Health Science Centre for the CR program type you were randomized to. Copies of your heart-related 
health records (i.e. blood work, ECG, discharge notes) will be sent to the CR program, in order to help 
them process the referral so that they are fully informed of your health status.  
The study coordinator will contact you to let you know which CR program type you will be 
participating in. The CR program will contact you to book an intake appointment where a tailored 
program will be set up to meet your needs.  We are not involved in your direct relationship with the 
CR program, except that they will share some of your assessments with us.  
2. final survey - Six months after you complete the first survey or when you graduate from CR, a
second paper-and-pencil survey will be mailed to your home. This will also take approximately 30 
minutes to complete. The survey asks questions about your feelings, supports, your exercise and eating 
habits, and other health conditions. In the mailed package we will include a pre-paid, pre-addressed 
return envelope so you can mail your completed survey back at no charge to you. 
If your survey responses suggest you attended a different type of CR program than we thought, we 
may call you to ask why, if you are willing. 
At both time points, interested participants will be mailed a pedometer package, to objectively 
measure exercise behaviour.  
3. measuring steps –For this portion, we would provide you a pedometer (a device that measures
the number of steps you take while walking around) that would record your physical activity 
during the time that you wear it. You would also receive an activity log. We would ask you to 
wear the pedometer for 7 days, and then note the number of steps showing, on a daily basis, on 
the log provided. Once the log is complete, we would ask you to return to us by mail (in a 
postage-paid envelope provided) the pedometer and the completed activity log-sheet. If you are 
interested, we would ask you to record your steps for 7 days before CR, and again 6 months later 
when you are asked to complete your second and final survey.  
If you enroll in CR after being referred, we will extract some of your results they measure as part 
of standard care at both intake and discharge. This will include stress tests, waist circumference, 
blood pressure, quality of life, and cholesterol.  We will also record your participation level and 
dates. This information will be securely couriered to the central study coordinator at Toronto 
General Hospital. 
While you are in this study you may continue with everything your family doctor or cardiac specialist 
has recommended. In all groups, you will still receive your usual care from your family doctor and 
cardiac specialist. You do not have to stop or change anything. 
Are There Any Risks? 
There are no foreseeable risks if you take part in this study, but being in this study may make you feel 
uncomfortable. You may refuse to answer questions at any time if there is any discomfort. 
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Are There Any Benefits? 
You may receive direct benefit from being in this study due to participating in CR. Information 
learned from this study may help other women with heart disease in the future. Results will be mailed 
to participants at the end of the study. 
Will I be Paid to Participate in the Study? 
You also will be paid $20 to participate in this study after all your final assessments are completed. 
Will There be Any Costs to Me in this Study? 
You will not have to pay for any of the CR sessions involved with this study. You will not be 
reimbursed for transportation to CR sessions or for your time to complete the surveys.  
What Will Happen to my Personal Information? 
If you agree to join this study, the investigators and study staff will look at your personal health 
information and collect only the information they need for the study. We will collect the 
following information: your name, address, telephone number, and age. We will also collect 
specific elements of new or existing medical records, such as the types, dates and results of 
medical tests or procedures, your heart risk factors, medications you are taking, and other health 
conditions you may have.   
The information that is collected for the study will be kept in a locked and secure area by the 
principal investigator for 10 years.  Only the study staff will be allowed to look at your records.   
All information collected during this study, including your personal health information, will be 
kept confidential and will not be shared with anyone outside the study unless required by law.  
Any information about you that is sent out of the hospital will have a numbered code. This code 
will be linked to your name in a separate and secure file. You will not be named in any reports, 
publications, or presentations that may come from this study.   
Representatives of the Research Ethics Board, a group of people who oversee the ethical conduct 
of research studies may come to the hospital to look at the study records and at your personal 
health information to check that the information collected for the study is correct and to make 
sure the study followed proper laws and guidelines. 
If you decide to leave the study, the information about you that was collected before you left the 
study will still be used.  No new information will be collected without your permission.  
Can Participation End Early? 
The investigators may decide to remove you from this study without your consent for the 
following reason:   
• Your intake CR stress test results demonstrate you are not eligible for participation in CR.
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If you are removed from this study, the investigators will discuss the reasons with you and plans 
will be made for your continued care outside of the study. 
You can also choose to end your participation at any time. If you withdraw voluntarily from 
the study, you are encouraged to contact the study coordinator at (xxx) xxx-xxxx.  
We will give you new information that is learned during the study that might affect your decision 
to stay in the study.  If you leave the study, the information about you that was collected before 
you left the study will still be used. No new information about you will be collected without your 
permission. 
Are There Any Alternatives I Should Know About? 
If you decide not to participate in this study, you may still discuss getting a CR referral to the program 
and site of your choice with any one of your healthcare providers. 
What Happens If I Have a Research-Related Injury? 
If you become ill, injured or harmed as a result of taking part in this study, you will receive care. The 
reasonable costs of such care will be covered for any injury, illness or harm that is directly a result of 
being in this study. In no way does signing this consent form waive your legal rights nor does it relieve 
the investigators, sponsors or involved institutions from their legal and professional responsibilities. 
You do not give up any of your legal rights by signing this consent form.  
If I Have Questions About the Study, Who Should I Call? 
If you have any questions, concerns or would like to speak to the study team for any reason, 
please call the study coordinator of the University Health Network at xxx-xxx-xxxx. 
Alternatively, you may also contact Dr. Heather Arthur, the local Principal Investigator 
McMaster University, at xxx-xxx-xxxx.  
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Consent 
Participant:   
I have read the preceding information thoroughly. I have had an opportunity to ask questions and 
all of my questions have been answered to my satisfaction. I agree to participate in this study. I 
understand that I will receive a signed copy of this form. 
Name Signature Date 
Person obtaining consent:  
I have discussed this study in detail with the participant. I believe the participant understands 
what is involved in this study. 
Name, Role in Study Signature Date 
This study has been reviewed by the Hamilton Health Sciences/McMaster Faculty of Health 
Sciences Research Ethics Board (HHS/FHS REB). The REB is responsible for ensuring that 
participants are informed of the risks associated with the research, and that participants are free 
to decide if participation is right for them. If you have any questions about your rights as a 
research participant, please call The Office of the Chair, HHS/FHS REB at xxx-xxx-xxxx.
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Appendix D – Informed Consent Form (SHSC) 
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
Full Study Title: A Randomized Controlled Trial of Women’s Adherence to 
Women-only, Home-based, and Traditional Cardiac 
Rehabilitation  
(Cardiac Rehabilitation for her heart event recovery 
[CR4HER]). 
Principal Investigator:  Paul Oh, MD 
Medical Director and Assistant 
Professor (xxx) xxx-xxxx 
Co-Investigators: Sherry L. Grace, PhD. Scientist and Associate Professor 
Kenneth Melvin, MD. Cardiologist 
Heather Arthur, PhD. Professor and Research Chair 
Louise Pilote, MD. Associate Professor and Research Chair 
Stephanie Brister, MD. Medical Director and Associate 
Professor 
Donna E. Stewart, MD. Professor and Research Chair 
Sponsor: This study is being funded by the Heart and Stroke Foundation of Ontario. 
______________________________________________________________________ 
INFORMED CONSENT 
You are being invited to consider participating in a research study.  A research study is 
a way of gathering information on a treatment, procedure or medical device or to 
answer a question about something that is not well understood.   
This form explains the purpose of this research study, provides information about the 
study, the tests and procedures involved, possible risks and benefits, and the rights of 
participants.   
Please read this form carefully and ask any questions you may have.  You may take as 
much time as you wish to decide whether or not to participate. Please ask the study 
staff or one of the investigator(s) to clarify anything you do not understand or would like 
to know more about. Make sure all your questions are answered to your satisfaction 
before deciding whether to participate in this research study. 
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INTRODUCTION 
You are being asked to consider participating in this study because you are a female 
patient receiving cardiac care at Sunnybrook Health Sciences Centre. This research 
study examines women’s participation in cardiac rehabilitation (CR) programs. CR is an 
outpatient program where you learn about heart disease and behaviour changes that 
can improve your heart health. CR is proven to improve the health of participants, but 
not many women attend.  
WHY IS THIS STUDY BEING DONE? 
The purpose of this study is to explore different types of CR for female heart patients, to 
see which ones women prefer to participate in. We are particularly interested in the 
number of sessions women attend, and how this might be different depending on the 
type of program you participate in.  
We will also explore women’s exercise, eating habits, pill-taking and smoking, and see if 
they are different depending on what type of cardiac rehab program you participate in. 
Finally, we will also explore whether your mood or supports might affect how many CR 
sessions women attend. 
WHAT WILL HAPPEN DURING THIS STUDY? 
Participants in this study will be randomly (by chance) placed in one of three study 
conditions: 1) Co-ed CR (both women and men are participating),  
2) Women-only CR (only women participating), OR
3) Home-based CR (you will be supported in making heart healthy
changes at home by telephone).
Neither you, the study staff nor the investigator(s) can influence which CR type you are 
in. You will have a 33% chance of being referred to any of the CR types. You and the 
study staff will know which CR type you are in.  
These CR types are offered at 2 local hospitals: Toronto Western Hospital, and Toronto 
Rehabilitation Institute. We will refer you to the program that is closest to your home or 
work.  
Another way to find out what will happen during this study is to read the study plan 
below.  Start reading at the top and read down the list, following the arrows. 
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HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
It is anticipated that about 326 people will participate in this study, recruited from about 
three centres within Toronto. About 108 people will participate in this study at 
Sunnybrook. The length of this study for participants is 6 months.  The entire study is 
expected to take about 36 months to complete and the results should be known in 4 
years.   
WHAT ARE THE RESPONSIBILITIES OF STUDY PARTICIPANTS? 
If you decide to participate in this study you will be asked to do the following: 
Screening: If you provide informed consent to participate in this study, the study 
coordinator will discuss with you in the hospital whether you are eligible for the study. 
This will involve asking you a few questions, mainly about your cardiac condition or 
procedure, and general location of your residence and/or work. There is a chance that 
you will not be eligible to participate in the study after screening is completed. 
We would like your permission to access some basic medical information from your 
health records. This personal health information will help us ensure you are eligible for 
Start Here 
Informed Consent 
Screening 
Randomization 
Women-Only CR Co-ed CR Home-based CR 
6 month follow up 
Survey in mail 
6 month follow up 
Survey in mail 
 
6 month follow up 
Survey in mail 
 
Physician 
Clearance for CR 
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the study and to complete your CR referral form. This will include the nature of your 
cardiac problem and heart history, your age, medications, other health problems, heart 
risk factors, diagnostic test results, and the name of your doctors.  
First survey: If you are eligible for the study, the study coordinator will provide you with 
a paper-and-pencil survey to complete. The survey will require about 30 minutes of your 
time to complete. The study coordinator will provide you a clipboard and pen to 
complete the survey. The survey asks questions about your feelings, supports, your 
exercise and eating habits, smoking status, alcohol use, medications and other health 
conditions. You have the choice not to answer any questions. You will only be identified 
by a study identification number. You can complete the survey in hospital and seal it in 
the envelope provided. The study coordinator will pick it up from you.  
While CR is very safe and will be tailored to your needs, we would also like your 
consent to ask your family doctor or cardiac specialist if it would be safe for you to 
participate in a CR program. 
Once we have completed these steps, we will arrange your CR referral to the site 
closest to your home offering the CR program type you were randomized to. Copies of 
your heart-related health records (i.e. blood work, ECG, discharge notes) will be sent to 
the CR program in order to help them process the referral so that they are fully informed 
of your health status. They will contact you to book an intake appointment.  
CR is part of the regular care for heart patients. If you enroll in the program after 
referral, this could involve weekly visits to the CR program or regular phone calls with 
CR staff. 
Measuring steps: If you are interested, a pedometer package will be mailed to you to 
objectively measure exercise behaviour. This is completed 7 days before you begin CR 
and 9 months later or when you are asked to complete your second and final survey. 
For this portion, we would provide you a pedometer (a device that measures the 
number of steps you take while walking around) that would record your physical activity 
during the time that you wear it. You would also receive an activity log. We would ask 
you to wear the pedometer for 7 days, and then write down on a daily basis the number 
of steps showing for each day in the log provided. Once the log is complete, we would 
ask you to return to us by mail (in a postage-paid envelope provided) the pedometer 
and the completed activity log-sheet. You can choose not to participate in this part of 
the study. 
If you enroll in CR after being referred, you will undergo both CR intake and discharge 
assessments. The CR program will securely send some of your results including 
personal health information to the central study coordinator at Toronto General Hospital 
(i.e., stress test, waist circumference, blood pressure, quality of life, cholesterol).  We 
will also contact the CR program to ask about your participation level and dates. 
127
Final survey: Nine months after you complete the first survey or when you graduate 
from CR, a second paper-and-pencil survey will be mailed to your home. Once again, 
this survey will take about 30 minutes to complete and will ask similar questions as the 
first survey. We will include a pre-paid, pre-addressed return envelope so you can mail 
your completed survey back at no charge to you. If we do not receive your completed 
survey in the following 3 weeks, we may try to reach you by telephone or email. 
The total time commitment to participate in this study is approximately 2 hours if you do 
not participate in the step measurement portion of the study, and approximately 6 hours 
if you do. 
If your survey responses suggest you attended a different type of CR program than we 
thought, we may call you to ask why, if you are willing. 
WHAT ARE THE RISKS OR HARMS OF PARTICIPATING IN THIS STUDY? 
There are no medical risks if you take part in this study, but being in this study may 
make you feel uncomfortable. You may refuse to answer questions at any time if there 
is any discomfort. 
WHAT ARE THE BENEFITS OF PARTICIPATING IN THIS STUDY? 
You may or may not directly benefit from being in this study. However, possible benefits 
include lower rates of death and disability, and better lifestyle and quality of life if you 
fully participate in CR. Information learned from this study may or may not help other 
people with heart disease in the future.  
CAN PARTICIPATION IN THIS STUDY END EARLY? 
The investigators may decide to remove you from this study without your consent for 
any of the following reason:   
• Your intake CR stress test results demonstrate you are not eligible for
participation in CR. 
If you are removed from this study, the investigators will discuss the reasons with you 
and plans will be made for your continued care outside of the study. 
You can also choose to end your participation at any time. If you withdraw voluntarily 
from the study, you are encouraged to contact Mary Attia, at (xxx) xxx-xxxx. 
If you leave the study, the information about you that was collected before you left the 
study will still be used. No new information about you will be collected without your 
permission. 
WHAT ARE THE COSTS OF PARTICIPATING IN THIS STUDY? 
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Participation in this study will not involve any additional costs to you or your private 
health care insurer.  
ARE STUDY PARTICIPANTS PAID TO PARTICIPATE IN THIS STUDY? 
You will be paid $20 to participate in this study after all your final assessments are 
completed. You will not be reimbursed for transportation costs to, or parking for your CR 
sessions, nor for your time to complete the surveys. If you participate in the pedometer 
portion of the study, upon return of the pedometer and log, you will receive a 
complimentary pedometer in the mail. 
WHAT OTHER CHOICES ARE THERE?  
If you decide not to participate in this study, you may still discuss getting a CR referral to 
the program and site of your choice with any one of your healthcare providers. 
DO THE INVESTIGATORS HAVE ANY CONFLICTS OF INTEREST? 
There are no conflicts of interest to declare related to this study. 
COMMUNICATION WITH YOUR FAMILY DOCTOR 
For the purposes of this research study, we will be soliciting approval for you to 
participate from your family doctor.  
Should you enroll, your family doctor may receive progress summaries from the CR 
program.  
Should your questionnaire responses indicate that you are having suicidal thoughts, for 
your safety we will send a letter to your family doctor.  
WHAT ARE THE RIGHTS OF PARTICIPANTS IN A RESEARCH STUDY? 
All participants in a research study have the following rights: 
1. You have the right to have this form and all information concerning this study
explained to you and if you wish translated into your preferred language.
2. Participating in this study is your choice (voluntary). You have the right to choose not
to participate, or to stop participating in this study at any time without having to
provide a reason.  If you choose to withdraw, your choice will not have any effect on
your current or future medical treatment or health care.  Should you choose to
withdraw from the study you are encouraged to contact the Study Coordinator, at
(416) 340-4800 ext.6593#.
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3. You have the right to receive all significant information that could help you make a 
decision about participating in this study. You also have the right to ask questions 
about this study and your rights as a research participant, and to have them 
answered to your satisfaction, before you make any decision. You also have the right 
to ask questions and to receive answers throughout this study. If you have any 
questions about this study you may contact the person in charge of this study
(Principal Investigator) Paul Oh, Cardiology, xxx-xxx-xxxx. If you have questions 
about your rights as a research participant or any ethical issues related to this study 
that you wish to discuss with someone not directly involved with the study, you may 
call Dr. Philip C. Hébert, Chair of the Sunnybrook Research Ethics Board at 
(xxx) xxx-xxxx, or the Toronto Rehabilitation Institute Research Ethics Board, 
xxx-xxx-xxxx.
4. You have the right to have any information about you and your health that is
collected, used or disclosed for this research study to be handled in a confidential
manner.
If you decide to participate in this study, the investigator(s) and study staff will look at
your personal health information and collect only the information they need for this
study. “Personal health information” is health information about you that could identify
you because it includes information such as your;
• name,
• address,
• telephone number,
• date of birth,
• new and existing medical records, or
• the types, dates and results of various tests and procedures.
The following people may come to the hospital to look at your personal health 
information to check that the information collected for the study is correct and to 
make sure the study followed the required laws and guidelines:  
• Representatives of the Sunnybrook Research Ethics Board, a group of people who
oversee the ethical conduct of research studies at Sunnybrook; and
Access to your personal health information will take place under the supervision of 
the Principal Investigator. 
In addition, any study data about you that is collected will be securely transported to 
the central study site at Toronto General Hospital using a numbered code, and will 
remain separate from forms that contain your name or address, or any information 
that directly identifies you.  “Study data" is information about you that is collected for 
the research study, but that does not directly identify you.   
Study data that is sent outside of the hospital will be used for the research purposes 
explained in this consent form.  
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The investigators, study staff and the other people listed above will keep the 
information they see or receive about you confidential, to the extent permitted by 
applicable laws. Even though the risk of identifying you from the study data is very 
small, it can never be completely eliminated.  
When the results of this study are published, your identity will not be disclosed.  
The Principal Investigator will keep any personal information about you in a secure 
and confidential location for 10 years and then destroyed as required by Sunnybrook 
policy.  
5. By signing this consent form, you do not give up any of your legal rights.
6. You have the right to receive a copy of this signed and dated informed consent form
before participating in this study.
7. You have the right to be told about any new information that might reasonably affect
your willingness to continue to participate in this study as soon as the information
becomes available to the study staff.
8. You have the right to access, review and request changes to your personal health
information.
9. You have the right to be informed of the results of this study once the entire study is
complete.
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DOCUMENTATION OF INFORMED CONSENT 
Full Study Title: A Randomized Controlled Trial of Women’s Adherence to Women-
only, Home-based, and Traditional Cardiac Rehabilitation (Cardiac 
Rehabilitation for her heart event recovery [CR4HER]). 
Name of Participant:  ________________________________________ 
Participant/Substitute decision-maker 
By signing this form, I confirm that: 
• This research study has been fully explained to me and all of my questions answered
to my satisfaction
• I understand the requirements of participating in this research study
• I have been informed of the risks and benefits, if any, of participating in this research
study
• I have been informed of any alternatives to participating in this research study
• I have been informed of the rights of research participants
• I have read each page of this form
• I authorize access to my personal health information (medical record) and research
study data as explained in this form
• I have agreed for the study coordinator to obtain consent from my family doctor or
cardiac specialist for my eligibility to participate in cardiac rehabilitation
• I have agreed to participate in this study or agree to allow the person I am responsible
for to participate in this study
____________________________        ____________________________        _____________________ 
Name of participant/Substitute       Signature             Date 
decision-maker (print)       
Person obtaining consent 
By signing this form, I confirm that: 
• This study and its purpose has been explained to the participant named above
• All questions asked by the participant have been answered
• I will give a copy of this signed and dated document to the participant
____________________________        ____________________________        _____________________  
Name of Person obtaining             Signature                                       Date 
consent (print) 
Statement of Investigator 
I acknowledge my responsibility for the care and well being of the above participant, to 
respect the rights and wishes of the participant as described in this informed consent 
document, and to conduct this study according to all applicable laws, regulations and 
guidelines relating to the ethical and legal conduct of research. 
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____________________________        ____________________________        _____________________ 
Name of Investigator (print)                    Signature                           Date 
ASSISTANCE DECLARATION □ (check here if not applicable) 
The participant/substitute decision-maker was assisted during the consent process as 
follows: 
 The consent form was read to the participant/substitute decision-maker, and the
person signing below attests that the study was accurately explained to, and
apparently understood by, the participant/substitute decision-maker.
 The person signing below acted as a translator for the participant/substitute
decision-maker during the consent process.  He/she attests that they have
accurately translated the information for the participant/substitute decision-
maker, and believe that that participant/substitute decision-maker has
understood the information translated.
____________________________        ____________________________        _____________________  
Name of Person Assisting (Print)           Signature                           Date 
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Appendix E – Baseline Survey 
Cardiac Rehab for Her Study 
(CR4HER) 
Instructions for completing the survey questions appear at the beginning of each 
section. 
Please seal your completed questionnaire in the stamped envelope 
provided, and return it to the study coordinator. 
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SECTION A: USUAL ACTIVITIES 
Instructions:  The following questions have to do with your current activity status.  
Circle     Yes    or      No   in response to each question.  
1. Can you take care of yourself that is, eating, dressing, bathing or using the toilet?  Yes No
2. Can you walk indoors, such as around your house? Yes No 
3. Can you walk a block or two on level ground? Yes No 
4. Can you climb a flight of stairs or walk up a hill? Yes No 
5. Can you run a short distance? Yes No 
6. Can you do light work around the house like dusting or washing dishes? Yes No
7. Can you do moderate work around the house like vacuuming, sweeping floors, or carrying in the
groceries? Yes No
8. Can you do heavy work around the house like scrubbing floors, or lifting or moving heavy
furniture? 
Yes   No 
9. Can you do yard work like raking leaves, weeding or pushing a power mower? Yes No 
10. Can you have sexual relations? Yes No 
11. Can you participate in moderate recreational activities like golf, bowling, dancing, doubles tennis, or
throwing a   baseball or football?
Yes No 
12. Can you participate in strenuous sports like swimming, singles tennis, football, basketball or skiing?
     Yes No 
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SECTION B: OTHER HEALTH PROBLEMS 
Instructions: Please check  whether or not you experience the following health problems in the circle 
provided: 
Health Problem Have it? If yes, please specify 
a. Joint repair or
replacement (such
as hips, knees)
YES    
 NO      
b. Arthritis YES    
 NO      
c. Osteoperosis YES    
 NO      
d. Asthma YES    
 NO      
e. Chronic
Obstructive
Pulmonary Disease
(COPD)
YES    
 NO      
f. Diabetes YES    
 NO      
Type 1 _______   
Type 2 ________ 
g. Chronic Renal
Failure (liver)
YES    
 NO      
h. Urinary
Incontinence
YES    
 NO      
i. Cancer (such as
breast, lung, cervix,
stomach, colon,
kidney, bone,
metastasis or
spread, lymphoma,
leukemia, others)
YES    
 NO      
j. Other health
problems
YES    
 NO      
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SECTION C: EXERCISE 
1. During a typical 7-Day period (a week), how many times on the average do you do the
following kinds of exercise for more than 15 minutes during your free time (write on each line
the appropriate number). 
Times Per 
Week 
a) STRENUOUS EXERCISE
(heart beats rapidly)
 (e.g., running, jogging, hockey, football, soccer, 
  squash, basketball, cross country skiing, judo, __________ 
  roller skating, vigorous swimming, vigorous 
  long distance bicycling) 
b) MODERATE EXERCISE
(not exhausting)  __________ 
(e.g., fast walking, baseball, tennis, easy bicycling, 
 volleyball, badminton, easy swimming, alpine skiing, 
 popular and folk dancing)  
c) MILD EXERCISE
(minimal effort) __________ 
(e.g., yoga, archery, fishing from river bank, bowling, 
horseshoes, golf, snow-mobiling, easy walking) 
2. During a typical 7-Day period (a week), in your leisure time, how often do you engage in any
regular activity long enough to work up a sweat (heart beats rapidly)? 
OFTEN    SOMETIMES NEVER/RARELY 
  1.          2.   3.  
3. Cardiac rehabilitation is an outpatient program of structured activity and education to maximize your
recovery. For example, you might go to a hospital outpatient program to exercise 1-3 times per week for 6 
months or so.  
Have you previously attended a cardiac rehabilitation program?  
 Yes
 No
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SECTION D: NUTRITION 
MEAT, FISH AND POULTRY 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
1. Which type of ground meat do you usually eat?
       office use only 
1 Regular hamburger (30% fat) 
2 Lean ground beef (25% fat) 
3 Extra lean/ground chuck (20% fat) 
4 Ground round (15% fat) 
5 Super lean (4% - 10% fat), ground sirloin (10% fat), ground turkey breast, ground 
chicken breast 
6 Eat no ground meat 
   Score ______      
2. Which best describes your typical lunch?  “Lunch meat” means ham, bologna, salami,
pastrami, etc. 
1 Cheeseburger, pizza, typical cheeses, egg dishes (egg salad, quiche, frittata, etc) 
2 Sandwich (lunch meat, hamburger, grilled cheese,), meat/chicken entree (plain/fried), regular 
hot dog 
3 Skip lunch or sandwich (tuna, fish, peanut butter, chicken or turkey lunch 
meat/light mayo, etc),  
turkey hot dog, vegetarian dishes 
4 Tuna sandwich (w/mayo: 1 gm fat or less/Tbsp, Veggie burger (Garden, Boca), 
entree (fish [not fried], small bits of chicken or meat), low-fat yogurt, 
5 Salad (low-cal dressing), low-fat vegetarian dishes, hot dog (0-2 gm fat), deli meats/fat free 
sandwich (w/mayo: 1 gm fat or less/Tbsp), bagel (light cream cheese) 
6 Fat free vegetarian dishes, salad (fat free dressing), Veggie dog, Garden Vegan (fat free 
burger), 
       nonfat yogurt, dry cereal (skim milk), bagel (fat free cream cheese) 
Score________  
3. Circle all of the choices that reflect the entree at your main meal.
1 Cheese (Cheddar, Jack, etc), eggs, organ meats (liver, etc), pizza, vegetarian dishes once a 
week or more 
     2 Beef, lamb, pork or ham once a week or more 
     3 Very lean red meat (top round or flank steak), rabbit, veal, venison or elk once a 
week or more 
             4 Chicken, turkey, crab, lobster or shrimp twice a week or more 
     5 Fish, scallops, oysters, clams, low-fat vegetarian dishes twice a week or more 
     6 Fat free vegetarian dishes, fat free seafood dishes every day  
     Score 
4. Estimate the number of ounces of meat, cheese, fish and poultry you eat in a typical day.
Include all meals and snacks. (To guide you in your estimate (a piece the size of a deck of cards =
3 oz) 
1 hot dog  = 1 ½ oz   1 chicken thigh  = 2-3 oz 1 slice cheese  = 1 oz 
4 strips bacon  = 1 oz  ½ chicken breast = 3 oz 1-inch cube cheese     = 1 oz 
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1 small burger patty = 3-4 oz    average T-bone steak = 8 oz        meat in sandwiches  = 2-3 oz 
1 Eleven or more ounces a day 
2 Nine to 10 ounces a day 
3 Six to 8 ounces a day 
4 Four to 5 ounces a day 
5 Up to 1 ounce cheese or  3 oz lean meat, poultry, shrimp, crab, lobster or  6 oz fish, 
clams, oysters, scallops a day 
6 None or up to 3 ounces shrimp, crab, lobster or  6 ounces fish, clams, oysters, 
scallops a day     Score_ 
5. Which of these have you eaten in the past month?
1 Bacon, sausage 
2 Canadian bacon, turkey or chicken sausage 
4 Vegetarian sausage (Morningstar links or patties, other soy sausage) 
6 None      Score 
TOTAL SCORE (MEAT, FISH AND POULTRY) 
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DAIRY PRODUCTS AND EGGS 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
6. Which do you usually use for drinking (don’t forget lattes/mochas) or cooking?
office use only  
       (Most lattes/mochas contain whole milk unless you request otherwise). 
1 Whole milk 
2 Two percent milk 
4 One percent milk, buttermilk 
5 None or skim (nonfat) milk, nondairy beverages (Edensoy, Rice Dream, etc) 
Score 
7. Which toppings do you use?
1 Sour cream (real or imitation including IMO), whipped cream 
2 Light/low-fat sour cream, Cool Whip, Reddi-Whip aerosol dairy 
3 Cool Whip Lite, regular cottage cheese, whole milk yogurt 
4 Low-fat yogurt, low-fat cottage cheese, Reddi-Whip aerosol nondairy 
5 1% fat cottage cheese, Cool Whip Free, soy yogurt 
6 None or nonfat yogurt, nonfat sour cream, nonfat cottage cheese 
Score 
8. Which frozen desserts are you most likely to eat at least once a month?
1 Regular ice cream (5 g to 18 g fat per ½ cup) 
2 Light ice cream (4 g fat per 1/ 2 cup) 
3 Ice milk, most soft ice cream, frozen yogurt (cream added), Tofutti 
4 Sherbet, low-fat frozen yogurt, Soy Delicious 
5 None or nonfat frozen yogurt, sorbets, Popsicles 
               Score 
9. Which kind of cheese do you use?
2 Cheddar, Swiss, Jack, Brie, Feta, Montrachet, Blue, Jarlsberg, whole milk 
mozzarella, Neufchatel or regular cream cheese, processed cheese (Velveeta, American, Cheese 
Whiz), Kraft Delux Slices, Easy Cheese, Parmesan 
5 Part-skim mozzarella, light cream cheese, light Cheddar, light Jack, (Kraft Light 
Naturals, Alpine Lace-Lo, Velveeta Light or other part-skim cheeses), Cabot Vermont Cheddar 
(50% Light), string cheese 
8 Jarlsberg Lite, Athenos Reduced Fat Feta Cheese 
      10 Light part-skim mozzarella, low-fat and light ricotta, Lite-Line, nonfat Parmesan, Cabot 
Vermont cheddar (75% Light), Parm Plus, soy/rice cheese (cheddar, mozzarella)  
12 None or fat free cheeses (Cheddar, Jack, ricotta, cream, Healthy Choice, Alpine Lace, etc), soy 
(Tofu Rella), 
     Almond (cheddar, mozzarella, etc)   Score 
10. Check the type and number of "visible" eggs you eat (scrambled, fried, etc).
1 Six or more whole eggs a week 
2 Three to five whole eggs a week 
3 One to two whole eggs a week 
4 One whole egg a month 
140
 5 None or egg whites, egg substitute (Nulaid, Egg Beaters, Scramblers, Second Nature, 
etc)       Score   
 
11. Check the type of eggs usually used in food prepared at home or bought in grocery stores. 
 1 Whole eggs or mixes containing whole eggs (complete pancake mix, slice-and-bake 
cookies, etc) 
 3 Combination of egg whites, egg substitute and whole eggs 
 5 None or egg whites, egg substitute        
   Score   
      
      TOTAL SCORE (DAIRY PRODUCTS AND EGGS) 
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FATS AND OILS 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
12. Which kinds of fats are used most often to cook your food (vegetables, meats, etc)?
office use only 
1 Butter, shortening (with animal fat), lard, bacon grease, chicken fat 
2 Shortening (with vegetable fat), vegetable oil (cottonseed) 
3 Tub or stick margarine (all except canola), vegetable oil (soybean, olive) 
4 Vegetable oil (safflower, corn), tub or stick margarine (canola) 
5 Vegetable oil (canola) 
6 None or use nonstick cooking spray  
Score 
13. How much of these "added" fats do you eat in the typical day:  peanut butter, margarine,
mayonnaise, or salad dressing (including those made with olive oil)?  Do not count fat free products. 
             Examples of amounts people often use: 
1 Ten teaspoons or more on toast:  2 tsp margarine  
2 Eight to 9 teaspoons on salads:  12 tsp salad dressing 
3 Six to 7 teaspoons  on vegetables:  3 tsp margarine  
4 Four to 5 teaspoons on sandwiches:  6 tsp mayonnaise, 2 tsp margarine   
5 Three teaspoons  on potatoes:  3 tsp margarine 
6 None   on pasta, rice:  3 tsp margarine, oil or 6 tsp pesto 
 Score_________        
14. How often do you eat potato chips, corn or tortilla chips, fried chicken, fish sticks,
French fries, doughnuts, other fried foods, croissants or Danish pastries?
Do not count fat free products 
1 Two or more times a day 
2 Once a day 
3 Two to 4 times a week  
4 Once a week 
5 Less than twice a month 
6 Never    Score 
15. Which best describes the amount of margarine, butter, peanut butter, mayonnaise or
cream cheese that you put on breads, muffins, bagels, etc?  Do not count fat free products 
1 Average 
2 Lightly spread (can see the bread through it) 
4 "Scrape" (can barely see the spread) 
5 None  
Score 
16. Which kind of salad dressings do you use?
1 Real mayonnaise  
2     Miracle Whip, light mayo, Caesar, Thousand Island dressing 
3     Best Food’s Low-Fat Mayo (1gm fat/Tbs), Ranch, French, Blue Cheese or Roquefort, vinegar 
and oil,           Italian, Russian, low-fat mayonnaise dressing, Miracle Whip Light dressing and 
Italian dressings 
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4 Ranch Dressing (mix and light mayo) 
5 Low-cal salad dressing, Ranch Dressing (mix and low-fat yogurt) 
6   Use no salad dressing or fat free mayonnaise, Miracle Whip fat free, fat free salad dressings, 
    Ranch dressing (mix and nonfat dairy or yogurt/sour cream), vinegar, lemon juice         
Score  
TOTAL SCORE (FATS AND OILS) 
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SWEETS AND SNACKS 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
17. How often do you eat desserts or baked goods (sweet rolls, doughnuts,
office use only 
muffins, scones, cookies, cakes)?    Do not count fat free versions 
1  Once a day  
2  Five to 6 times a week 
3  Three to 4 times a week 
4  Two times a week 
5  One time a week or less 
6  Never  
Score _  
18. Which of the following desserts or snacks have you eaten in the last month?
1  Croissants, cheesecake, typical cakes with frosting 
2   Pies, cookies, cupcakes, muffins, scones, frosted doughnuts  
3   Granola bars (Nature Valley, Quaker Chewy) 
4   Low-fat muffins, desserts made using low-fat recipes, low-fat cookies (fig bars, 
ginger snaps,      
           Snackwell’s), low-fat granola bars (Power Bar, Quaker Chewy low-fat) 
5  Fat free desserts including angel food cake, fat free cookies 
6   Never eat baked goods listed above or eat fruit for dessert 
       Score  _ 
19. Which of the following snacks have you eaten in the last month?
1 Chocolate, commercial popcorn, Poppy Cock popcorn, caramel corn 
      2  Nuts, potato chips, corn chips, Doritos chips, microwave popcorn, homemade popcorn 
w/butter, 
          Cracker Jack, French fries, peanut butter, party/snack crackers (Ritz) 
4 Tortilla chips, baked potato chips, pretzels, light microwave popcorn, lightly 
buttered popcorn (1 tsp margarine for 3 cups popcorn), low-fat crackers (soda, graham), Toby’s 
Tofu Pate Original 
5 Baked tortilla chips, homemade popcorn w/no fat, fat free soda crackers and 
other fat free crackers, Toby’s Tofu Pate Lite 
6 Do not eat snacks or eat fruits and vegetables as snacks 
        Score __ 
TOTAL SCORE (SWEETS AND SNACKS) 
SEAFOOD 
Consider your eating habits during the last month. For each question, circle all items that apply. 
20. How often do you eat fish?  (tuna, snapper, perch, sole, halibut, cod, salmon,
shrimp/prawns, crab, lobster, scallops, clams, oysters, sardines, etc).
office us only 
1    Do not eat fish or eat fish less than once a month 
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2    One to 3 times a month 
3    Once a week 
4    Two times a week 
5    Three or more times a week or  eat vegetarian with no added fat 
Score 
21. Which fish (fresh, frozen or canned) have you eaten in the last month?
1    Ate no fish in the last month 
2    Scallops, clams, mussels, snowcrab (surimi) 
3    White fish (perch, cod, sole, halibut, snapper), oyster, lobster, tuna, crab 
4    Trout, steelhead, herring, catfish, salmon (Atlantic, pink) 
5    Salmon (Coho, red, Chinook), mackerel, sardines, shrimp/prawns, squid or eat 
vegetarian with no added fat 
Score 
TOTAL SCORE (FISH ) 
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GRAINS, BEANS, FRUITS AND VEGETABLES 
Consider your eating habits during the last month.  For this part of the quiz, list the number of 
servings of the following foods  you eat each day or week, as specified for the question. 
office use only 
22. How many pieces of fruit or cups of fruit juice do you consume a day?  (not "fruit-flavored"
drinks) 
 cups or pieces 
Score (cups x 5) 
23. How many cups of vegetables do you eat a day (tossed salad, cooked vegetables, soups,
casseroles, etc)?  (A typical serving size for tossed salad is 1 to 1 1/2 cups)
 cups 
Score (cups x 5) 
24. How many cups of legumes do you eat a week (refried beans, split peas, white beans, black
beans, 
blackeye peas, lentils, chili, etc)? 
 cups 
Score (cups x 5) 
25. List the number of servings of the following you ate last week.  (A typical cereal bowl holds
1 1/2 
to 2 cups; people typically eat 9 to 12 cups of popcorn). 
Amount eaten LAST WEEK 
cooked cereal   bowls/week 
ready-to-eat cereal  bowls/week 
English muffin   #/week 
hamburger bun  #/week 
bagel (plain or flavored)  #/week 
Pita or pocket bread   #/week 
eight-inch tortilla  #/week 
plain popcorn (4 cups/serving)   servings/week (1 microwave bag holds 10 ½ cups) 
fat free or low-fat muffin  muffins/week 
cornbread  pieces/week 
Total     Score  (svgs x 1.2) 
Amount eaten LAST WEEK 
bread or toast   slices/week 
dinner or hard roll   rolls/week 
French/Sourdough bread  slices/week 
four-inch pancake  pancakes/week 
low-fat crackers such as soda, graham, etc (8/serving)   servings/week 
regular sized rice cakes  (3/serving)  servings/week 
mini sized rice cakes (8/serving) ______  servings/week 
pretzels (1 cup or 1 large soft)   cups or #/week 
Total     Score (svgs x 0.7) 
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26. How many servings of grains and potatoes did you eat last week?  Be sure to count these
foods 
when they are in a mixed dish (casserole, burrito, etc).  This includes breakfast, lunch and 
dinner. 
Number of servings eaten LAST WEEK 
macaroni, spaghetti and other pastas   cups/week 
mashed potato     cups/week 
baked potato     large potato/week 
rice, corn, bulgur, barley, couscous, other grains     ____  cups/week 
Score 
Score:  (cups macaroni, etc x 1.5) + (cups mashed potato x 1.5) + (number baked potatoes x 
2) + (cups rice, corn, etc x 2)
TOTAL SCORE (GRAINS, BEANS, FRUITS AND VEGETABLES)
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BEVERAGES 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
27. Which of the following reflects your habits regarding alcoholic beverages?
office use only 
  1 drink = 12 ounces beer 
 1 1/2 ounces whiskey, gin, rum, etc 
4 ounces wine 
1 ounce liqueur 
1 One or more drinks a day 
2 Four to 6 drinks a week 
3 Three drinks a week 
4 One to 2 drinks a week 
5 One to 3 drinks a month 
6 Do not drink alcoholic beverages 
Score 
28. Which of the following reflects your habits regarding soda pop, sweetened seltzers, sports
drinks, 
       fruit punch, etc?       Do not count sugar free (diet) drinks 
            1 can         = 12 ounces 
          Big Gulp     = 32 ounces 
         1 Liter         = 33 ounces 
        2 Liter       = 67 ounces 
1 More than 48 ounces a week 
2 33-48 ounces a week 
3 25-32 ounces a week 
4 12-24 ounces a week 
5 None or less than 12 ounces a week 
Score 
29. How much coffee do you drink?  This includes espressos, lattes, mochas, etc.
Guidelines for Espresso Drinks 
“Short”            = 8-10 ounces 
     Small (“Tall”)           = 12 ounces 
    Medium (“Grande”)   = 16 ounces 
    Large (“Venti”)         = 20 ounces 
1 More than 40 ounces (more than 5 cups) a day 
3 25-40 ounces (4 to 5 cups) a day 
4 6-24 ounces (1 to 3 cups) a day 
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5 None or less than (1 cup) a day  
Score 
TOTAL SCORE (BEVERAGES) 
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SALT 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
30. Which type of "salt" do you normally use?
office use only 
1 Regular salt, sea salt, flavoring salts (seasoned salt, garlic salt, onion salt, celery salt, 
lemon pepper, etc), regular soy sauce 
3 Combination of regular and Lite Salt 
4 Lite Salt, lower-sodium soy sauce, reduced-sodium flavoring salts 
5 None or salt substitute (100% potassium chloride), Salt-free products (Mrs. Dash, 
etc) Score 
31. How often do you add salt to your food at the table?
1 Always 
2 Frequently 
4 Occasionally 
5 Never  
Score 
32. Which type of salt and how much do you use in cooking potatoes, rice, pasta, vegetables,
meat, 
casseroles and soups? 
1 Regular salt (typical amount) or eat in restaurants 4 or more times a week 
2 Regular salt (1/2 typical amount) or Lite Salt (typical amount) 
4 Lite Salt (1/2 typical amount) 
5 None or salt-free products (Mrs. Dash, etc), salt substitute   
Score 
33. Which type of cereals do you use?
1 Typical dry cereals (sweetened or unsweetened) or cereals cooked with regular salt 
(typical amount) 
3 Combination of typical dry cereals and salt-free dry cereals (Shredded Wheat, 
Puffed Wheat, Puffed Rice) or cereals cooked with regular salt (1/2 typical amount) or Lite Salt 
(typical amount) 
5 Do not eat cereal or eat salt-free dry cereals (Shredded Wheat, Puffed Wheat, 
Puffed Rice, etc) or 
      cereals cooked without salt 
Score 
34. How often do you use typical canned, bottled, or packaged foods:
salsa  salad dressings     boxed noodle entrees 
Picante sauce soups (chicken broth)     frozen entrees 
BBQ sauce chili      canned beans 
ketchup cured meats (lunch meat)     canned vegetables 
1 More than 15 times a week or eat in restaurant 4 or more times a week 
2 Ten to 14 times a week 
3 Six to 9 times a week 
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5 Five times a week or less 
            Score  
TOTAL SCORE (SALT) 
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RESTAURANTS AND RECIPES 
Consider your eating habits during the last month.   
For each question, circle all numbers or check the choices that apply. 
35. How often do you eat breakfast at a restaurant or cafeteria (this includes coffee shops)?
office use only 
1 More than twice a week 
2 Once or twice a week 
3 Once a week if you eat low-fat (unbuttered toast or English muffin, oatmeal) 
5 Less than once a month  
6 Never  
Score 
36. How often do you eat lunch at a restaurant or cafeteria or eat “take out”?
1 Daily 
2 Five days a week 
3 Two to 4 days a week 
4 One day a week 
5 Less than once a month 
6 Never  
Score 
37. How often do you eat dinner at a restaurant or cafeteria or eat “take out”?
1 More than 3 times a week 
2 Two to 3 times a week 
3 Once a week 
4 Once or twice a month  
5 Less than once a month 
6 Never  
Score 
38. Check the choices you make when eating in restaurants or cafeterias.
Select restaurants that offer low-fat choices and order those choices 
Order toast, muffins, cereal, pancakes, waffles for breakfast 
Order soup (not cream), salad or other meatless, cheeseless entrees for lunch 
Order vegetarian pizzas with half the cheese 
Avoid cheese, eggs, bacon on salads and avoid potato and macaroni salads 
Put garbanzo or kidney beans on salad at the salad bar 
Use a very small amount of salad dressing 
Order a fish, shellfish, chicken or lean red meat entree (but not fried) 
Use no more than 1 pat of margarine at any meal 
Order fruit, sorbet, sherbet, frozen yogurt or skip dessert 
SCORE:  (0-1 checks = 1; 2-3 checks = 2; 4-5 checks = 3; 6-7 checks = 4; 8-10 checks; or eat 
out less than once a  month = 5)        Score 
39. How often do you eat foods made using low-fat recipes or cook low-fat without recipes?
1 Once a month or less 
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2 One to 2 times a week 
3 Three to 4 times a week 
4 Five to 6 times a week 
5 Everyday  
Score 
TOTAL SCORE (RESTAURANTS AND 
RECIPES) 
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SECTION E: PILL TAKING  
Thinking of the medications PRESCRIBED to you by your doctor(s), please answer the following 
questions:  
1. Do you ever forget to take your medication?
 Yes
 No
2. Are you careless at times about taking your medication?
 Yes
 No
3. When you feel better, do you sometimes stop taking your medication?
 Yes
 No
4. Sometimes, if you feel worse when you take your medicine, do you stop taking it?
 Yes
 No
5. What percentage of the time would you say you take your pills as prescribed by your doctors?
(0% would be not taking as prescribed at any time, to 100% taking as prescribed all the time).
_____________ % 
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SECTION F: MOOD 
Instructions: This questionnaire consists of 21 groups of statements. Please read each group of 
statements  
carefully, and then pick out the one statement in each group that best describes the way you have been  
feeling during the past two weeks, including today. Mark (X) in the box beside the statement that you 
have picked. Be sure that you do not choose more than one statement for any group. 
1. Sadness
 I do not feel sad.
 I feel sad much of the time.
 I am sad all the time.
 I am so sad or unhappy that I
can’t stand it.
7. Self-Dislike
 I feel the same about myself as
ever. 
 I have lost confidence in myself.
 I am disappointed in myself.
 I dislike myself.
2. Pessimism
 I am not discouraged about my
future. 
 I feel more discouraged about
my future that I   used to be.
 I do not expect things to work
out for me.
 I feel that my future is
hopeless and will only get
worse.
8. Self-Criticalness
 I don’t criticize myself more
than usual. 
 I am more critical of myself
than I used to be.
 I criticize myself for all of my
faults. 
 I blame myself for everything
bad that happens.
3. Past Failure
 I do not feel like a failure.
 I have failed more than I
should have.
 As I look back on my life, I
see a lot of failures.
 I feel I am a complete failure as a
person.
9. Suicidal Thoughts or Wishes
 I don’t have any thoughts of
killing myself.
 I have thoughts of killing
myself, but I would not carry
them out.
 I would like to kill myself.
 I would kill myself if I had the
chance. 
4. Loss of Pleasure
 I get as much pleasure as I
ever did from the things I
enjoy.
 I don’t enjoy things the way I
used to. 
 I get very little pleasure from
the things that I used to enjoy.
 I can’t get any pleasure from
the things that I used to enjoy.
10. Crying
 I don’t cry any more than I
used to. 
 I cry more than I used to.
 I cry over every little thing.
 I feel like crying.
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5. Guilty Feelings
 I don’t feel particularly guilty
 I feel guilty over many things I
have done or should have
done.
 I feel quite guilty most of the
time. 
 I feel guilty all the time.
11. Agitation
 I am no more restless or
wound up than usual.
 I feel more restless or wound
up than usual.
 I am so restless or agitated that
it is hard to stay still.
 I am so restless or agitated that
I have to keep moving or doing
something.
6. Punishment Feelings
 I don’t feel I am being
punished. 
 I feel I may be punished.
 I expect to be punished.
 I feel I am being punished.
12. Loss of Interest
 I have not lost interest in other
people or activities. 
 I am less interested in other
people or things than before.
 I have lost most of my interest
in other people or things. 
 It is hard to get interested in
anything. 
13. Indecisiveness
 I make decisions about as well
as ever. 
 I find it more difficult to make
decisions than usual.
 I have much greater difficulty in
making decisions than I used to.
 I have trouble making decisions.
18. Changes in Appetite
 I have not experienced any
changes in my appetite.
 My appetite is somewhat less
than usual. 
 My appetite is somewhat
greater than   usual. 
 My appetite is much less than
before. 
 My appetite is much greater
than usual. 
 I have no appetite at all.
 I crave food all of the time.
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14. Worthlessness
 I do not feel I am worthless.
 I don’t consider myself as
worthwhile and useful as I
used to.
 I feel more worthless than
other people.
 I feel utterly useless.
 
19. Concentration Difficulty
 I can concentrate as well as
ever. 
 I can’t concentrate as well as
usual.
 It is hard to keep my mind on
anything for very long. 
 I can’t concentrate on
anything.
15. Loss of Energy
 I have as much energy as ever.
 I have less energy than I used
to have.
 I don’t have enough energy to
do very much.
 I don’t have enough energy to
do anything.
20. Tiredness or Fatigue
 I am no more tired or fatigued
than usual.
 I get more tired or fatigued
more easily than usual.
 I am too tired or fatigued to do
a lot of the things I used to 
do. 
 I am too tired or fatigued to
do most of the things I used to
do.
16. Changes in Sleeping Pattern
 I have not experienced any
change in my sleeping pattern.
 I sleep somewhat more than
usual. 
 I sleep somewhat less than
usual.
 I sleep a lot more than usual.
 I sleep a lot less than usual.
 I sleep most of the day.
 I wake up 1-2 hours early and
can’t get back to sleep.
21. Loss of Interest in Sex
 I have not noticed any recent
changes in my interest in sex. 
 I am less interested in sex than
I used to be. 
 I am much less interested in
sex now. 
 I have lost interest in sex
completely. 
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17. Irritability
 I am no more irritable than
usual. 
 I am more irritable than usual.
 I am much more irritable than
usual. 
 I am irritable all the time.
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SECTION G: MOOD CONTINUED 
Over the past 2 
weeks, how often 
have you been 
bothered by any 
of the following 
problems? 
Not 
At 
All 
Several 
Days 
More 
Than 
Half 
the 
Days 
Nearly 
Every 
Day 
1. Little interest or
pleasure in doing 
things 
0 1 2 3 
2. Feeling down,
depressed or 
hopeless 
0 1 2 3 
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SECTION H: SOCIAL SUPPORT 
Instructions: Please read the following questions and circle the number that most closely describes 
your current situation.  
HOW OFTEN WOULD 
THERE BE…. 
All 
or 
Most 
of 
the 
Time 
Some 
of 
the 
Time 
None 
of 
the 
Time 
1. Someone to encourage you to
follow a healthy diet? 2 1 0 
2. Someone available to help you
to prepare healthy meals? 2 1 0 
3. Someone to encourage you to
take your medications? 2 1 0 
4. Someone available to help you
get access to your medications 
(getting your prescriptions filled)? 
2 1 0 
5. Someone available to actually
take you to go with you to the 
hospital/doctor when you are 
sick? 
2 1 0 
6. Someone to encourage you to
exercise? 2 1 0 
7. Someone who could participate
in exercise with you? 2 1 0 
8. Someone to encourage you to
quit smoking? 2 1 0 
9. Someone who could discuss
your condition or health concerns 
with your doctor? 
2 1 0 
10. Someone who you can talk to
about important things in your 
life? 
2 1 0 
11. Someone who could visit you
or check up on you while you are 
in the hospital or at home? 
2 1 0 
12. Someone who makes you
laugh? 2 1 0 
13. Someone you can go out with
just for fun (go to the movies)? 2 1 0 
14. Someone who could make
sure you get enough rest and 
relaxation? 
2 1 0 
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15. Someone to encourage you,
tell you “things will be okay,” or 
reassure you? 
2 1 0 
16. Someone (other than your
doctor) you could turn to for 
general advice regarding your 
health (eating, dieting, exercise, 
medications)? 
2 1 0 
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SECTION I: YOUR THOUGHTS       
Instructions: 
People think and do many different things when they feel sad, blue, or depressed.  Read each of the 
following items. Using a four-point scale, please indicate whether you never, sometimes, often, or always 
think or do each one when you feel sad, down, or depressed.   Please indicate what you generally do, not 
what you think you should do. 
N
e
v
e
r 
Some
times 
O
f
t
e
n 
A
l
w
a
y
s 
1. I think about how alone I feel 1 2 3 4 
2. I think about my feelings of fatigue
and achiness 1 2 3 4 
3. I think about how hard it is to
concentrate 1 2 3 4 
4. I think about how passive and
unmotivated I feel 1 2 3 4 
5. I think “Why can’t I get going?” 1 2 3 4 
6. I think about a recent situation,
wishing it had gone better 1 2 3 4 
7. I think about how sad I feel 1 2 3 4 
8. I think about all my shortcomings,
failings, faults, and mistakes 1 2 3 4 
9. I think about how I don’t feel up to
doing anything 1 2 3 4 
10. I think “Why can’t I handle things
better?” 1 2 3 4 
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SECTION J: YOUR IRRITABILITY  
Instructions: Please mark “x” in the box beside each item that best describes how you have been 
feeling in the past week: 
N ot
 
at
 
A
 
lit tle O
f
te n M os t  
1. I have been feeling mad
2. I have been feeling ready to explode
3. I have yelled at others
4. I have been irritable when someone touched me
5. I have been easily flying off the handle
6. It feels like there has been a cloud of anger over
me 
7. I have been rather sensitive
8. I have been quick to criticize others
9. Noises have seemed louder
10. I have been getting annoyed with myself
11. I have been so angry that I lost control
12. There has been a flood of tension through my
body 
13. I said nasty things to others that I did not mean
14. It took very little for things to bother me
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SECTION K: SLEEPING DIFFICULTIES 
These questions ask about your sleep habits. Please mark 1 of the answers for each of the following 
questions.  
Pick the answer that best describes how often you experienced the situation in the past 4 weeks. 
1. Did you have trouble falling asleep?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
2. Did you wake up several times at night?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
3. Did you wake up earlier than you planned to?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
4. Did you have trouble getting back to sleep after you woke up too early?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
5. Overall, was your typical night’s sleep during the past 4 weeks?
□ Very
sound or 
restful 
□ 
Sound 
□ 
Average 
quality 
□ 
Restless 
□ Very
Restless 
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or 
restful 
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SECTION L: QUALITY OF LIFE  
Please check the box () on one sentence for each of the following groups that reflect the state of your 
general health IN THE PAST 4 WEEKS.   
A. Mobility        
 No problems walking about          
 Some problems walking about       
 Confined to bed      
B. Self-Care                
 No problems with washing or dressing  
 Some problems with washing or dressing 
 Unable to wash or dress myself       
C. Usual Activities (e.g. work, study, housework, leisure) 
 No problem with performing usual activities  
 Some problems with performing usual activities  
 Unable to perform usual activities   
D. Pain and Discomfort   
 No pain or discomfort   
 Moderate pain or discomfort  
 Extreme pain or discomfort   
E. Anxiety and Depression   
 Not anxious or depressed     
 Moderately anxious or depressed  
 Extremely anxious or depressed 
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SECTION M: TALKING WITH HEALTH CARE PROVIDERS ABOUT MOOD & 
ANXIETY 
(I) History of Depressed Mood 
1. Have you ever had problems with depressed mood?  YES     NO 
1b. If yes, how many years has it been since you first had problems with depressed 
mood?  _____(yrs) 
1c. If yes, how many times in your life have you had problems with depressed mood? 
_____ (times) 
2. Has a health care provider ever diagnosed you with depression?  YES     NO
2b. If yes, how many years ago were you first given the diagnosis? _______ (yrs) 
2c. If yes, who diagnosed you with depression?  Family doctor 
 Heart doctor (cardiologist) 
 Psychiatrist or psychologist 
 Nurse 
 Other: 
_______________________ 
(II) History of Anxiety 
3. Have you ever had problems with anxiety?  YES     NO
3b. If yes, how many years has it been since you first had problems with anxiety? 
_______ (yrs) 
4. Has a health care provider ever diagnosed you with an anxiety disorder?     YES     
NO 
4b. If yes, how many years ago were you first given the diagnosis?
___________________ (yrs) 
4c. If yes, who diagnosed you with anxiety?  Family doctor 
 Heart doctor (cardiologist) 
 Psychiatrist or psychologist 
 Nurse 
 Other: 
_______________________ 
(III) Current Depression or Anxiety 
5. Are you currently having problems with depressed mood or anxiety?      YES     NO
5b. If yes, are you having problems with:     Depressed mood. 
           Anxiety 
           Both depressed mood and anxiety
5c. If yes, who is treating you for these problems?  Family doctor 
      (check all that apply)  Heart doctor (cardiologist) 
 Psychiatrist or psychologist 
 Nurse 
 Other: 
__________________ 
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 Not being treated by health 
care provider 
5d. If yes, what treatments are you using:  Medication (antidepressant or anti-
anxiety pills) 
      (check all that apply)  Counseling/Talk therapy 
 Exercise 
 Other: 
_______________________________ 
 My depression/anxiety is not being 
treated 
(IV) Treatment for Depression or Anxiety 
6. Have you ever taken anti-depressant or anti-anxiety medications?
 Never taken     I took them in the past     I take them now: (name: 
______________________) 
7. Have you ever had counseling or ‘talk therapy’ for depression or anxiety?
 Never had        I had it in the past            I’m in counseling/therapy now 
(V) Mood and Anxiety Since Start of Heart Problems 
8. How often do you feel down or blue because of your heart condition?
 Never         Sometimes           A lot of the time 
          8b. If you answered Sometimes or A lot of the time, what is your main 
concern? 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
9. Since being diagnosed with a heart problem, have any health care providers asked about your
mood or  
anxiety?  YES  NO 
9b. If yes, who asked about your mood or anxiety?    Family doctor 
      (check all that apply)  Heart doctor (cardiologist) 
 Psychiatrist or psychologist 
 Nurse 
 Other: 
__________________ 
10. Since being diagnosed with a heart problem, have you ever been asked to fill in a survey or
had an interview with questions about your mood or anxiety?  
 Survey   Interview        Both   Neither  
If yes to either survey or interview: 
10b. Please describe the survey or interview: 
______________________________________________________________________
____________ 
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______________________________________________________________________
____________ 
10c. Did anyone talk to you about the results?     YES   NO     
10d. What happened next (check all that apply)?   
 I was prescribed medicine for my mood or anxiety  
 I was referred to a psychiatrist, psychologist or counselor 
 I was referred for other mental health treatment – please specify: 
___________________    
 My healthcare provider is going to follow-up with me about this 
 Nothing (and I do have problems with mood or anxiety) 
 Nothing (and I do not have problems with mood or anxiety)  
 Other, please specify: _______________________________ 
 I don’t know 
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SECTION N: DEMOGRAPHICS and CARDIAC RISK FACTORS 
1. What do you consider to be your racial/ethnic background? Please check   one (1) of
the following boxes:
 White (Caucasian)
 French-Canadian
 Jewish
 Arab / West Asian (e.g., Afghan, Armenian, Iranian, Egyption, Lebanese, Morrocan)
 South Asian (e.g., East Indian, Punjabi, Pakistani, Bengali, Nepali, Sri Lankan)
 South East Asian (e.g., Cambodian, Indonesian, Malaysian, Singaporean,
Vietnamese, Thai) 
 Chinese
 Japanese
 Filipino
 Korean
 Black (e.g., African, Haitian, Jamaican, Somali)
 Latin American
 Aboriginal (e.g., Métis, Inuit)
 Other (specify: _______________________________)
 Multiple cultural backgrounds (specify: _____________________________)
2a)     Who do you live with? 
 Family (spouse, children, etc.)
 Alone (skip to question #3)
 Other (specify:_______________________________________________________)
b) If you do not live alone, how many other people do you live with? (not including
yourself):________
c) Do you live with someone who requires caregiving (e.g., ill spouse, grandchildren)?
 Yes
 No
d) If yes you live with someone who requires care giving, please describe 1) for whom you
provide care, 2) the type of care giving you do, 3) the number of hours in an average
week you spend care giving:
1.__________________________________________________________________________
___________ 
2.__________________________________________________________________________
___________ 
3.__________________________________________________________________________
__________ 
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e) If you have a spouse or partner, would you say his/her health is (please  one):
Excellent Very good Good Fair Poor 
3a)     Do you have children? 
 Yes
 No
b) If ‘Yes’ how many children do you have? ________________ #
4. On average, how many hours a week do you usually spend doing housework (e.g., cooking, cleaning,
washing)? 
__________________ hours per week     
5. What is your marital status:
 Married/common-law
 Separated/divorced
 Single
 Widow/Widower
6. What is the highest level of education you have completed?
 less than grade 9
 less than high school
 completed high school
 some college or university courses
 completed college or university degree
 Graduate School/Professional Program
7. What is your gross annual family income?
 $19, 999 or less
 $20, 000 – $29, 999
 $30, 000 – $39, 999
 $40, 000 – $49, 999
 $50, 000 - $59, 999
 $60, 000 - $69, 999
 $70,000 or greater
8. Which option best matches your work status?
 full-time work
 part-time work
 full-time caregiver or homemaker (inside your home)
 unemployed
 receiving disability
 retired
 other: ______________________
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9a)  What is your height? ______ feet and _____ inches or ( ________ cm) 
b) What is your weight? ________ pounds or ( _________ kgs )
10. Please describe your smoking status:
 I have never smoked
 I currently smoke
• How many cigarettes per day on average? __________ cigarettes per day
• For how many years have you smoked? ____________ years
 I quit smoking
• When did you quit? Month _________ year___________
• How many cigarettes per day did you smoke on average? __________ cigarettes per
day
• For how many years did you smoke? ____________ years
11. Do you have a history of heart disease in your family?
 Yes
 No
12. Do you have high cholesterol, or take cholesterol-lowering medication?
 Yes
 No
13. Do you have high blood pressure, or take blood pressure medication?
 Yes
 No
14. Did you exercise to the point of getting short of breath on a regular basis (as an adult) prior to your
cardiac event?
 Yes
 No
15. Did a doctor tell you that you were diagnosed with heart disease before this hospitalization?
 Yes
 No
If yes, approximately when were you diagnosed? _____________/__________ 
(Month) (Year) 
16. Have you previously experienced any of the following health problems? Please  all that apply:
 Heart Attack
 Angina
 Angioplasty (stent)
 Bypass Surgery
 Valve Surgery
 Heart Failure
 Arrhythmia (irregular heart rhythm)
 Heart transplant
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 Cardiac device: pacemaker or implantable cardioverter defibrillator
 Stroke / TIA (i.e., blocked arteries in neck or brain)
 Peripheral Vascular Disease (e.g., blockages in legs)
 None of the above
17. Are you ( check one):
 Pre-menopausal
 Going through menopause
 Post-menopausal
18. Please check your medication bottles. Please list below the names of all of the medications you are
currently taking and the dose per day.  
Others: 
_______________________________________________________________________ 
_______________________________________________________________________ 
_______________________________________________________________________ 
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Thank you for taking the time to complete this survey. Your assistance in providing this 
information is very much appreciated. If there is anything else you would like to tell us 
about this survey, or about your experiences with cardiac disease and/or recovery, please 
do so in the space provided below. 
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Please return your completed questionnaire in the envelope provided to the study coordinator personally, 
OR mail it in the stamped envelope to: 
CR4HER Study Coordinator 
Toronto General Hospital 200 
Elizabeth Street Toronto, ON 
M5G 2C4 
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Appendix F - Case Report Form 
1. Study ID #: _________
2. Today’s Date
dd mmm yyyy 
3. Index Cardiac Condition and/or Procedure (check all that apply):
 PCI  
 CABG Surgery 
 Angina / ACS / CAD 
 MI  
 Valve surgery 
4. Patient Ineligible for Study:         Yes   (if yes, specify below)    No 
 Musculoskeletal, neuromuscular, vision, cognitive or non-dysphoric psychiatric condition 
which precludes CR eligibility, specify: 
_______________________________________________________ 
 Does not speak/read English proficiently 
 Lives and works too far from CR sites (Hwy 427, across Hwy 7 to far end of Scarborough) 
 Planning to leave the province or region in the next 9 months 
 Not eligible for home-based CR, specify:  
 Complex ventricular dysrhythmia 
 Ejection fraction <40% and NYHA Class > 2  
 CCS Class 4 
 Didn’t pass GXT at CR intake (< 3 min tolerated of modified Bruce Treadmill Protocol) 
 Enrolled in other study with behavioural intervention 
 Referral to CR program prior to study randomization 
 Terminal illness or life-threatening condition 
 Being discharged to long-term care 
 Previous participation in CR, so recent that CR program deems pt not eligible to re-enroll at 
this time   
 Patient does not have cardiac diagnosis or procedure meeting inclusion criteria (e.g., 
angiogram results negative, review of discharge note) 
 Physician clearance not received 
 Physician does not deem patient eligible (clearance received, negative response) 
 Other, please specify: _____________________________________________________ 
5. Patient Decline to Participate:
 No       Yes -Reason, if willing:
____________________________________________________ 
6. PI / Investigator confirm patient eligible:
         Eligible       Ineligible, Reason:  
_____________________________________________________ 
P.I. Signature Date 
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Stop here if patient is ineligible or declined. 
CRF Completed By: ____________________ 
Date: ____________________ 
CRF Entered By: 
______________________ 
Date:______________________ 
Study ID#: __________________ 
7. Age yrs 
8. Admission Date
dd mmm yyyy 
9. Discharge Date
dd mmm yyyy 
10. Index Cardiac Condition and/or Procedure:
 PCI          Date:_________________ 
   Procedure:      Vessel(s): 
 Primary 
 Non-Primary 
 Unknown 
 LM 
 RCA 
 LAD 
              (circle: prox / med / dist) 
 Circ 
 Ramus 
 CABG      Date: _______________ 
     Vessel(s): 
 LM 
 RCA 
 LAD (circle: prox / med / dist) 
 Circ 
 Ramus 
 Valve               Date:_____________        
     Surgery:              Valve(s):  
 Repair 
 Replace 
 Aortic 
 Tricuspid  
 Bicuspid 
 Pulmonary 
 MI                    Date:______________ 
11. Current Medications (check all):
 ACE Inhibitors 
 Anti-coagulants 
 ASA 
 Ca2+ antagonists 
 Statin 
 LL – fibrate 
 LL – nicotinic acid 
 LL – resin drugs 
 Diuretics 
 Clopidogrel or ticlopidine 
 Other anti-platelet 
 Nicotine         
Replacement
 Anti-arrhythmic 
 Anti-platelets 
 Beta-blockers 
 Digoxin 
 Nitrates  
(not PRN) 
 ARBs 
 Anti-depressant 
 Coumadin 
 Heparin 
 HRT 
 Insulin 
 Oral  
hypoglycemics 
 Other: __________________________ 
12. CCS Angina Class:
 0     1     2     3     4
         IV-a   IV-b   IV-c  IV-d  
13. NYHA Functional Class:
       1     2     3     4 
14. LV Function:
 Nuclear     Echo      
ngiogram 
 LVEF %: _____________ 
 Narrative: 
________________________ 
___________________________________ 
   Normal    Mild   Moderate     Severe 
 Date assessed: 
_______________ 
17. Complications during stay:
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 Location(s):       Type: 
 Anterior 
 Inferior 
 Lateral  
 Posterior 
 Septal  
 Rt Ventricular 
 STEMI 
 NSTEMI 
 Q-Wave 
 BBB 
 NON-Q-Wave 
 Unstable Angina 
 ACS/CAD Confirmation   
Date:______________ 
      ECG   Angiogram   Enzymes   Symptoms 
 Other cardiac cond(s)       Date:_______________ 
 Aneurysm  
 Infection  
 Heart Failure 
 Arrhythmia 
 Congenital HD 
 Cardiomyopathy  
 Other:__________
Study ID#: __________________ 
18. Risk Factors:
Y N 
  Diabetes:  Type I    Type II 
HbA1c%: __________ 
Date assessed:______________ 
  Obesity (BMI>30) 
BMI (kg/m2): ________ 
Waist circ (cm): _______ 
Date assessed:______________ 
  Hypertension 
BP: syst:______/ diast:_______ 
Date assessed:______________ 
  Dyslipidemia 
Total Cholesterol: ________ 
HDL: ________ 
LDL: ________ 
Triglycerides: ________ 
Date assessed:______________ 
19. CRP: ________
            Date assessed: __________ 
20. Heart rate: _______
                  Date assessed:___________ 
 Arrhythmia 
 Recurrent Angina / 
ischemia 
 Cardiogenic shock 
 Cerebrovascular Accident 
 Readmit (ICU /   CCU) 
 Infection 
 Cardiac Arrest  
 Pericarditis 
 Pneumonia 
 Acute Renal 
Failure 
 DVThrombosis 
 MI 
 Cardioversion  
 Cardiac           
 Other: specify: 
ONLY FILL IF PATIENT IS AN 
INPATIENT 
23. Family Physician:
________________________________
Phone #:_______________________________ 
24. Cardiac Specialist:
 _______________________________ 
Phone #:_______________________________ 
24. Clearance Received:
  Yes     No
25. Received By:
 Family Physician  Cardiac
Specialist 
 Both
26. Cleared for CR referral:
  Yes     No
27. Randomized to:
 Home based
 Co-ed hospital based
 Women only
28. Site referred to:
  TRI     TWH      HHSC 
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Study ID#: _________________ 
1. Patient’s First Name:
2. Patient’s Last Name:
3. Preferred Salutation:
 Ms. 
 Mrs. 
 Dr. 
4. Patient’s Telephone Number:
21. Previous cardiac diagnosis?
 CAD 
 CHF 
 Arrhythmia 
 Congenital HD 
 ACS/MI 
 Infection  
 Valve condition 
 Cardiomyopathy  
 Other: ___________ 
 None 
22. Comorbid Conditions
23.  
29. Referral Date:
yyyy 
30. Call to patient re: program site &
model:  
          Yes     No 
              Date: 
Notes:       
_______________________________
_______ 
_______________________________
_______ 
31. Did patient go off-study?
          Yes     No 
 If yes, specify: 
________________________ 
CR4HER Case Report Form (CRF) 
 Cancer 
 Hyperthyroid 
 Liver Disease 
 PAD/PVD 
 Depression 
 Renal Disease 
 MSK / Joint Replacement, specify: _____ 
 Other: _____________________ 
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(Area code) 
5. Patient’s Address:
Street Address 
City 
Province ON Postal Code 
6. Patient’s email address: _____________________
7. Alternate Contact Information (if willing):
Name 
Relationship 
Telephone 
8. If patient works rather than lives close to the Toronto CR programs, record office postal
code:_________________ 
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Appendix G - Request for Physician Clearance 
CR4HER Trial  
Request for Physician Clearance 
Date: _____________________ 
Dear Dr. __________________: 
Your patient ____________________________ has provided written consent to participate in 
the Cardiac Rehabilitation for her Heart Event Recovery (CR4HER) trial funded by HSF, being 
conducted at the University Health Network, Sunnybrook Health Sciences Centre, Toronto 
Rehabilitation Institute, Mount Sinai, and Hamilton Health Sciences Centre. As you know, CR is 
an evidence-based outpatient program of structured exercise and education. Patients who attend 
CR have 25% lower mortality rates, fewer rehospitalizations and recurrent events, improved 
quality of life, and risk factor reduction. Clinical practice guidelines promote CR as the standard 
of care, yet few patients actually enroll and participate. The physical activity component of each 
CR program is based on a graded exercise test supervised by a physician, which enables 
individualized recommendations for moderate-intensity activity such as walking at a target heart 
rate. Cardiac rehab is very safe and is facilitated by multi-disciplinary health professionals. 
We are randomizing patients to one of three study conditions: (1) hospital-based co-ed CR, (2) 
hospital-based women-only CR, or (3) home-based CR. We will complete the referral for 
eligible patients. Six months later, we will mail participants a survey to assess program 
adherence, lifestyle, and risk factors. As you can see, your patient’s participation in this study 
may result in health benefits, while there is no extra work for you. You may receive a CR 
discharge summary.  
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We are writing to request ‘clearance’ for your patient to participate in a cardiac rehab program.  
Please check one.  
__________________________  has clearance to participate in a cardiac rehab program as part 
(Patient’s Name)                           of the CR4HER trial. 
 Yes  No 
__________________________________ ________________________ 
Physician signature  Date 
When complete, please fax this form to Study Coordinator at (xxx) 
xxx-xxxx. 
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Appendix H - Referral for Cardiac Rehabilitation (TRI) 
Name: ___________________DOB: _____/_____/____   Sex: M __  F 
Street Address: ______________________   Apt. # :______ 
City: ____________________ Postal Code: _____  Health Card # __________________ 
Tel: (_____)___________________    (_____)________________________   
(_____)________________________     
Home          Business Cell 
Relative or Contact Person: ___________________  Tel  
 (Mandatory  if patient does not speak English) 
Referral Diagnosis Date   Date 
MI  ________________________ Heart Failure 
___________________________ 
PTCA  ________________________ Stable angina 
___________________________ 
AC Bypass ________________________ Valve surgery 
___________________________ 
Pacemaker/ICD _______________________    Arrhythmia 
___________________________ 
Other  ________________________ CVA/TIA 
___________________________ 
LV (if known) Grade I ___II ___III ___IV __ 
Does patient have and orthopedic/neuromuscular/vascular limitations?  If yes, briefly describe: 
_____________________________________________________________________________________
____ 
_____________________________________________________________________________________
____ 
Include with: 
All referrals:  discharge summary & post event ECG. 
Add: 
Surgical patients: pre-op assessment, discharge medications 
PCI patients:   pre-cath assessment, cath diagram 
Heart Failure patients: echo result 
Interventionalist: ___________________Cardiologist: _________________ Surgeon 
_________________ 
Toronto Rehabilitation Institute 
A Teaching Hospital of  
the University of Toronto 
Rumsey Centre 
347 Rumsey Road, Toronto, Ontario M4G 1R7 
Tel: (xxx) xxx-xxxx Fax: (xxx) xxx-xxxx 
www.torontorehab.on.ca 
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Physicians – please ‘cc’ Toronto Rehab, Cardiac Rehab Program, 347 Rumsey Road on discharge 
summaries and procedure notes 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ _ 
Patient Waiver for Disclosure of Personal Health Information 
 ______________________________________________________________ _____/_____/____ 
(Print) Last Name   First Name Date of Birth (D/M/Y) 
I hereby authorize Sunnybrook Health Sciences Centre to release to Toronto Rehab Institute any 
pertinent Medical Records or information concerning my recent admission.  I understand that this 
information is to be used for the provision of heath care services. 
Signature of patient/ 
Legal Representative: _________________________ Witness: ________________________ Date: 
______________ 
Relationship (if not patient): ___________________ Print Name of Witness: 
_________________________________ 
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Appendix I – Referral for Cardiac Rehabilitation (TWH) 
 
 
 
REFERRALS INTERNAL TO UHN – clinical information will be extracted from EPR. 
Please complete #1-8: 
1. Date of Referral: ________ ______________ _________ 
dd mmm yyyy 
2. I agree my patient can undergo a medically-supervised exercise stress test for the
purpose of exercise prescription and triage (please check  one box):       Yes     
No
(see below for timing considerations, if any):
 anytime after referral    2 weeks after referral   4 weeks after referral  
other: 
_____ 
3. Physician signature: _______________________________
4. Referring Physician: _________________________________
5. Family Physician: ___________________________________    Send intake & d/c 
summaries to GP only
6. Referral Source:  Cardiologist   
 Internist 
 CV Surgery 
 PCI Unit 
 GP 
 Other clinic/office 
7. Name of relative/contact person if limited English proficiency: ___________________, 
(____) _____________
8. Interpreter required:  Yes, specify language of proficiency: 
____________________ 
REFERRALS EXTERNAL TO UHN – in addition to completing #1-8 above, please provide 
information below: 
1. Please fax discharge summary, consult notes and all available cardiac / respirology investigations
with referral form (i.e., EKG, echo, perfusion scan, angiogram, lipid profile), discharge medications.
2. Indication for Referral (check  all that apply, and specify date where applicable):
Cardiovascular Rehabilitation & Prevention 
(Chronic Disease Mgmt & Risk Reduction) 
Peter Munk Cardiac Centre 
REFERRAL FORM
FAX completed form to: (xxx) xxx-xxxx 
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  MI / ACS   CABG and / or valve surgery 
  PCI   Congenital HD 
  Pre/post heart or heart & lung transplant   Stable CHF 
  PVD / PAD   Pacemaker, ICD, Other: 
  Stroke / TIA (pt can ambulate)   Diabetes,  
with multiple cardiac risk factors 
3. Known cardiac risk factors (check  all that apply):
 Hyperlipidemia  Diabetes  Sedentary  Psychosocial 
di t   Hypertension  Obesity  Smoking 
 
4. Any notes, specific issues of concern with this patient
(e.g., comorbidities, restrictions, contraindications):
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Appendix J  – Referral to Cardiac Rehabilitation (HHS) 
HAMILTON HEALTH SCIENCES 
Cardiac Health & Rehabilitation Centre           
TELEPHONE: xxx-xxx-xxxx FAX: xxx-xxx-xxxx 
    Name: 
        Last Name First Name Mr./Mrs./Miss/Ms.  
Address:  
 Telephone Number: 
Hospital ID Number: ___________________________ HIN _____________________ 
RISK  FACTORS (if present) :
REASON FOR REFERRAL (Check all that apply) 
ST Elevation   Non ST Elevation   Location: Anterior   Posterior   Right Ventricle
Inferior   Lateral
Post MI: Date ___________ 
Thrombolytics:  
Streptokinase TN  rTP 
Date 
Cardiac Surgery: Date: __________________ CABG   Valve   Other: 
Coronary Angioplasty: Date: __________________ Vessel(s) ________ 
Stent
Coronary Angiogram No   Yes   Date: 
  Vessels Diseased: RCA   LAD Circumflex   Other: __________ 
   Angina  
            Peripheral Vascular Disease   CHF   Defibrillator (ICD)  Pacemaker
LV Function: Greater than 50%   35-49%   20-34%   Less than 20%
MEDICATIONS   
(Name and Dose and Frequency) 
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LIPID PROFILE  
Date: ____________ Total cholesterol __________ LDL _______ HDL _______ Triglycerides 
Date ________________________ Fasting Blood Sugar _______________ AIC ___________ 
Height ______________ cm 
Weight _______________  g 
Post Event Complications/Health Care Team Concerns: 
  Appointment Date and Time: _____________________Information Package Given   
            Completed By: _____________________________________ Date: ____________________  
  Signature of most responsible physician: ___________________ Date: _______________ 
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Appendix K – Pedometer Log 
Participant #: ________   Assign Date: ___/____/_____ 
Pedometer #: _____ 
CR4HER Pedometer Activity Log Sheet 
Instructions: Record the start date of your log. At the end of each day, write down the number of steps that’s shown on the pedometer 
in the slot of that corresponding day. Keep recording for 7 days. Record the end date of your log.  
Contact the study coordinator with any questions – xxx-xxx-xxxx 
Start Date: ___/____/_____ 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
End Date: ___/____/_____ 
Send completed log sheet, along with the pedometer, back to: University Health Network, TWH 8e-403, using the postage-
stamped envelope. 
Record 
number of 
steps here 
Record 
number of 
steps here 
Record 
number of 
steps here 
Record 
number of 
steps here 
Record 
number of 
steps here 
Record 
number of 
steps here 
Record 
number of 
steps here 
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Appendix L – Intake Report Form 
Name 
(Last, First) Year of Birth 
Date of 
Intake Appt 
(d/m/y) 
Expected 
Date of CR 
Graduation 
(d/m/y) HDL LDL 
Total 
Cholesterol 
Triglyce
rides 
Waist 
Circumf
erence BP 
Peak 
METs VO2peak 
Cpa? 
y/n 
Comments re: 
GXT. Symptom 
limited? 
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Appendix M – Post-Test Survey 
Cardiac Rehab for Her 
Study (CR4HER) 
Final Survey 
Instructions for completing the survey questions appear at the 
beginning of each section.  
Please seal your completed questionnaire in the stamped 
envelope provided, and return it by mail to the study 
coordinator.  
191
SECTION A: CARDIAC REHABILITATION 
PARTICIPATION  
Instructions: Cardiac rehabilitation (CR) is an outpatient program of structured exercise 
and education to maximize your recovery. Please check the appropriate box in response to 
each question. If your checked answer has an arrow leading to another box, answer the 
questions in the attached box. Please print any written answers clearly.  
1. Did you attend a cardiac rehabilitation assessment (intake
appointment)? 
 Yes (If Yes) 1.Where? 
_____________________________________ 
2. How many minutes did you take you to travel there one-way? _______ mins
 No
(If No) Why not? 
3. Did you participate in cardiac rehabilitation?
 YES
NO
(If Yes) 
4. Approximately how many weeks passed between being discharged from hospital, and
starting the cardiac rehab program? ___________ wks 
5. Did you consider this to be an acceptable or unacceptable length of time to wait for
cardiac rehab?
Why?  
 acceptable
 unacceptable
6. Approximately what percentage of cardiac rehabilitation sessions did
you complete on the phone or at the hospital? 
% of sessions completed  
(If No) Why not? Please be as specific as you can. 
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SECTION B: CARDIAC REHAB BARRIERS  
The following questions ask about some of the factors influencing your participation in cardiac 
rehabilitation sessions. Please answer all of the questions on this page regardless of whether you 
participated or did not participate, and whether you participated in a home-based or hospital-
based cardiac rehabilitation program. If you participated in a home-based program, answer these 
questions in reference to your visits to the cardiac rehabilitation site and your telephone visits.  
I did not attend a cardiac rehabilitation program, or if I did attend, I 
missed some sessions because:  
1.  of distance (e.g., not located in your area, too far to travel
2.  of cost (e.g., parking, gas) 
of transportation problems (e.g., access to car, public transportation)3. 
4.  of family responsibilities (e.g., caregiving) 
5. I didn't know about cardiac rehab (e.g. doctor didn't tell me about it)
6. I don't need cardiac rehab (e.g., feel well, heart problem treated, not serious)  
7. 
8. 
I already exercise at home, or in my community
9.  I find exercise tiring or painful 
10.  travel (e.g., holidays, business, cottage) 
11.  of time constraints (e.g., too busy, inconvenient class time)
12.  ofwork responsibilities 
13. I don't have the energy
other health problems prevent me from going 14.
(specify:___________) 
15.  I am too old 
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 Severe weather
16.  my doctor did not feel it was necessary 
17.  many people with heart problems don't go, and they are fine
18.    I can manage my heart problem on my own
19.   I think I was referred, but the rehab program didn't contact me
20.  it took too long to get referred and into the program 
21.  I prefer to take care of my health alone, not in a group
22. Other reason (s) for not attending a cardiac rehabilitation program:
________________________________________________________
___________________________________  
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SECTION C: CARDIAC REHABILITATION PROGRAM 
PREFERENCES  
Please rate the importance of each of the following cardiac rehabilitation program features.  
Please answer all of the questions on this page regardless of whether you attended or did not 
attend a cardiac rehabilitation program. Please also answer if you attended a home-based or 
hospital-based program.  
1. Discuss progress
2. Ease of learning exercises
3. Not get overly tired
4. Set own goals
5. Discuss problems
6. Not have pain while exercising
7. Exercises are not boring
8. Receive individualized attention
9. Receive encouragement from professionals
10. Exercise with someone
11. Acceptable distance from home
12. Convenience of parking
13. Flexible hours
14. Does not interfere with other activities
15. Available transport
Im
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SECTION D: USUAL ACTIVITIES 
Instructions: The following questions have to do with your current activity status. 
Circle Yes or No  in response to each question.  
1. Can you take care of yourself, that is, eating, dressing, bathing or using the toilet? Yes  No
2. Can you walk indoors, such as around your house? Yes  No  
3. Can you walk a block or two on level ground? Yes  No  
4. Can you climb a flight of stairs or walk up a hill? Yes  No  
5. Can you run a short distance? Yes  No  
6. Can you do light work around the house like dusting or washing dishes?  Yes  No
7. Can you do moderate work around the house like vacuuming, sweeping floors, or carrying in the
groceries?  Yes  No  
8. Can you do heavy work around the house like scrubbing floors, or lifting or moving heavy
furniture? 
Yes No 
9. Can you do yard work like raking leaves, weeding or pushing a power mower?  Yes  No
10. Can you have sexual relations?  Yes  No
11. Can you participate in moderate recreational activities like golf, bowling, dancing, doubles tennis,
or throwing a baseball or football? 
Yes  No  
12. Can you participate in strenuous sports like swimming, singles tennis, football, basketball or
skiing? 
Yes  No  
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SECTION E: EXERCISE 
1. During a typical 7-Day period (a week), how many times on the average do you do the
following kinds of exercise for more than 15 minutes during your free time (write on each line 
the appropriate number).  
Times Per Week 
a) STRENUOUS EXERCISE
(heart beats rapidly)
(e.g., running, jogging, hockey, football, soccer, 
squash, basketball, cross country skiing, judo,  
roller skating, vigorous swimming,  
vigorous long distance bicycling)  
b) MODERATE EXERCISE
(not exhausting)
(e.g., fast walking, baseball, tennis, easy 
bicycling,  
volleyball, badminton, easy swimming, 
alpine skiing,  
popular and folk dancing)  
c) MILD EXERCISE
(minimal effort)
(e.g., yoga, archery, fishing from river bank, 
bowling,  
horseshoes, golf, snow-mobiling, easy 
walking)  
__________ 
__________ 
__________ 
2. During a typical 7-Day period (a week), in your leisure time, how often do you
engage in any  
regular activity long enough to work up a sweat (heart beats rapidly)? 
OFTEN  SOMETIMES NEVER/RARELY 
1. 2. 3.
3. In the past 9 months, what kinds of physical activities did you engage in (check
all that apply)? 
 walking
 swimming  gardening
 others (please
specify:___________________________________________________) 
4. On average, for how many minutes did you engage in the activity each session?
___________ minutes 
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5. Where did you exercise in the last 9 months?
 At home or in my community
 At cardiac rehabilitation only
 At home or in my community AND at cardiac rehabilitation
 I didn't exercise anywhere
6. Describe your experiences exercising at home or in your community.
__________________________________________________________________
______________________  
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 SECTION D: NUTRITION 
MEAT, FISH AND POULTRY 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
1. Which type of ground meat do you usually eat?
1 Regular hamburger (30% fat) 
2 Lean ground beef (25% fat) 
3 Extra lean/ground chuck (20% fat) 
4 Ground round (15% fat) 
5 Super lean (4% - 10% fat), ground sirloin (10% fat), ground turkey breast, ground 
chicken breast 
6 Eat no ground meat 
   Score ______      
2. Which best describes your typical lunch?  “Lunch meat” means ham, bologna, salami,
pastrami, etc. 
1 Cheeseburger, pizza, typical cheeses, egg dishes (egg salad, quiche, frittata, etc) 
2 Sandwich (lunch meat, hamburger, grilled cheese,), meat/chicken entree (plain/fried), regular 
hot dog 
3 Skip lunch or sandwich (tuna, fish, peanut butter, chicken or turkey lunch 
meat/light mayo, etc),  
turkey hot dog, vegetarian dishes 
4 Tuna sandwich (w/mayo: 1 gm fat or less/Tbsp, Veggie burger (Garden, Boca), 
entree (fish [not fried], small bits of chicken or meat), low-fat yogurt, 
5 Salad (low-cal dressing), low-fat vegetarian dishes, hot dog (0-2 gm fat), deli meats/fat free 
sandwich (w/mayo: 1 gm fat or less/Tbsp), bagel (light cream cheese) 
6 Fat free vegetarian dishes, salad (fat free dressing), Veggie dog, Garden Vegan (fat free 
burger),  
       nonfat yogurt, dry cereal (skim milk), bagel (fat free cream cheese) 
   Score________ 
3. Circle all of the choices that reflect the entree at your main meal.
1 Cheese (Cheddar, Jack, etc), eggs, organ meats (liver, etc), pizza, vegetarian dishes once a 
week or more 
     2 Beef, lamb, pork or ham once a week or more 
     3 Very lean red meat (top round or flank steak), rabbit, veal, venison or elk once a 
week or more 
             4 Chicken, turkey, crab, lobster or shrimp twice a week or more 
     5 Fish, scallops, oysters, clams, low-fat vegetarian dishes twice a week or more 
     6 Fat free vegetarian dishes, fat free seafood dishes every day  
     Score 
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4. Estimate the number of ounces of meat, cheese, fish and poultry you eat in a typical day.
Include all meals and snacks. (To guide you in your estimate (a piece the size of a deck of cards =
3 oz) 
1 hot dog  = 1 ½ oz   1 chicken thigh  = 2-3 oz 1 slice cheese  = 1 oz 
4 strips bacon  = 1 oz  ½ chicken breast = 3 oz 1-inch cube cheese     = 1 oz 
1 small burger patty = 3-4 oz    average T-bone steak = 8 oz        meat in sandwiches  = 2-3 oz 
1 Eleven or more ounces a day 
2 Nine to 10 ounces a day 
3 Six to 8 ounces a day 
4 Four to 5 ounces a day 
5 Up to 1 ounce cheese or  3 oz lean meat, poultry, shrimp, crab, lobster or  6 oz fish, 
clams, oysters, scallops a day 
6 None or up to 3 ounces shrimp, crab, lobster or  6 ounces fish, clams, oysters, 
scallops a day     Score_ 
5. Which of these have you eaten in the past month?
1 Bacon, sausage 
2 Canadian bacon, turkey or chicken sausage 
4 Vegetarian sausage (Morningstar links or patties, other soy sausage) 
6 None      Score 
TOTAL SCORE (MEAT, FISH AND POULTRY) 
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DAIRY PRODUCTS AND EGGS 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
6. Which do you usually use for drinking (don’t forget lattes/mochas) or cooking?
       (Most lattes/mochas contain whole milk unless you request otherwise). 
1 Whole milk 
2 Two percent milk 
4 One percent milk, buttermilk 
5 None or skim (nonfat) milk, nondairy beverages (Edensoy, Rice Dream, etc) 
Score 
7. Which toppings do you use?
1 Sour cream (real or imitation including IMO), whipped cream 
2 Light/low-fat sour cream, Cool Whip, Reddi-Whip aerosol dairy 
3 Cool Whip Lite, regular cottage cheese, whole milk yogurt 
4 Low-fat yogurt, low-fat cottage cheese, Reddi-Whip aerosol nondairy 
5 1% fat cottage cheese, Cool Whip Free, soy yogurt 
6 None or nonfat yogurt, nonfat sour cream, nonfat cottage cheese 
Score 
8. Which frozen desserts are you most likely to eat at least once a month?
1 Regular ice cream (5 g to 18 g fat per ½ cup) 
2 Light ice cream (4 g fat per 1/ 2 cup) 
3 Ice milk, most soft ice cream, frozen yogurt (cream added), Tofutti 
4 Sherbet, low-fat frozen yogurt, Soy Delicious 
5 None or nonfat frozen yogurt, sorbets, Popsicles 
               Score 
9. Which kind of cheese do you use?
2 Cheddar, Swiss, Jack, Brie, Feta, Montrachet, Blue, Jarlsberg, whole milk 
mozzarella, Neufchatel or regular cream cheese, processed cheese (Velveeta, American, Cheese 
Whiz), Kraft Delux Slices, Easy Cheese, Parmesan 
5 Part-skim mozzarella, light cream cheese, light Cheddar, light Jack, (Kraft Light 
Naturals, Alpine Lace-Lo, Velveeta Light or other part-skim cheeses), Cabot Vermont Cheddar 
(50% Light), string cheese 
8 Jarlsberg Lite, Athenos Reduced Fat Feta Cheese 
      10 Light part-skim mozzarella, low-fat and light ricotta, Lite-Line, nonfat Parmesan, Cabot 
Vermont cheddar (75% Light), Parm Plus, soy/rice cheese (cheddar, mozzarella)  
12 None or fat free cheeses (Cheddar, Jack, ricotta, cream, Healthy Choice, Alpine Lace, etc), soy 
(Tofu Rella), 
     Almond (cheddar, mozzarella, etc)   Score
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10. Check the type and number of "visible" eggs you eat (scrambled, fried, etc).
1 Six or more whole eggs a week 
2 Three to five whole eggs a week 
3 One to two whole eggs a week 
4 One whole egg a month 
5 None or egg whites, egg substitute (Nulaid, Egg Beaters, Scramblers, Second Nature, 
etc) 
Score 
11. Check the type of eggs usually used in food prepared at home or bought in grocery stores.
1 Whole eggs or mixes containing whole eggs (complete pancake mix, slice-and-bake 
cookies, etc) 
3 Combination of egg whites, egg substitute and whole eggs 
5 None or egg whites, egg substitute   
  Score 
TOTAL SCORE (DAIRY PRODUCTS AND EGGS)
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FATS AND OILS 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
12. Which kinds of fats are used most often to cook your food (vegetables, meats, etc)?
1 Butter, shortening (with animal fat), lard, bacon grease, chicken fat 
2 Shortening (with vegetable fat), vegetable oil (cottonseed) 
3 Tub or stick margarine (all except canola), vegetable oil (soybean, olive) 
4 Vegetable oil (safflower, corn), tub or stick margarine (canola) 
5 Vegetable oil (canola) 
6 None or use nonstick cooking spray  
Score  
13. How much of these "added" fats do you eat in the typical day:  peanut butter, margarine,
mayonnaise, or salad dressing (including those made with olive oil)?  Do not count fat free products.  
             Examples of amounts people often use: 
1 Ten teaspoons or more on toast:  2 tsp margarine  
2 Eight to 9 teaspoons on salads:  12 tsp salad dressing 
3 Six to 7 teaspoons  on vegetables:  3 tsp margarine  
4 Four to 5 teaspoons on sandwiches:  6 tsp mayonnaise, 2 tsp margarine   
5 Three teaspoons  on potatoes:  3 tsp margarine 
6 None   on pasta, rice:  3 tsp margarine, oil or 6 tsp pesto 
 Score_________        
14. How often do you eat potato chips, corn or tortilla chips, fried chicken, fish sticks,
French fries, doughnuts, other fried foods, croissants or Danish pastries?
Do not count fat free products 
1 Two or more times a day 
2 Once a day 
3 Two to 4 times a week  
4 Once a week 
5 Less than twice a month 
6 Never    Score
15. Which best describes the amount of margarine, butter, peanut butter, mayonnaise or
cream cheese that you put on breads, muffins, bagels, etc?  Do not count fat free products 
1 Average 
2 Lightly spread (can see the bread through it) 
4 "Scrape" (can barely see the spread) 
5 None  
 Score 
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16. Which kind of salad dressings do you use?
1 Real mayonnaise  
2     Miracle Whip, light mayo, Caesar, Thousand Island dressing 
3     Best Food’s Low-Fat Mayo (1gm fat/Tbs), Ranch, French, Blue Cheese or Roquefort, vinegar 
and oil,           Italian, Russian, low-fat mayonnaise dressing, Miracle Whip Light dressing and 
Italian dressings 
4 Ranch Dressing (mix and light mayo) 
5 Low-cal salad dressing, Ranch Dressing (mix and low-fat yogurt) 
6   Use no salad dressing or fat free mayonnaise, Miracle Whip fat free, fat free salad dressings, 
    Ranch dressing (mix and nonfat dairy or yogurt/sour cream), vinegar, lemon juice         
Score  
TOTAL SCORE (FATS AND OILS) 
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SWEETS AND SNACKS 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
17. How often do you eat desserts or baked goods (sweet rolls, doughnuts,
muffins, scones, cookies, cakes)?    Do not count fat free versions 
1  Once a day  
2  Five to 6 times a week 
3  Three to 4 times a week 
4  Two times a week 
5  One time a week or less 
6  Never  
     Score _  
18. Which of the following desserts or snacks have you eaten in the last month?
1  Croissants, cheesecake, typical cakes with frosting 
2   Pies, cookies, cupcakes, muffins, scones, frosted doughnuts  
3   Granola bars (Nature Valley, Quaker Chewy) 
4   Low-fat muffins, desserts made using low-fat recipes, low-fat cookies (fig bars, 
ginger snaps,      
           Snackwell’s), low-fat granola bars (Power Bar, Quaker Chewy low-fat) 
5  Fat free desserts including angel food cake, fat free cookies 
6   Never eat baked goods listed above or eat fruit for dessert 
       Score  _ 
19. Which of the following snacks have you eaten in the last month?
1 Chocolate, commercial popcorn, Poppy Cock popcorn, caramel corn 
      2  Nuts, potato chips, corn chips, Doritos chips, microwave popcorn, homemade popcorn 
w/butter, 
          Cracker Jack, French fries, peanut butter, party/snack crackers (Ritz) 
4 Tortilla chips, baked potato chips, pretzels, light microwave popcorn, lightly 
buttered popcorn (1 tsp margarine for 3 cups popcorn), low-fat crackers (soda, graham), Toby’s 
Tofu Pate Original 
5 Baked tortilla chips, homemade popcorn w/no fat, fat free soda crackers and 
other fat free crackers, Toby’s Tofu Pate Lite 
6 Do not eat snacks or eat fruits and vegetables as snacks 
        Score __ 
TOTAL SCORE (SWEETS AND SNACKS)
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SEAFOOD 
Consider your eating habits during the last month. For each question, circle all items that apply. 
20. How often do you eat fish?  (tuna, snapper, perch, sole, halibut, cod, salmon,
shrimp/prawns, crab, lobster, scallops, clams, oysters, sardines, etc).
office us only 
1    Do not eat fish or eat fish less than once a month 
2    One to 3 times a month 
3    Once a week 
4    Two times a week 
5    Three or more times a week or  eat vegetarian with no added fat 
Score 
21. Which fish (fresh, frozen or canned) have you eaten in the last month?
1    Ate no fish in the last month 
2    Scallops, clams, mussels, snowcrab (surimi) 
3    White fish (perch, cod, sole, halibut, snapper), oyster, lobster, tuna, crab 
4    Trout, steelhead, herring, catfish, salmon (Atlantic, pink) 
5    Salmon (Coho, red, Chinook), mackerel, sardines, shrimp/prawns, squid or eat 
vegetarian with no added fat 
Score 
TOTAL SCORE (FISH ) 
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GRAINS, BEANS, FRUITS AND VEGETABLES 
Consider your eating habits during the last month.  For this part of the quiz, list the number of 
servings of the following foods  you eat each day or week, as specified for the question. 
22. How many pieces of fruit or cups of fruit juice do you consume a day?  (not "fruit-flavored"
drinks) 
 cups or pieces 
Score (cups x 5) 
23. How many cups of vegetables do you eat a day (tossed salad, cooked vegetables, soups,
casseroles, etc)?  (A typical serving size for tossed salad is 1 to 1 1/2 cups)
 cups 
Score (cups x 5) 
24. How many cups of legumes do you eat a week (refried beans, split peas, white beans, black
beans, 
blackeye peas, lentils, chili, etc)? 
 cups 
Score (cups x 5) 
25. List the number of servings of the following you ate last week.  (A typical cereal bowl holds
1 1/2 to 2 cups; people typically eat 9 to 12 cups of popcorn). 
Amount eaten LAST WEEK 
cooked cereal   bowls/week 
ready-to-eat cereal  bowls/week 
English muffin   #/week 
hamburger bun  #/week 
bagel (plain or flavored)  #/week 
Pita or pocket bread   #/week 
eight-inch tortilla  #/week 
plain popcorn (4 cups/serving)   servings/week (1 microwave bag holds 10 ½ cups) 
fat free or low-fat muffin  muffins/week 
cornbread  pieces/week 
Total     Score  (svgs x 1.2)
Amount eaten LAST WEEK 
bread or toast   slices/week 
dinner or hard roll   rolls/week 
French/Sourdough bread  slices/week 
four-inch pancake  pancakes/week 
low-fat crackers such as soda, graham, etc (8/serving)   servings/week 
regular sized rice cakes  (3/serving)  servings/week 
mini sized rice cakes (8/serving) ______  servings/week 
pretzels (1 cup or 1 large soft)   cups or #/week 
Total     Score (svgs x 0.7) 
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26. How many servings of grains and potatoes did you eat last week?  Be sure to count these
foods when they are in a mixed dish (casserole, burrito, etc).  This includes breakfast, lunch and 
dinner. 
Number of servings eaten LAST WEEK 
macaroni, spaghetti and other pastas   cups/week 
mashed potato     cups/week 
baked potato     large potato/week 
rice, corn, bulgur, barley, couscous, other grains     ____  cups/week 
Score 
Score:  (cups macaroni, etc x 1.5) + (cups mashed potato x 1.5) + (number baked potatoes x 
2) + (cups rice, corn, etc x 2)
TOTAL SCORE (GRAINS, BEANS, FRUITS AND 
VEGETABLES) 
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BEVERAGES 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
27. Which of the following reflects your habits regarding alcoholic beverages?
  1 drink = 12 ounces beer 
 1 1/2 ounces whiskey, gin, rum, etc 
4 ounces wine 
1 ounce liqueur 
1 One or more drinks a day 
2 Four to 6 drinks a week 
3 Three drinks a week 
4 One to 2 drinks a week 
5 One to 3 drinks a month 
6 Do not drink alcoholic beverages 
Score 
28. Which of the following reflects your habits regarding soda pop, sweetened seltzers, sports
drinks, fruit punch, etc?       Do not count sugar free (diet) drinks 
            1 can         = 12 ounces 
          Big Gulp     = 32 ounces 
         1 Liter         = 33 ounces 
        2 Liter       = 67 ounces 
1 More than 48 ounces a week 
2 33-48 ounces a week 
3 25-32 ounces a week 
4 12-24 ounces a week 
5 None or less than 12 ounces a week 
Score 
29. How much coffee do you drink?  This includes espressos, lattes, mochas, etc.
Guidelines for Espresso Drinks 
“Short”            = 8-10 ounces 
     Small (“Tall”)           = 12 ounces 
    Medium (“Grande”)   = 16 ounces 
    Large (“Venti”)         = 20 ounces 
1 More than 40 ounces (more than 5 cups) a day 
3 25-40 ounces (4 to 5 cups) a day 
4 6-24 ounces (1 to 3 cups) a day 
5 None or less than (1 cup) a day   
Score 
TOTAL SCORE (BEVERAGES)
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SALT 
Consider your eating habits during the last month.  For each question, circle all numbers that 
apply. 
30. Which type of "salt" do you normally use?
1 Regular salt, sea salt, flavoring salts (seasoned salt, garlic salt, onion salt, celery salt, 
lemon pepper, etc), regular soy sauce 
3 Combination of regular and Lite Salt 
4 Lite Salt, lower-sodium soy sauce, reduced-sodium flavoring salts 
5 None or salt substitute (100% potassium chloride), Salt-free products (Mrs. Dash, 
etc) Score 
31. How often do you add salt to your food at the table?
1 Always 
2 Frequently 
4 Occasionally 
5 Never  
Score 
32. Which type of salt and how much do you use in cooking potatoes, rice, pasta, vegetables,
meat, casseroles and soups? 
1 Regular salt (typical amount) or eat in restaurants 4 or more times a week 
2 Regular salt (1/2 typical amount) or Lite Salt (typical amount) 
4 Lite Salt (1/2 typical amount) 
5 None or salt-free products (Mrs. Dash, etc), salt substitute   
Score 
33. Which type of cereals do you use?
1 Typical dry cereals (sweetened or unsweetened) or cereals cooked with regular salt 
(typical amount) 
3 Combination of typical dry cereals and salt-free dry cereals (Shredded Wheat, 
Puffed Wheat, Puffed Rice) or cereals cooked with regular salt (1/2 typical amount) or Lite Salt 
(typical amount) 
5 Do not eat cereal or eat salt-free dry cereals (Shredded Wheat, Puffed Wheat, 
Puffed Rice, etc) or  cereals cooked without salt 
Score 
34. How often do you use typical canned, bottled, or packaged foods:
salsa  salad dressings     boxed noodle entrees 
Picante sauce soups (chicken broth)     frozen entrees 
BBQ sauce chili      canned beans 
ketchup cured meats (lunch meat)     canned vegetables 
1 More than 15 times a week or eat in restaurant 4 or more times a week 
2 Ten to 14 times a week 
3 Six to 9 times a week 
5 Five times a week or less 
            Score 
TOTAL SCORE (SALT) 
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RESTAURANTS AND RECIPES 
Consider your eating habits during the last month.   
For each question, circle all numbers or check the choices that apply. 
35. How often do you eat breakfast at a restaurant or cafeteria (this includes coffee shops)?
1 More than twice a week 
2 Once or twice a week 
3 Once a week if you eat low-fat (unbuttered toast or English muffin, oatmeal) 
5 Less than once a month  
6 Never  
Score 
36. How often do you eat lunch at a restaurant or cafeteria or eat “take out”?
1 Daily 
2 Five days a week 
3 Two to 4 days a week 
4 One day a week 
5 Less than once a month 
6 Never  
Score 
37. How often do you eat dinner at a restaurant or cafeteria or eat “take out”?
1 More than 3 times a week 
2 Two to 3 times a week 
3 Once a week 
4 Once or twice a month  
5 Less than once a month 
6 Never  
Score 
38. Check the choices you make when eating in restaurants or cafeterias.
Select restaurants that offer low-fat choices and order those choices 
Order toast, muffins, cereal, pancakes, waffles for breakfast 
Order soup (not cream), salad or other meatless, cheeseless entrees for lunch 
Order vegetarian pizzas with half the cheese 
Avoid cheese, eggs, bacon on salads and avoid potato and macaroni salads 
Put garbanzo or kidney beans on salad at the salad bar 
Use a very small amount of salad dressing 
Order a fish, shellfish, chicken or lean red meat entree (but not fried) 
Use no more than 1 pat of margarine at any meal 
Order fruit, sorbet, sherbet, frozen yogurt or skip dessert 
SCORE:  (0-1 checks = 1; 2-3 checks = 2; 4-5 checks = 3; 6-7 checks = 4; 8-10 checks; or eat 
out less than once a  month = 5)        Score
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39. How often do you eat foods made using low-fat recipes or cook low-fat without recipes?
1 Once a month or less 
2 One to 2 times a week 
3 Three to 4 times a week 
4 Five to 6 times a week 
5 Everyday  
Score 
TOTAL SCORE (RESTAURANTS AND 
RECIPES) 
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SECTION G: USING MEDICAL CARE  
Instructions: Please answer the questions below by entering in the number of times in the past 9 
months that you have seen:  
A) Your family doctor …… .  
B) A Heart Specialist …… .  
C) Gone to the Emergency Department for your symptoms related to your heart …….
D) Been admitted to the hospital for symptoms related to your heart? .
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SECTION H: PILL TAKING  
Thinking of the medications PRESCRIBED to you by your doctor(s), please answer the following 
questions:  
1. Do you ever forget to take your medication?
 Yes
 No
2. Are you careless at times about taking your medication?
 Yes  No
3. When you feel better, do you sometimes stop taking your medication?
 Yes  No
4. Sometimes, if you feel worse when you take your medicine, do you stop taking it?
 Yes
 No
5. What percentage of the time would you say you take your pills as prescribed by your
doctors? (0% would be not taking as prescribed at any time, to 100% taking as prescribed 
all the time).  
_____________ %  
214
SECTION I: FOLLOW-UP WITH YOUR FAMILY DOCTOR 
1. Have you had an appointment with your family doctor or nurse practitioner since
graduating from cardiac rehab? 
 Yes  No  
 I have an upcoming appointment booked  
 I do not have a family doctor or nurse practitioner 
 I did not attend cardiac rehab  
2. At your last appointment with your family doctor or nurse practitioner, did your
healthcare provider have any mail or letters from the cardiac rehab program? 
 Yes  No  
 I don't know  
 Not applicable, because I didn't go to cardiac rehab 
3. Did your healthcare provider discuss with you your experiences and health changes from
the cardiac rehab program? 
 Yes  No  
 Not applicable, because I didn't go to cardiac rehab 
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SECTION J: YOUR EMOTIONS 
Instructions: Read each item below and put an x in one box for each question which 
comes closest to how you have been feeling in the past week.  
I feel tense or 'wound up' 
 Most of the time  A lot of
the time 
 From time to time,
occasionally 
 Not at all
I still enjoy the things I used to 
enjoy  
 Definitely as much  Not
quite as much  
 Only a little  Hardly at all
I feel as if I am slowed down 
 Nearly all the time
 Very often  Sometimes
 Not at all
I get a sort of frightened feeling like 
'butterflies' in the stomach  
 Not at all
 Occasionally
 Quite often  Very often
I get a sort of frightened feeling as if         I have lost interest in my appearance 
something awful is about the 
happen  
 Very definitely and quite
badly 
 Yes, but not too badly
 A little, but it doesn't worry me
 Not at all
 Definitely
 I don't take as much care as I should
 I may not take quite as much care
 I take just as much care as ever
I can laugh and see the funny side of    I feel restless as if I have to be on the 
things  
 As much as I always
could  
 Not quite as much
now  
 Definitely not so
much now  
 Not at all
move  
 Very much indeed
 Quite a lot
 Not very much
 Not at all
Worrying thoughts go through my mind  
 A great deal of the time
 A lot of the time
 Not too often
 Very little
I feel cheerful 
 Never
 Not often
 Sometimes
 Most of the time
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I can sit at ease and feel relaxed 
 Definitely
 Usually
 Not often
 Not at all
I look forward with enjoyment to things 
 As much as I ever did
 Rather less than I used to
 Definitely less than I used to
 Hardly at all
I get sudden feelings of panic 
 Very often indeed
 Quite often
 Not very often
 Not at all
I can enjoy a good book or radio or 
television programme  
 Often
 Sometimes
 Not often
 Very seldom
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SECTION K: MOOD 
Over the past 2 weeks, how often 
have you been bothered by any of 
the following problems? 
NOT AT ALL SEVERAL DAYS MORE THAN HALF 
THE DAYS 
NEARLY 
EVERYDAY 
1. Little interest or pleasure
in doing things 
0 1 2 3 
2. Feeling down, depressed
or hopeless 
0 1 2 3 
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SECTION L: PERSONALITY  
Instructions: Below are a number of statements that people often use to describe 
themselves. Please read each statement and then circle the appropriate number next to that 
statement to indicate your answer. There are no right or wrong answers. Your own 
impression is the only thing that matters. 
1. I make contact easily when I meet new people 0 1 2 3 4 
2. I often make a fuss about unimportant things 0 1 2 3       4 
3. I often talk to strangers 0 1 2 3 4 
4. I often feel unhappy 0 1 2 3 4 
5. I am often irritated 0 1 2 3 4 
6. I often feel inhibited in social interactions 0 1 2 3 4 
7. I take a gloomy view of things 0 1 2 3 4 
8. I find it hard to start a conversation 0 1 2 3 4 
9. I am often in a bad mood 0 1 2 3 4 
10. I am a closed kind of person 0 1 2 3 4 
11. I would rather keep other people at a distance 0 1 2 3 4 
12. I often find myself worrying about something 0 1 2 3 4 
13. I am often down in the dumps 0 1 2 3 4 
14. When socializing, I don't find the right things to talk 0 1 2 3 4
about
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SECTION N: YOUR THOUGHTS 
Instructions: 
People think and do many different things when they feel sad, blue, or depressed. Read each of 
the following items. Using a four-point scale, please indicate whether you never, sometimes, 
often, or always think or do each one when you feel sad, down, or depressed. Please indicate 
what you generally do, not what you think you should do (never =1, always =4) 
Never   Sometimes   Often   Always 
1. I think about how alone I feel
2. I think about my feelings of fatigue and achiness
3. I think about how hard it is to concentrate
4. I think about how passive and unmotivated I feel
5. I think "Why can't I get going?"
6. I think about a recent situation, wishing it had gone better
7. I think about how sad I feel
8. I think about all my shortcomings, failings, faults, and
mistakes 
9. I think about how I don't feel up to doing anything
10. I think "Why can't I handle things better?
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SECTION O: YOUR IRRITABILITY 
Instructions: Please mark “x” in the box beside each item that best describes how you have been 
feeling in the past week:   NOT AT ALL / A LITTLE OR SOME OF THE TIME / OFTEN / MOST OR ALL OF THE
TIME
1. I have been feeling mad
2. I have been feeling ready to explode
3. I have yelled at others
4. I have been irritable when someone touched me
5. I have been easily flying off the handle
6. It feels like there has been a cloud of anger over
me 
7. I have been rather sensitive
8. I have been quick to criticize others
9. Noises have seemed louder
10. I have been getting annoyed with myself
11. I have been so angry that I lost control
12. There has been a flood of tension through my
body 
13. I said nasty things to others that I did not mean
14. It took very little for things to bother me
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SECTION P: SLEEPING DIFFICULTIES 
These questions ask about your sleep habits. Please mark 1 of the answers for each of the 
following questions.  
Pick the answer that best describes how often you experienced the situation in the past 4 weeks. 
1. Did you have trouble falling asleep?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
2. Did you wake up several times at night?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
3. Did you wake up earlier than you planned to?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
4. Did you have trouble getting back to sleep after you woke up too early?
□ No, not in
the past 4 
weeks 
□ 
Yes, 
less 
than 
once 
a 
week 
□ 
Yes, 
1 or 2 
times 
a 
week 
□ 
Yes, 
3 or 4 
times 
a 
week 
□ 
Yes, 
5 or 
more 
times 
a 
week 
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5. Overall, was your typical night’s sleep during the past 4 weeks?
□ Very
sound or 
restful 
□ 
Sound 
or 
restful 
□ 
Average 
quality 
□ 
Restless 
□ Very
Restless 
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SECTION Q: QUALITY OF LIFE  
Please check the box () on one sentence for each of the following groups that reflect the state 
of your general health IN THE PAST 4 WEEKS.   
A. Mobility        
 No problems walking about          
 Some problems walking about       
 Confined to bed      
B. Self-Care                
 No problems with washing or dressing  
 Some problems with washing or dressing 
 Unable to wash or dress myself       
C. Usual Activities (e.g. work, study, housework, leisure) 
 No problem with performing usual activities  
 Some problems with performing usual activities  
 Unable to perform usual activities   
D. Pain and Discomfort   
 No pain or discomfort   
 Moderate pain or discomfort  
 Extreme pain or discomfort   
E. Anxiety and Depression   
 Not anxious or depressed     
 Moderately anxious or depressed  
 Extremely anxious or depressed 
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SECTION R: TALKING WITH HEALTH CARE PROVIDERS ABOUT MOOD & 
ANXIETY  
1. Since being referred to cardiac rehab, have you had problems with depressed mood
or anxiety? 
 YES  NO 
1b. If yes, have you had problems with:  Depressed mood. 
 Anxiety  
 Both depressed mood 
and anxiety  
1c. If yes, who has treated you for these problems? Family doctor 
(check all that apply)  Heart doctor 
(cardiologist)  
 Psychiatrist or psychologist  
 Nurse  
 Other: 
__________________  
 Not being treated by health care 
provider
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1d. If yes, what treatments have you used:  Medication (antidepressant or anti-anxiety pills) 
(check all that apply) Counseling/Talk therapy 
 Exercise  
 Other: 
_______________________________ 
 My depression/anxiety is not 
being treated  
2. Since you were referred to cardiac rehab, have any health care providers asked about
your mood or anxiety?   YES   NO  
2b. If yes, who asked about your mood or anxiety?  Family doctor 
(check all that apply)        Heart doctor (cardiologist) 
 Psychiatrist or psychologist 
 Nurse  
 Other: 
__________________  
3. Since you were referred to cardiac rehab, have you ever been asked to fill in a survey or
to have an interview with questions about your mood or anxiety? 
 Survey   Interview   Both   Neither  
If yes to either survey or interview:  
10b. Please describe the survey or interview:  
___________________________________________________________________________ 
10c. Did anyone talk to you about the results?  YES   NO  
10d. What happened next (check all that apply)?  
 I was prescribed medicine for my mood or anxiety  
 I was referred to a psychiatrist, psychologist or counselor  
 I was referred for other mental health treatment - please specify: ___________________  
 My healthcare provider is going to follow-up with me about this  
 Nothing (and I do have problems with mood or anxiety)  
 Nothing (and I do not have problems with mood or anxiety)  
 Other, please specify: _______________________________  
 I don't know  
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SECTION S: CARDIAC REHAB PROGRAM TYPE  
 
1. Please indicate your degree of satisfaction with the CR program you were referred to (check 
one):  
 
 Very unsatisfied  
 Unsatisfied  
 Neither satisfied nor unsatisfied  
 Satisfied  
 Very satisfied  
I did not enroll in the program  
 
2b. Please tell us why you were satisfied or why you were unsatisfied with 
your CR program:  
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________  
3. If you were given a choice, which CR program type would you prefer to attend?  
 Women-only hospital-based  
 Men and women hospital-based  
 Home-based  
 
3b) Please tell us why you would prefer this particular type of 
CR program:  
_______________________________________________________________
_______________ 
_______________________________________________________________
________________  
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Please rate how much you agree or disagree with each statement, regardless of what cardiac rehab 
program you attended.  
a. I felt comfortable in my workout clothes when exercising.
b. I was satisfied with the amount of discussion in cardiac rehab about
psychosocial issues.  
c. I was satisfied with the amount of discussion of women's health
issues such as menopause and bone health / osteoporosis. 
d. The environment I exercised in felt too competitive.
e. I was satisfied with the nature of the education I received in the
program. 
f. I was satisfied with the direction I received about resuming my
household, caregiving and other life roles. 
g. I felt that the behaviour change counseling I received suited my
situation as a woman. 
D
isa
gr
ee
  
D
isa
gr
ee
  
D
isa
gr
ee
  
A
gr
ee
 o
r  
N
ei
th
er
  
A
gr
ee
  
St
ro
ng
ly
  
A
gr
ee
  
St
ro
ng
ly
  
228
SECTION T: DEMOGRAPHICS and HEART RISK STATUS 
1. What is today's date?
Day  Month  Year  
2. Have you experienced any of the following heart problems or procedures in the last 9
months since you were recruited for this study from the hospital? Please check all that apply: 
 Heart Attack
 Angina
 Angioplasty (stent)
 Bypass Surgery
 Valve Surgery
 Heart Failure
 Heart transplant
 Cardiac device: pacemaker or implantable cardioverter defibrillator
 Stroke
 Peripheral Vascular Disease
 None of the above
3a) What is your height? ______ feet and _____ inches or ( ________ cm) 
3b) What is your weight? ________ pounds or ( _________ kgs )  
4. Please describe your current smoking status:
 I have never smoked
 I currently smoke
 How many cigarettes do you smoke per day, on average? __________ cigarettes per day
 For how many years have you smoked? ____________ years
 I quit smoking
 When did you quit smoking? month _________ year ____________
 How many cigarettes did you smoke per day, on average? __________ cigarettes per day
 For how many years did you smoke? ____________ years
5. Which option best matches your current work status?
 full-time work
 part-time work
 full-time caregiver or homemaker (inside your home)
 unemployed
 receiving disability
 retired
 other: ______________________
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6. Which option best matches your desired work status?
 full-time work
 part-time work
 full-time caregiver or homemaker (inside your home)
 unemployed
 receiving disability
 retired
 other: ______________________
7. Do you know your blood pressure numbers from the last time it was assessed?
 Yes  No 
8. Is your blood pressure under control at present? (i.e., it is below cut-off values, possibly from medications
to lower your blood pressure) 
 Yes  No  
9. Do you know your cholesterol numbers from the last time it was assessed?
 Yes  No 
10. Is your cholesterol under control at present? (i.e., it is below cut-off values, possibly from medications to
lower it) 
 Yes  No 
11. Please check your medication bottles. Please list below the names of all of the medications you
are currently taking and the dose per day. 
Other medications 
_________________________________________________________
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Thank you for taking the time to complete this survey. Your assistance in providing this 
information is very much appreciated. If there is anything else you would like to tell us about this 
survey, or about your experiences with cardiac disease and/or recovery, please do so in the space 
provided below.  
Please return your completed questionnaire in the stamped and addressed envelope provided to the 
study coordinator by mail:  
CR4HER Study Coordinator 
Toronto General Hospital 
200 Elizabeth Street 
Toronto, ON 
 M5G 2C4 
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Appendix N – Survey Cover Letter 
RE: Cardiac Rehab for Her Study (CR4HER)
Dear Ms. ______________
I am writing to request that you complete the second and final survey in our research study on 
women’s participation in cardiac rehabilitation programs, the study that you consented to 
participate in 6 months ago while in hospital. We very much appreciate the time and effort you 
have put into helping us with this study and hope that you will be willing to complete this final 
questionnaire. 
This survey, like the previous one, requests information on your perception of your health care, 
your feelings and mood, as well as specific information regarding any participation in a cardiac 
rehabilitation program.  Enclosed is a pre-addressed and stamped envelope in which you can 
return the completed survey.   
If you have any questions regarding the survey or the study please feel free to contact the study 
coordinator at (xxx) xxx-xxxx.  
We want to stress that your participation in this study is completely voluntary, and will not 
impact the care or services you or your family receive.  Please know that your help would be 
greatly appreciated and any information you could give us would further aid us in improving the 
quality of cardiac rehabilitation for female heart patients such as yourself. 
Thank you for your consideration. 
Sincerely, 
Dr. Sherry L. Grace 
Toronto General Hospital and 
York University 
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Appendix O – Replacement Survey Cover Letter 
RE: Cardiac Rehab for Her Study (CR4HER)
Dear Ms. ___________: 
About four weeks ago I sent a questionnaire to you that asked about any participation in cardiac 
rehabilitation after hospitalization for your heart problem. To the best of our knowledge, it’s not 
yet been returned. 
The comments of people who have already responded include a wide variety of answers 
regarding their experiences in cardiac rehab along with potential barriers that may have hindered 
their adherence to this program. We think the results are going to be very useful to improve 
secondary prevention programs for female cardiac patients.  
We are writing again because of the importance that your questionnaire has for helping to get 
accurate results. It’s only by hearing from nearly everyone in the sample that we can be sure that 
the results are truly representative. 
A comment on our survey procedures: a questionnaire identification number is printed on the 
pages of the questionnaire so that we can check your name off of the mailing list when it is 
returned. The list of names is then destroyed so that individual names can never be connected to 
the results in any way. Protecting the confidentiality of people’s answers is very important to us.    
We hope that you will fill out and return the questionnaire soon, but if for any reason you prefer 
not to answer it, please let us know by returning a note or blank questionnaire in the enclosed 
stamped envelope.  
If you have any questions about this funded study, please feel free to contact the study 
coordinator at xxx-xxx-xxxxx. 
Sincerely, 
Dr. Sherry L. Grace 
University Health Network, Toronto General Hospital 
and York University 
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Appendix P - Discharge Report Form 
1. Participant ID#: __________
2. Date of data extraction:
3. Did the patient complete the program (circle one)? Yes No 
             2b. If yes: Date of discharge: 
            2c.  If no, Date last attended rehab:  
 2d.  If no, specify whether (circle one):              Medical  Non-Medical 
2e.  Describe: 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
4. Number of Sessions prescribed (on site or via telephone): _____________
5. Number of sessions completed (on site or via telephone): _____________
6. Number of Sessions prescribed to drop out for medical reason (if
applicable):_____________
7. Number of Sessions completed to drop out for medical reason (if
applicable):_____________
8. Blood lipid profile:
 
 
 
 
9. Waist Circumference (cm): ________
dd mmm yyyy 
dd mmm yyyy 
dd mmm yyyy 
Total Cholesterol mmol/L 
HDL mmol/L 
LDL mmol/L 
Triglycerides mmol/L 
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10. Discharge Exercise Stress Test:
a. Resting SBP blood pressure:________
b. Resting DBP blood pressure:________
c. Peak METs: ______________
d. Peak VO2: _______________
e. CPA Completed: Yes No 
11. Other comments:
________________________________________________________________________
________________________________________________________________________
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